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 Phosphopantothenoylcysteine synthetase (PPCS) is the second enzyme in the 
universal Coenzyme A (CoA) biosynthetic pathway. PPCS is responsible for catalyzing 
the condensation of 4’-phosphopantothenate (PPA) and L-cysteine via nucleotide 
triphosphate activation of PPA. PPCSs have been broadly classified into three types 
(Type I-III) based upon expression profile and nucleotide triphosphate specificity. Type I 
PPCSs are found in a majority of bacteria and archaea, utilize CTP for activation of PPA 
in the first half reaction, and are expressed as the C-terminal domain of a fusion protein 
with phosphopantothenoylcysteine decarboxylase (PPCDC). Type II PPCSs are in 
eukaryotes, utilize both CTP and ATP, and expressed separately from PPCDC as a 
monofunctional enzyme. Type III PPCSs are found in certain bacteria, utilize CTP, and 
are expressed as a monofunctional enzyme. Based upon the difference in nucleotide 
triphosphate specificity and PPCS type between human and bacteria, PPCS was chosen 
for exploration as a possible novel antibacterial target. 
 Four mimics of the activated intermediate produced from the first half reaction 
catalyzed by PPCS were synthesized in twelve steps in average of 18% overall yield. 
These four intermediate mimics were tested in vitro for PPCS inhibition against PPCS 
from E. coli, E. faecalis, S. pneumoniae, and human. IC50s were obtained for all four 
intermediate mimics and the best mimic had a Ki of 24 nM against efPPCS. The best 
intermediate mimic displayed low nanomolar potency versus the bacterial forms of PPCS 
while displaying 100-1000 fold selectivity for the bacterial PPCS over human PPCS. 
Further, three of the intermediate mimics were used in a structural study to elucidate how 
they bind within the PPCS active site. The co-crystal structures of PPCS and the three 
intermediate mimics were solved to 2.11-2.37 Å. Analogs of PPA where the 
carboxylate was replaced with either an amine or thiol. The phosphorylated thiol PPA 
mimic was found to act as a competitive inhibitor of PPCS with respect to PPA with a Ki 
of 12 µM.  This study shows that it is possible to selectively inhibit bacterial PPCS 
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 Since the discovery of the sulfa drugs in the mid 1930s, antibacterial research has 
provided society with unprecedented improvements in quality of life in dealing with a 
very wide range of pathogens.1 Despite the tremendous benefits gained from antibacterial 
agents, antibacterial resistant strains of bacteria are emerging at a rapid pace due to 
questionable and unnecessary antibiotic usage, and pose a major threat to public health.2 
Nowhere is this phenomenon more apparent than in hospitals and more specifically 
intensive care units (ICUs).3 Due to this current state of antibiotic resistance in the public 
health sector it is imperative that alternative antibiotic targets be investigated in hopes of 
producing novel antibacterial agents with new targets and mechanisms of action. 
 Unfortunately, in response to this emerging crisis the pace at which novel 
antibiotics with new targets have been entering the market has slowed.3 Only two new 
chemical classes of antibacterial agents, the oxazolidinones and lipopeptides, have been 
introduced since 1970 and resistance to these agents has already been observed (Figure 
1.1).4 Currently, only nine of the fifteen major pharmaceutical companies in the United  
 
Figure 1.1: Timeline of antibacterial deployment and resistance observed4 
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States have active research programs in antimicrobial agents. There are several 
contributing factors that have lead to the major pharmaceutical sector shifting its research 
focus from antimicrobials to other areas of interest. 
 
Figure 1.2: Sales of antimicrobials by company in millions (2006)5 
 This shift in research focus is in part due to the fact that antimicrobial agents are 
not very profitable commodities as compared to agents in other therapeutic areas. Despite 
the antimicrobial market being quite substantial as a whole with sales of $25.5 billion in 
2007, only three individual antimicrobial agents generated more than $1 billion in sales in 
2007.6 One cause of this low profitability for antimicrobials is the short duration of 
administration. An effective antimicrobial agent would have an acute dosing regimen, 
usually lasting only two weeks, which is in stark contrast to the chronic dosing regimen 
of an erectile dysfunction or cholesterol lowering agent, which are regularly taken over 
the course of years and thus create a disparity in profit window. Another factor limiting 
the profitability of an antimicrobial agent is the heavily saturated antimicrobial market. 
As of 2006, there were 21 total classes of antimicrobials of which 4 classes represented 
72% of the market. 6 In order to gain a foothold in the antibacterial market, a novel agent 
would not only be competing against these already established  antimicrobials, but it 
would also be competing against their overwhelming number of less expensive generic 
alternatives.6 Further evidence of the saturated antimicrobial market can be seen by 
looking at the market sales of the large pharmaceutical companies (Figure 1.2).5 While 
several large pharmaceutical companies such as Pfizer and Johnson and Johnson still 




 Another factor that has driven many major pharmaceutical companies out of 
antimicrobial research is the stringent FDA regulations associated with bringing a new 
antimicrobial agent to the market. Despite antibacterial agents requiring relatively short 
clinical trials, the FDA is requiring data to prove that a new anti-infective agent is 
superior to the current treatment rather than just equivalent. Since 2008, the FDA has 
denied four of six New Drug Applications (NDA) for antibacterial agents based upon the 
results from the Phase III trial.7 Failure from a costly Phase III trial is a huge deterrent for 
pharmaceutical companies to continue anti-infective research programs. The average 
Phase III trial costs $21,000 per patient and as the FDA requirements are becoming more 
stringent the cost rises because more patients are necessary to meet the rising demands.8
 As major pharmaceutical companies reduce antibacterial research, the onus has 
been placed on smaller biotech companies and the academic sector. While small biotech 
companies and academia cannot conduct large phase II and phase III trials, they can 
continue to explore novel chemical scaffolds and targets. To this end, my research project 
has been studying phosphopantothenoylcysteine synthetase (PPCS) as a new antibacterial 
target. 
 
Figure 1.3: Structure of phosphopantetheine 
 Phosphopantetheine-containing compounds are essential cofactors across all 
kingdoms of life. Phosphopantetheine is a dipeptide composed of cystamine and β-
alanine modified with a phosphorylated pantoyl group, which is derived from α-
ketoisovalerate (Figure 1.3). Phosphopantetheine-containing biomolecules are 
responsible for carbonyl activation and transfer in a variety of biological reactions 
through the thiol group on the terminal cystamine portion. Phosphopantetheine is found 




Figure 1.4: Phosphopantetheine and its location in acyl carrier protein and coenzyme A 
modified, conserved serine in acyl carrier protein (ACP) (Figure 1.4).  It has been 
estimated through a survey of the Braunschweig enzyme database (BRENDA) that up to 
8-12% of all known cellular enzymatic activity utilizes phosphopantetheine in the form of 
CoA, ACP, or one of their thioesters.9 Among these, phosphopantetheine plays an 
important role in the bacterial fatty acid synthase Type II (FAS II) and tricarboxylic acid 
cycle (TCA), which are both essential for bacterial growth.10, 11 
 Pantothenate (vitamin B5), discovered in 1933 by Williams et al., is the common 
precursor for the synthesis of phosphopantetheine across all kingdoms of life. Humans 
and animals rely on the uptake of exogenous pantothenate via a Na+ coupled 
multivitamin transporter.12 Conversely, most bacteria, fungi, and plants are able to 
synthesize pantothenate from α-ketoisovalerate and β-alanine. E. coli can produce up to 
15 times the pantothenate required for CoA biosynthesis, and enough pantothenate to 
sustain a mammal without further vitamin B5 supplementation.12 Whether taken up or 
synthesized de novo, pantothenate is converted to phosphopantetheine and eventually 
CoA by the universal CoA biosynthetic pathway (Figure 1.5). 
 The CoA biosynthetic pathway consists of five enzymatic steps starting from 
pantothenate. 13-18 Brown and Abiko were responsible for the early elucidation of the 
pathway in the late 1950’s and 1960’s.13-18 The first step in the pathway is the ATP-
dependent phosphorylation of the 4’ position hydroxyl group on pantothenate by 





Figure 1.5: CoA biosynthetic pathway 
step is the formation of an amide bond between L-cysteine and PPA to form 4’-
phosphopantothenoylcysteine, which is catalyzed using a nucleotide triphosphate co-
substrate by PPCS.13, 19 4’-phosphopantothenoylcysteine is then oxidatively 
decarboxylated by phosphopantothenoylcysteine decarboxylase (PPCDC) to yield 4’-
phosphopantetheine. The fourth step is the condensation of 4’-phosphantetheine with the 
α phosphate of ATP, adding an AMP moiety to 4’-phosphopantetheine to produce de-
phospho CoA. Lastly, de-phospho CoA is phosphorylated on the 3́  alcohol of the ribose 
ring by de-phospho CoA kinase (DPCK). Importantly, Brown established that in order for 
PPA to be converted into CoA using isolates from Proteus morganii, cytidine 
triphosphate (CTP) was required.13 Specifically, CTP was needed for PPCS to catalyze 
the amide bond formation in the second step of the pathway.13 
 Despite this pioneering work conducted in the 1950’s and 1960’s, it was not until 
the early 2000’s that all of the genes for the CoA pathway in human and bacteria were 
cloned and characterized.19 With the ability to clone, overexpress, and purify all the 
enzymes in the pathway, the CoA biosynthetic pathway has been fully elucidated. Recent 
studies have also focused on studying the differences between human and bacterial CoA 




 PPCS, which is responsible for the condensation of L-cysteine and PPA, was 
chosen as the target to explore in this study. Due to the differences in PPCSs across the 
various species of life, PPCSs have been put into three different classes (Types I-III).  
Type I PPCSs are found in a majority of bacteria and archaea, utilize CTP for activation 
of PPA in the first half reaction, and are expressed as the C-terminal domain of a fusion 
protein with PPCDC (Figure 1.6). Type II PPCSs are found in eukaryotes, utilize both 
CTP and ATP, and expressed separately from PPDC as a monofunctional enzyme. Type 
III PPCSs are found in certain bacteria, utilize CTP in the first half reaction of PPCS, and 
are expressed as a monofunctional enzyme. In E. coli, a prototypical Type I PPCS, the 
PPCS domain and PPCDC domain are encoded on the same gene and expressed as a 
homododecamer. The PPCDC domain consists of serine 2 through asparagine 190, while 
the PPCS domain consists of the C-terminal amino acids from isoleucine 191 to arginine 
406 (Figure 1.6). In humans, PPCS (Type II) and PPCDC are encoded on two separate 
genes and PPCS is expressed as dimer. 
 
Figure 1.6: Differences in PPCS Type 
 PPCS was chosen for exploration as a novel antibacterial target because it was a 
well validated target based upon previous studies. In the mid 1980s, Spitzer and 
coworkers characterized a conditional lethal E. coli mutant which was auxotrophic for 
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pantothenate at 30°C and at non-permissive temperatures (42°C) did not grow even in 
media supplemented with pantothenate.26 The affected gene locus was designated dfp 
(dna flavoprotein).  Recently, the dfp gene product was identified as a bifunctional 
protein composed of PPCS and PPCDC, and the temperature sensitive allele 
characterized as a mutation within the PPCDC domain of the protein leading to decreased 
solubility of the PPCDC/PPCS protein at non-permissive temperatures.27 It has also been 
shown using genome-wide transposon mutagenesis studies in E. coli that the gene 
responsible for PPCS/PPCDC is essential for bacterial growth.26 In this study, 
transposable elements were allowed to randomly insert into the E. coli genome in the 
presence and absence of extra-chromosomal copies of genes involved in mammalian 
CoA biosynthesis.  In the absence of the extra-chromosomal copies, no viable mutants 
were isolated containing transposon insertions in genes associated with the biosynthesis 
of phosphopantetheine-containing molecules from pantothenate. However, when the 
extra-chromosomal copies were present, they were able to complement the lethal 
insertions and cells were isolated containing transposable elements in genes associated 
with CoA biosynthesis.  Therefore, each catalytic step in the vitamin B5 to CoA pathway 
has been shown to be required.  Furthermore, the absence of a transport system for the 
phosphorylated intermediates in the pathway eliminates the possibility of extra-cellular 
CoA uptake or transport of phosphorylated precursors from the growth medium. 
 Further, an amino acid sequence similarity analysis revealed low sequence 
similarity between human PPCS and most bacterial PPCSs (Figure 1.7).28  When 
comparing human PPCS to the various bacterial PPCSs in Figure 1.7 (right column), 
there is less than 20% similarity between human PPCS and ecPPCS and the other Type I 
PPCSs and only 20-30% similarity with E. faecalis and S. pneumoniae PPCSs (Type 
III).28 This low sequence similarity between bacterial and human PPCSs provides 
evidence that the selective inhibition of bacterial PPCS by a therapeutic agent is 
possible.28 ecPPCS shows 20% or greater similarity when compared to every other 
bacteria in Figure 1.7 (left column) and in most cases greater than 40%, which suggests 





Figure 1.7: Sequence Similarity of CoA enzymes. Left column is sequence similarity 
relative to E. coli PPCS. Right column is sequence similarity relative to human PPCS.28 
 
 Another attractive feature of PPCS as a possible drug target is that the structure 
for both a mutant E. coli PPCS and human PPCS have been solved in literature.19, 24 The 
crystal structure of a mutant PPCS from E. coli provides us with information on the 
important binding contacts within the active site. The conditions used within this study 
provide us with a foundation to begin our own structural study of PPCS with our 
proposed inhibitors bound in the active site. The crystal structure can be used as a model 
and allow for the solving of any future crystal structures using molecular replacement, 
which is easier and less time consuming than having to use multiple isomorphous 
replacement. Our studies would allow us to look at the differences between the structure 
of the intermediate mimic and its binding mode in order to glean information that will 
allow for the design of second generation inhibitors. 
 Mechanistically, bacterial PPCS (Type I & III) is responsible for binding PPA and 
catalyzing its reaction with CTP to form the active acyl-cytidylate intermediate in the 
first half reaction (Figure 1.7).22, 29 Cysteine then enters the active site of the enzyme and 
initiates a nucleophilic displacement of the cytidine monophosphate (CMP) to form a 





Figure 1.8: Mechanism of PPCS 
second half reaction.22 The 4’-phosphopantothenoylcysteine is oxidatively 
decarboxylated by PPCDC to form 4’-phosphopantetheine.22 Conversely, Human PPCS 
(Type II) can utilize both CTP and ATP in catalyzing the first half reaction of PPCS and 
had been reported to display a 4:1 preference for ATP over CTP, which presented an 
opportunity for differential inhibition of bacterial and human PPCS.30, 31 Utilizing ATP in 
the first half reaction of human PPCS catalysis leads to the formation of an activated 
adenylate intermediate, this differs drastically in the size and binding contacts of the 
nucleobase as compared to the activated cytidylate intermediate formed in bacterial PPCS 
catalysis (Figure 1.8). By designing inhibitors to mimic the activated cytidylate 
intermediate of bacterial PPCS catalysis, one should be able to utilize a majority of the 
binding contacts of the activated intermediate resulting in tight binding, while 
maintaining selectivity based upon the differences in the nucleotide binding pockets 
between human and bacterial PPCS.  
 It is known that cysteine attacks the carbonyl on the mixed anhydride of the 
activated intermediate, forms the amide bond in PPA and releases CMP, it is not known 
whether the amine of cysteine simply attacks the activated intermediate and forms the 
amide bond in PPA or if the more nucleophilic thiol of cysteine initiates the attack on the 
activated intermediate to form a labile thioester that rearranges to form the more 
thermodynamically stable amide bond of PPA (Figure 1.9). Identification of the cysteine 
binding site and the orientation of cysteine binding to the PPCS-acyl cytidylate complex, 
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have yet to be ascertained and have mechanistic implications toward the ability of PPCS 
to discriminate between cysteine and serine.21  This discrimination has critical biological 
implications, since incorporation of serine would lead to the production of potentially 
toxic CoA antimetabolites. Attempts by other researchers at obtaining PPCS with 
cysteine bound at the active site have not been successful due to product formation upon 
adding cysteine to the intermediate-bound enzyme.  A definitive answer to the 
mechanism of selective cysteine incorporation awaits a PPCS structure with a substrate 
analog bound at the active site. 
 












Synthesize and evaluate phosphodiester and sulfamate PPCS intermediate mimics 
against PPCS from E. coli, E. faecalis, S. pneumoniae, and Human 
. 
Figure 1.10: Proposed intermediate mimics 
 Based on this strategy, phosphodiester and sulfamate intermediate mimics were 
designed (Figure 1.10). The phosphodiester mimic was designed by removing the 
electrophilic carbonyl attacked during the second half reaction from the activated 
intermediate. This proposed inhibitor should be able to utilize the binding contacts of the 
intermediate mimic within PPCS’s active site, but is not enzymatically competent due to 
the inability of cysteine to attack an activated carbonyl, form an amide bond, and release 
CMP. The sulfamate mimic replaces the internal mixed anhydride of the activated 
intermediate with a less chemically labile sulfamate linkage. The proposed sulfamate 
inhibitor maintains the electrophilic carbonyl attacked during the second half reaction, 
but the negative charge of the phosphate has been replaced. This strategy should provide 
information about the ability of PPCS to accommodate differences in charge and 
geometry in the internal linkage of the intermediate mimics. 
Structural study of PPCS from E. coli co-crystallized with intermediate mimics to 
elucidate the differences in binding contacts for selectivity and potency 
 Beyond using these first generation inhibitors to selectively inhibit bacterial 
PPCS, the intermediate mimics can be used in structural studies. Obtaining IC50 values 
for the inhibitors will give us a relative idea of how structural changes to the intermediate 
mimic are accommodated by PPCS, but a structural study will show us which binding 
contacts are most important when targeting PPCS. This information will be vital in 




Synthesize and evaluate mechanistic probes of PPCS 
 In an alternative strategy, PPCS can be studied using mechanistic probes designed 
to be reactive with the other substrates within the enzyme active site. The first set of 
mechanistic probes is a pair of analogs of PPA (Figure 1.11). These molecules were 
designed by replacing the carboxylic acid of PPA with either a thiol or an amine. Upon 
incubation of the nucleophilic PPA mimic with CTP and PPCS, the PPA mimic should  
 
 
Figure 1.11: Proposed PPA analogs 
attack the α phosphate of CTP displacing pyrophosphate and concurrently forming a an 
intermediate mimic analogous to the proposed phosphodiester inhibitor in the PPCS 
active site (Figure 1.12). 
 
Figure 1.12: Mechanism of nucleophilic PPA analogs 
 The alternative mechanistic probe was designed to study the mechanism of the 
cysteine attack during the second half reaction. To study the mechanism of the 
nucleophilic attack during the second half reaction, a vinyl sulphone intermediate mimic 





Figure 1.13: Mechanism of action of cysteine trap 
 PPCS is an interesting and attractive target for possible novel antibacterial agents. 
To date PPCS has not been studied as a potential antibacterial target and as such there is 
little information about how to specifically target bacterial PPCS over human PPCS. This 
study represents the first time probes or inhibitors have been synthesized and evaluated, 
based upon their action on PPCS to gather information about how to specifically inhibit 
bacterial PPCS. These probes represent the first attempt to prove PPCS is a viable 
antibacterial target. While these molecules are not potential drug candidates due to their 
physiochemical property, these probes are the first inhibitors of PPCS and can be used as 














1. Levin, S. A.; Andreasen, V., Disease transmission dynamics and the evolution of 
antibiotic resistance in hospitals and communal settings - Commentary. Proceedings of 
the National Academy of Sciences of the United States of America 1999, 96, (3), 800-801. 
2. Beovic, B., The issue of antimicrobial resistance in human medicine. 
International Journal of Food Microbiology 2006, 112, (3), 280-287. 
3. Levin, B. R.; Bonten, M. J. M., Cycling antibiotics may not be good for your 
health. Proceedings of the National Academy of Sciences of the United States of America 
2004, 101, (36), 13101-13102. 
4. Clatworthy, A. E.; Pierson, E.; Hung, D. T., Targeting virulence: a new paradigm 
for antimicrobial therapy. Nat Chem Biol 2007, 3, (9), 541-548. 
5. Christoffersen, R. E., Antibiotics--an investment worth making? Nature 
Biotechnology 2006, 24, (12), 1512(3). 
6. Kresse, H.; Belsey, M. J.; Rovini, H., The antibacterial drugs market. Nature 
Reviews Drug Discovery 2007, 6, (1), 19(2). 
7. Jarvis, L. M., Anitbiotics Yo-Yo. Chemical and Egineering News 2010, pp 30-33. 
8. Fletcher, L., Cubist highlights FDA's antibiotic resistance. Nat Biotech 2002, 20, 
(3), 206-207. 
9. Spry, C.; Kirk, K.; Saliba, K. J., Coenzyme A biosynthesis: an antimicrobial drug 
target. Fems Microbiology Reviews 2008, 32, (1), 56-106. 
10. Zhang, Y.-M.; White, S. W.; Rock, C. O., Inhibiting Bacterial Fatty Acid 
Synthesis. Journal of Biological Chemistry 2006, 281, (26), 17541-17544. 
11. Strauss, E.; Kinsland, C.; Ge, Y.; McLafferty, F. W.; Begley, T. P., 
Phosphopantothenoylcysteine Synthetase from Escherichia coli. Identification and 
characterization of the last unidentified Coenzyme A biosyntheticenzyme in bacteria. J. 
Biol. Chem. 2001, 276, (17), 13513-13516. 
12. Leonardi, R.; Zhang, Y. M.; Rock, C. O.; Jackowski, S., Coenzyme A: Back in 
action. Progress in Lipid Research 2005, 44, (2-3), 125-153. 
13. Brown, G. M., The Metabolism of Pantothenic Acid. Journal of Biological 
Chemistry 1959, 234, (2), 370-378. 
14. Abiko, Y., Investigations on Pantothenic Acid and Its Related Compounds: X. 
Biochemical Studies (5). Purification and Substrate Specificity of 
Phosphopantothenoylcysteine Decarboxylase from Rat Liver. J Biochem 1967, 61, (3), 
300-308. 
15. Abiko, Y., Investigations on Pantothenic Acid and Its Related Compounds: IX. 
Biochemical Studies (4). Separation and Substrate Specificity of Pantothenate Kinase and 
Phosphopantothenoylcysteine Synthetase. J Biochem 1967, 61, (3), 290-299. 
16. Abiko, Y.; Suzuki, T.; Shimizu, M., Investigations on Pantothenic Acid and Its 
Related CompoundsXI. Biochemical Studies (6). A Final Stage in the Biosynthesis of 
CoA. J Biochem 1967, 61, (3), 309-312. 
17. Abiko, Y.; Tomikawa, M.; Shimizu, M., Further Studies on 
Phosphopantothenoylcysteine Synthetase. J Biochem 1968, 64, (1), 115-117. 
18. Suzuki, T.; Abiko, Y.; Shimizu, M., Investigations on Pantothenic Acid and Its 
Related Compounds XII. Biochemical Studies (7). Dephospho-CoA Pyrophosphorylase 
and Dephospho-CoA Kinase as a Possible Bifunctional Enzyme Complex. J Biochem 
1967, 62, (6), 642-649. 
15 
 
19. Stanitzek, S.; Augustin, M. A.; Huber, R.; Kupke, T.; Steinbacher, S., Structural 
Basis of CTP-Dependent Peptide Bond Formation in Coenzyme A Biosynthesis 
Catalyzed by Escherichia coli PPC Synthetase. Structure 2004, 12, (11), 1977-1988. 
20. Strauss, E.; Begley, T. P., The Antibiotic Activity of N-Pentylpantothenamide 
Results from Its Conversion to Ethyldethia-Coenzyme A, a Coenzyme A Antimetabolite. 
Journal of Biological Chemistry 2002, 277, (50), 48205-48209. 
21. Kupke, T., Active-site residues and amino acid specificity of the bacterial 4'-
phosphopantothenoylcysteine synthetase CoaB. European Journal of Biochemistry 2004, 
271, (1), 163-172. 
22. Kupke, T., Molecular Characterization of the 4'-Phosphopantothenoylcysteine 
Synthetase Domain of Bacterial Dfp Flavoproteins. J. Biol. Chem. 2002, 277, (39), 
36137-36145. 
23. Strauss, E.; Tadhg, P. B., The Selectivity for Cysteine over Serine in Coenzyme A 
Biosynthesis. ChemBioChem 2005, 6, (2), 284-286. 
24. Manoj, N.; Strauss, E.; Begley, T. P.; Ealick, S. E., Structure of Human 
Phosphopantothenoylcysteine Synthetase at 2.3 Å Resolution. Structure 2003, 11, (8), 
927-936. 
25. Zhao, L.; Allanson, N. M.; Thomson, S. P.; Maclean, J. K. F.; Barker, J. J.; 
Primrose, W. U.; Tyler, P. D.; Lewendon, A., Inhibitors of phosphopantetheine 
adenylyltransferase. European Journal of Medicinal Chemistry 2003, 38, (4), 345-349. 
26. Spitzer, E. D.; Weiss, B., dfp Gene of Escherichia coli K-12, a locus affecting 
DNA synthesis, codes for a flavoprotein. J. Bacteriol. 1985, 164, (3), 994-1003. 
27. Blaesse, M.; Kupke, T.; Huber, R.; Steinbacher, S., Crystal structure of the 
peptidyl-cysteine decarboxylase EpiD complexed with a pentapeptide substrate. EMBO J 
2000, 19, (23), 6299-6310. 
28. Genschel, U., Coenzyme A Biosynthesis: Reconstruction of the Pathway in 
Archaea and an Evolutionary Scenario Based on Comparative Genomics. Mol Biol Evol 
2004, 21, (7), 1242-1251. 
29. Yao, J.; Patrone, J. D.; Dotson, G. D., Characterization and Kinetics of 
Phosphopantothenoylcysteine Synthetase from Enterococcus faecalis. Biochemistry 2009, 
48, (12), 2799-2806. 
30. Yao, J. W.; Dotson, G. D., Kinetic characterization of human 
phosphopantothenoylcysteine synthetase. Biochimica Et Biophysica Acta-Proteins and 
Proteomics 2009, 1794, (12), 1743-1750. 
31. Daugherty, M.; Polanuyer, B.; Farrell, M.; Scholle, M.; Lykidis, A.; de Crecy-
Lagard, V.; Osterman, A., Complete Reconstitution of the Human Coenzyme A 
Biosynthetic Pathway via Comparative Genomics. Journal of Biological Chemistry 2002, 












oxopropylamino)-2,2-dimethyl-4-oxobutyl dihydrogen phosphate) is a fundamental 
feature in many biological acyl transfer reactions.  The molecule is found embedded 
within coenzyme A (CoA), as well as on a post-translationally modified, conserved serine 
of acyl carrier protein (ACP).  Both CoA and ACP play essential roles as acyl group 
donor substrates in several reactions associated with intermediary metabolism and cell 
membrane assembly in living organisms.1 Additionally, CoA has been determined to be 
the major low molecular weight thiol in non-glutathione producing bacteria, and is 
responsible for maintaining thiol/disulfide homeostasis in several human pathogens, such 
as Staphylococcus aureus, Borrelia burgdorferi, and Bacillus anthracis.2 The critical 
nature of phosphopantetheine-containing molecules to the integrity and viability of cells 
makes the biosynthetic pathway leading to the production of these compounds an 
intriguing target for antimicrobial development.   
 In 1959, Brown showed that in addition to pantothenate, cysteine, and ATP, 
bacterial phosphopantetheine biosynthesis had an additional requirement for cytidine 
triphosphate (CTP), which was needed for the coupling of phosphopantothenate and 
cysteine by phosphopantothenoylcysteine synthetase (PPCS) in partially purified extracts 
of Proteus morganii.3 The CTP-dependence of bacterial PPCS, in contrast to its ATP-
utilizing mammalian counterpart, has been recently confirmed using purified protein 
from E. coli.4 In most bacteria PPCS and phosphopantothenoylcysteine decarboxylase 
(PPCDC) are expressed as a single bifunctional polypeptide (~46 kDa; coaBC gene 
17 
 
product, formerly known as dfp), consisting of a N-terminal flavin mononucleotide 
(FMN) binding domain (PPCDC; ~21 kDa), and C-terminal PPCS domain (~25 kDa).5, 6 
This is in contrast to their mammalian counterparts which are expressed as separate 
polypeptides (PPCS, 34 kDa; PPCDC, 22 kDa).  The exceptions in the list of bacterial 
pathogens expressing bifunctional PPCS-PPCDC are Streptococci and Enterococci 
species, which contain two separate ORFs, coaB and coaC, in one operon.  In addition, 
Bacillus anthracis (as well as Bacillus cereus) contains both a bifunctional PPCDC/PPCS 
and a monofunctional PPCS ortholog, but no monofunctional PPCDC.7 Monofunctional 
PPCSs from Enterococcus faecalis, Streptococcus pneumoniae, and B. anthracis reveal 
very high sequence similarity to each other, but they are quite divergent from the PPCS 
domain of the bifunctional PPCDC/PPCS proteins.  In contrast to other bacterial 
orthologs, they produce a low but reliable similarity score compared with the human 
monofunctional PPCS.  Thus, PPCS exists in nature in three types:  Type I PPCS are 
found in a majority of bacteria and archaea, are CTP specific, and are expressed as the C-
terminal domain of a bifunctional protein fusion in conjunction with 
phosphopantothenoylcysteine decarboxylase (PPCDC),8, 9 Type II PPCS are found 
mainly in eukaryotes, can utilize both ATP and CTP to support catalysis, and are 
expressed as a monofunctional enzyme,10, 11  and Type III PPCS are found in a smaller 
subset of bacteria, and are expressed as monofunctional enzymes and have been shown to 
be CTP specific.12  
 PPCS utilizes three substrates and catalysis proceeds through two half reactions, 
consisting of the formation of a nucleotide-activated phosphopantothenate intermediate in 
the first half reaction, followed by an acylation reaction in the second half reaction, 
resulting in amide bond formation yielding phosphopantothenoylcysteine (Figure 2.1).  
PPCS is a member of the aminoacyl-tRNA synthetase superfamily and the mechanism for 
formation of the phosphopantothenoyl cytidylate is similar to that for formation of the 
aminoacyl adenylate intermediate.  It is of interest to note that the topical antibiotic 
mupirocin inhibits bacterial isoleucyl tRNA synthetase by mimicking binding contacts of 





Figure 2.1: Mechanism of PPCS 
 As stated, one of the main differences between bacterial and human PPCS is the 
nucleotide triphosphate specificity, where bacterial PPCSs are CTP specific and thus 
generate an activated cytidylate intermediate for amide bond formation (Figure 2.1). 
Kinetic and structural studies have shown that the nucleobase binding sites of bacterial 
PPCS (Types I and III) differ greatly from that of the human Type II enzyme. We have 
therefore employed a strategy to achieve selective bacterial inhibition by exploiting the 
differences in the nucleobase binding pocket between the bacterial and human enzymes 
by basing the inhibitor design on the activated cytidylate intermediate. The proposed 
inhibitors should bind tightly to the bacterial nucleotide binding pocket, and less tightly 
to the human PPCS based upon the difference in the nucleobase binding pocket and the 
nucleotide triphosphate specificity. The proposed phosphodiester intermediate mimic was 
designed to mimic the activated intermediate, except that the electrophilic carbonyl on 
the phosphopantothenate portion of the molecule has been completed removed (Figure 
2.2). Changing the chemically labile mixed anhydride to a chemically stable 
phosphodiester should allow the phosphodiester mimic to take advantage of the binding 
contacts of the activated intermediate in the PPCS active site while eliminating the 
possibility for cysteine attack and amide bond formation of the second half reaction. The 
proposed sulfamate intermediate mimic was designed by replacing the mixed anhydride 
linkage of the activated intermediate with a sulfamate linkage. The non-hydrolysable 
sulfamate linkage was chosen based upon recent success using it as a phosphate isostere 
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for activated intermediates in systems such as asparagine biosynthesis in humans and 
siderophore biosynthesis in Mycobacterium tuberculosis and Yersinia pestis to give 
inhibitors with IC50s ranging from low µM to nM.15-18  
 
 
Figure 2.2: Design of Intermediate Mimics 
Synthesis of Intermediate Mimics  
 
Figure 2.3: Retrosynthetic Analysis of the phosphodiester mimic 
 After retrosynthetic analysis of the phosphodiester mimic, one can envision the 
first disconnection is the terminal phosphate from the primary alcohol of the 1,3 diol of 
the panthenol portion of the mimic, which may be installed synthetically late in the 
synthesis by phosphitylation and in situ oxidation (Figure 2.3). The second disconnection 
of the molecule dissects the molecule into the two major fragments: a commercially 
available cytidine portion, and the N-3 phosphorylated panthenol fragment. The N-3 
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panthenol fragment can simply be disconnected to panthenol, a commercially available 
triol and a phosphate group, which may be installed via an appropriately substituted 
phosphitylating reagent using a tetrazole mediated coupling and oxidation. 
 
Scheme 2.1: Synthesis of phosphite 2 
 The synthesis of the phosphodiester mimic begins with the protection of the 1,3 
diol of panthenol as the p-methoxybenzylidene (PMB) acetal 1 (Scheme 2.1).19, 20 The 
PMB acetal was chosen as the protecting group because it is more readily removed under 
acidic conditions than other acetals such as the benzylidene or acetonide due to the 
electron donating capability of the p-methoxy group.21, 22 Also, the acid labile PMB acetal 
provides the ability to utilize an orthogonal base labile protecting group strategy on the 
cytidine portion. This is a key feature because it allows for the installation of the terminal 
phosphate on the panthenol portion of the molecule later in the synthetic scheme. The 
PMB acetal 1 was then phosphitylated on the open N-3 alcohol using O-allyl-N,N,N,N-
tetraisopropylphosphoramidite and 5-(ethylthiol)-1H-tetrazole as the activating agent to 
yield the phosphite 2 in 65% yield.23, 24 The P(III) phosphoramidite chemistry was chosen 
as the method to install the phosphate moieties in the proposed inhibitors due to the 
increased reactivity of the activated P(III) species generated in situ and the stability of the 
phosphitylated intermediates unless treated with an activator. The P(III) chemistry was 
also advantageous because it allowed for asymmetric substitution of the phosphorous 
species based upon the order of addition and equivalents of the desired substituting 
nucleophile.24 
 The cytidine fragment of the phosphodiester mimic was selectively protected at 
the 2́ and 3ʹ  alcohol positions on the rib ose ring and the N5 exocyclic amine on 
cytosine moiety with base labile benzoate esters following the procedures of Cohen et 
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al.23 The first step is to selectively protect the 5ʹ alcohol as the tert-butyldiphenylsilyl 
(TBDPS) ether (Scheme 2.2).23 The 2ʹ and 3 ʹ  secondary alcohols and the N5 exocyclic 
amine were then protected as  benzoate esters to give the fully protected cytidine 3 in 
80%.23 The silyl ether 3 was then treated with 1.1 equivalents of tetrabutylammonium 
fluoride (TBAF) to selectively deprotect the 5’ alcohol and give the tribenzoyl cytidine 
4.23 
 
Scheme 2.2: Synthesis of tribenzoyl cytidine 4 
   
 
Scheme 2.3: Synthesis of diol 6 
 The phosphite 2 and tribenzoyl cytidine 4 were then linked via 5-(ethylthiol)-1H-
tetrazole activation and displacement of the diisopropyl group of the phosphoramidite on 
2 followed by in situ oxidation using (1S)-(+)-(10-camphorsulfonyl)oxaziridine  (CSO) to 
yield the phosphodiester 5 in 94% (Scheme 2.3).23-25 Phosphodiester 5 was then treated 
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with 80% acetic acid, which selectively deprotected the PMB acetal on the 1,3 diol on the 
panthenol fragment to yield diol 6.21, 22 
   
 
Scheme 2.4: Synthesis of phosphodiester mimics 8 & 10 
 The final phosphorylation of the primary alcohol of the 1,3 diol proved to be more 
synthetically challenging than initially anticipated. Initial strategies utilized P(V) 
chemistry to install a phosphate protected with ethyl, benzyl, and allyl groups. In all cases 
phosphorylation of the 4’ hydroxyl of the panthenol portion was accomplished in low to 
moderate yields. Deprotection of the phosphate esters proved to be problematic leading 
either to decomposition of the molecule due to harsh reaction conditions or ineffective 
deprotection of the terminal phosphate. Finally, a strategy utilizing P(III) 
phosphoramidate chemistry with β-cyanoethyl protecting groups on the phosphate was 
employed (Scheme 2.4). Initially, Diol 6 was phosphitylated using 5-(ethylthiol)-1H-
tetrazole as the activator at room temperature and oxidized in situ using CSO.23, 25 
However, in the presence of the 1,3 diol, these conditions actually yielded the protected 
cyclic phosphodiester 9. While not the desired product, the protected phosphate 9 was 
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taken forward due to its interesting cyclic phosphate on the panthenol portion in order to 
conduct an initial SAR study. The protected phosphate 9 was deprotected over two steps. 
First, the β-cyanoethyl phosphate ester was removed in the presence of DBU and 
TMSCl.26 The β-cyanoethyl protecting groups were chosen because deprotection is 
accomplished under mild conditions using DBU to deprotonate the β hydrogen and 
eliminate acrylonitrile and expose the negative charge on the phosphate. The TMSCl 
temporarily protects the negative charge on the phosphate and allows for complete 
deprotection. Next, the benzoate esters and the allyl group on the internal phosphate 
linkage were removed upon treatment with NH4OH and β-mercaptoethanol (allyl 
scavenger) at 55°C for 1 hour.27 The cyclic phosphate mimic 10 was purified by anion 
exchange column chromatography, followed by salt removal using gel filtration 
chromatography (BioGel P2) to yield the disodium salt in 80% yield. 
 In order to give the desired terminal phosphate mimic, alternative phosphitylating 
procedures were explored. Initial attempts to conduct the phosphitylation at temperatures 
below -40°C yielded unreacted diol 6. Next, 6 was phosphitylated at -20°C, using O,O-
bis β-cyanoethyl-N,N-diisopropyl phosphoramidite and pyridinium HCl as the activator, 
for 1 hour followed by in situ oxidation to yield the protected phosphate in 60%.28 These 
conditions were chosen to suppress the unwanted cyclization based upon the hypothesis 
that the less acidic activator (pyridinium HCl), lower temperature, and shorter reaction 
time would not allow formation of the thermodynamically more stable six membered 
phosphorous containing ring before the reaction was quenched by in situ oxidation of the 
phosphite to the less reactive phosphate. Phosphate 7 was globally deprotected in the 
aforementioned two step sequence used to deprotect 9, and the resulting phosphodiester 8 
was purified via anion exchange chromatography and desalted by gel filtration 
chromatography to give the trisodium salt in an overall yield of 19%.23  
 The proposed sulfamate mimic was synthesized using a similar convergent 
synthetic strategy. The first step involves the protonation of the calcium salt of 
pantothenate followed by the selective protection of the 1,3 diol to give PMB acetal 12 
(Scheme 2.5).19, 20  In order to facilitate the coupling of the two fragments of the 
sulfamate mimic, the carboxylic acid of PMB acetal 12 was activated as the NHS ester 




Scheme 2.5: Synthesis of NHS ester 13 
 The sulfamoyl moiety of the molecule was generated by treating tribenzoyl 
cytidine 4 with freshly prepared sulfamoyl chloride in N,N-dimethylacetamide (DMA) to 
yield sulfamoyl tribenzoyl cytidine 11 (Scheme 2.6).15, 30, 31 The internal sulfamate 
linkage between the cytidine and pantothenate portions of the molecule was installed by 
combining activated NHS ester 13 and sulfamoyl tribenzoyl cytidine 11 in the presence 
of Cs2CO3 to yield acetal 14 in 58%.15 PMB acetal 14 was selectively deprotected using 
80% acetic acid to yield the desired diol 15.21, 22 
 
 
Scheme 2.6: Synthesis of Diol 15 
 The final stages of the synthesis of the sulfamate mimic involved selective 
phosphitylation of the primary alcohol of the 1,3 diol at -20°C using pyridinium HCl as 
the activator and in situ oxidation to the phosphate 16 (Scheme 2.7). Global deprotection 
was accomplished over two steps using DBU and TMSCl followed by NH4OH at 55°C 
for 1 hour to afford the sulfamate mimic 17 after purification using anion exchange and 
size exclusion chromatography. Alternatively, diol 15 was phosphitylated at room 
temperature using 5-(ethylthiol)-1H-tetrazole as the activating agent and in situ oxidation 
to the cyclic phosphate 18. The protected cyclic phosphate 18 was deprotected over two 
steps using DBU and TMSCl followed by NH4OH at 55°C for 1 hour and purification via 
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anion exchange and size exclusion chromatography to yield the desired sulfamate mimic 
19 with the cyclic phosphate in 86%. 
 
 
Scheme 2.7: Synthesis of sulfamate mimics 
 
Biochemical Evaluation of Intermediate Mimics  
 The initial biochemical studies carried out with intermediate mimics 8, 10, 17 and 
19 were to obtain the IC50 values against PPCS from human (Type II), E. coli (Type I), S. 
pneumonia (Type III), and E. faecalis (Type III). PPCS activity was monitored using the 
commercially available pyrophosphate reagent (Figure 2.4). The pyrophosphate reagent 
is a coupled assay, which actually monitors the pyrophosphate liberated during the 
activation of PPA by CTP during the first half reaction of PPCS. The assay couples four 
enzymes from the glycolysis pathway and results in the oxidation of two molecules of 
NADH to NAD+ for every PPi generated. The oxidation of NADH is monitored by the 
disappearance of the UV absorbance at 340 nm. The pyrophosphate reagent is 
advantageous due to the fact it is a continuous assay. The continuous monitoring of PPCS 
activity over time is more efficient for data collection over the time course of the 
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enzymatic reaction than an end point assay, and is amenable to a 96 well or 384 well 
format giving the assay the capacity to be used in a high throughput fashion.   
 
Figure 2.4: The pyrophosphate reagent coupled assay system 
 However, due to the fact the pyrophosphate reagent is coupled to four enzymes in 
order to elicit the signal actually being monitored, several controls had to be run. The first 
control was to ensure that any and all enzymes in the pyrophosphate reagent were faster 
than PPCS itself and thus the signal measured at 340 nm would be a measure of PPCS 
activity and not a measure of an enzyme in the pyrophosphate reagent. This control was 
run by varying the concentration of PPCS and verifying the linearity of the PPCS velocity 
versus concentration (data not shown). The second control was to ensure that the 
intermediate mimics were inhibiting PPCS and not simply inhibiting one of the coupled 
enzymes of the pyrophosphate reagent. This control was run by adding known 
concentrations of pyrophosphate into the assay after PPCS activity had been inhibited by 
phosphodiester 8. In this case, the varying concentrations of pyrophosphate produced a 
nearly instantaneous disappearance of signal at 340 nm thus proving that the reporter 
enzymes were not inhibited by the intermediate mimic 8 (data not shown). 
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 IC50 values were generated by pre-incubating PPCS with varying concentrations 
of the desired inhibitor and initiating the enzyme reaction upon the addition of a fixed 
concentration of CTP (0.6 mM), PPA (0.6 mM), and cysteine (1 mM). All assays were 
run in triplicate monitoring the first 10% of PPCS activity (initial rates). The inhibition 
data was plotted as percent activity of PPCS versus inhibitor concentration with a 
representative graph in Figure 2.5 and all graphs contained in the Appendix to Chapter 
2. Then the IC50 values were determined using the equation: 
                      (1) 
and solving for IC50. 
 
Figure 2.5: Representative IC50 curve 
 The phosphodiester mimic 8, which most closely mimics the activated 
intermediate, was the most potent inhibitor with an IC50 ranging from 10-68 nM across 
the bacterial PPCSs (Types I & III) (Table 2.1). Phosphodiester 8 was able to achieve a 
150 fold selectivity E. coli and E. faecalis (Types I & III) and a 1000 fold selectivity for 
S. pneumoniae (Type III) over human (Type II). Cyclic phosphodiester 10 was less potent 
across all types of PPCS as compared to phosphodiester 8 displaying IC50s ranging from 
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3-18 µM. The cyclic inhibitor 10 displayed its most potent IC50 against ecPPCS (Type I) 
and was 4-6 fold less potent against Type III PPCSs. Despite being less potent against all 
PPCSs, the cyclic phosphate 10 maintained its selectivity for types I and III over Type II, 
PPCS with its most potent IC50 of 3 µM against E. coli and a 3 mM IC50 against human 
PPCS (Type II) and thus 1000 fold selectivity.  
 
Table 2.1: IC50 values of intermediate mimics. Standard error shown in parentheses. 
 The sulfamate mimics 17 and 19 displayed a similar pattern in their IC50s relative 
to their phosphodiester analogs 8 and 10. The non-cyclic phosphate mimic 17 was the 
more potent of the sulfamate inhibitors with an IC50 of 270 nM against E. coli (Type I) 
and 10-14 fold less potent against Type III PPCSs. Furthermore, inhibitor 17 displayed 
5o-740 fold selectivity as compared to human (Type II) PPCS. The cyclic phosphate 
mimic 19 displayed IC50 values analogous to the phosphodiester mimic 10 being the least 
potent inhibitor across all PPCSs with IC50s ranging from 16-280 µM for bacterial PPCSs 
and a 5.9 mM IC50 against human (Type II) PPCS. 
 Upon further investigation of the IC50 values, there are several trends between 
inhibitor structure and inhibition of PPCS type. E. coli (Type I) PPCS accommodates 
structural changes to both the internal linkage and terminal phosphate more readily than 
E. faecalis and S. pneumoniae (Type III) PPCS, with inhibitors 10, 17, and 19 all 
showing their most potent IC50 against E. coli PPCS and a 4-17 fold drop in potency 
against Type III PPCSs.  The terminal phosphate on the panthenol portion of the inhibitor 
is more important in binding as compared to the internal linker and/or its binding contacts 
are less accommodating to structural change.  This trend was evidenced by sulfamate 
inhibitor 17 displaying IC50 values 3-15 fold more potent across all PPCSs (Types I-III) 
than the cyclic phosphodiester 10. 
 The IC50 values of inhibitor 8 were on the same order of magnitude with the 
PPCS concentration, which by definition meant that inhibitor 8 was a tight-binding 
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inhibitor. Care must be taken when determining the Ki for a tight binding inhibitor 
because the assumption that concentration of free inhibitor is approximately equal the 
total concentration of total inhibitor is no longer valid. In order to determine the 
mechanism and obtain the inhibition constant of inhibitor 8, we chose to use efPPCS 
based upon the recent full steady state kinetic characterization.12 
 
Figure 2.6: Inhibition curves for phosphodiester 8 
Using the aforementioned pyrophosphate reagent assay as the monitoring system for 
PPCS activity, varying amounts of phosphodiester 8 were added to PPCS without pre-
incubation, in the presence of fixed concentrations of CTP, PPA, and cysteine. Plotting 
reaction progress versus time for the varying concentrations of inhibitor 8, the slow-onset 
binding mode can be seen from the time-dependent decrease in PPCS reaction rate 
(Figure 2.6).  
 Since phosphodiester 8 shows slow-onset, tight binding inhibition, we chose to 
use the method of Morrison et al. to determine the mode of binding. In slow-onset 
inhibition there are generally three modes of binding: simple reversible slow binding, 




Figure 2.7: Slow-onset binding modes. a) simple reversible b) enzyme isomerization c) 
mechanism-based inhibition 
 
The reaction progress curves from Figure 2.6 were fit to obtain the apparent first-order 
rate constant kobs, using the software KaleidaGraph (Synergy Software, Inc.) using 
equation 1, where P is the amount of pyrophosphate produced during a period of time t, νi 
and νs are the initial and equilibrium rates, [E] is the concentration of efPPCS in the 
assay, and [I] is the concentration of inhibitor in the assay. 
      (2) 
where 
                                                 (3) 
The obtained kobs were then plotted against inhibitor concentration to investigate the 
kinetic mechanism of inhibition (Figure 2.8). The linear relationship of the data in 
Figure 2.8 proved that inhibitor 8 was a single-step inhibition mechanism with a slow 
association and disassociation step and that there was no isomerization step of PPCS 
upon binding of compound 8. This result was unexpected as most slow-onset inhibitors 
have an isomerization step; however, based upon the linear fit in Figure 2.8, 
phosphodiester 8 is in the smaller subset of slow-onset inhibitors that are simply 
reversible inhibitors.  
 Beyond proving the binding mode of phosphodiester 8, Figure 2.8 can be used to 
solve for the Ki. Based upon the equation: 
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                                                              (4) 
k3app and k4 can be interpolated from the slope of the line and the y-intercept in Figure 
2.8, respectively, giving a k3app = 1.42 x 104 M-1s-1, and a k4 = 7.02 x 10-4s-1.  Kiapp for 
compound 8 was solved using equation 5 and was found to be 49 nM. Since 
phosphodiester 8 is a noncompetitive inhibitor (data not shown), Kiapp was converted to Ki 
via equation 6 (α = 2.9).32 After rearranging equation 6, phosphodiester 8 was shown to 
have Ki  = 24 nM.  
 
Figure 2.8:  kobs versus concentration of compound 8 
                                                                     (5) 
 
                                                                         (6)            
 
Conclusion  
 The phosphodiester mimics 8 and 10 and sulfamate mimics 17 and 19 represent 
the first selective bacterial inhibitors of PPCS. The most potent inhibitor 8 displayed low 
nM IC50 values ranging from 10-68 nM for both Types I and III bacterial PPCSs and 140-
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1000 fold selectivity compared to human PPCS (Type II). Further characterization of 
inhibitor 8 established it as a slow-onset, tight binding inhibitor with a simple one step 
mode of inhibition and a Ki of 24 nM against efPPCS. This set of four inhibitors has 
given us a foundation for inhibiting bacterial PPCS and the structural changes to the 
inhibitor in the linker and terminal phosphate regions that are allowed by the various 
types of PPCS. It has been established that changes to the linker region are tolerated 4-17 
fold more than perturbing the terminal phosphate. Also, E. coli (Type I) PPCS showed 
the greatest tolerance for structural change to the inhibitor with the best IC50 values for 
inhibitors 10, 17, and 19. 
 Despite these molecules’ effectiveness against isolated PPCS in the in vitro assay, 
they displayed no effect against E. coli in a zone of inhibition assay (data not shown). 
This lack of effect was not surprising and is most likely a consequence of the 
physiochemical properties of the molecules preventing cellular entry with all of the 
molecules having at least one negative charge and most possessing multiple negative 
charges. These molecules, however, are an important first step in exploring PPCS as an 
antibacterial target and will be used in future structural studies to gather more detailed 
information on binding contacts necessary for potency and selectivity against bacterial 
PPCSs. The information gleaned from these studies will be used to aid in the design of 
the second generation inhibitors into more drug-like molecules with maximized potency 
and selectivity.  
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Materials & Methods 
General Methods: All chemicals were used as purchased from Acros, Fisher, Fluka, 
Sigma-Aldrich, or Specialty Chemicals Ltd. and used without further purification unless 
otherwise noted. 1H NMR, 13C NMR, and 31P NMR spectra were recorded on a Bruker 
Avance DRX 500MHz spectrometer or Bruker Avance DPX 300MHz spectrometer. 
Proton assignments are reported in ppm from an internal standard of TMS (0.0ppm), and 
phosphorous assignments are reported relative to an external standard of 85% H3PO4 
(0.0ppm). Proton chemical data are reported as follows: chemical shift, multiplicity (ovlp 
= overlapping, s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, m = multiplet, 
br = broad), coupling constant in Hz, and integration. All high resolution mass spectra 
were acquired from the Mass Spectrometry facility in the Chemistry Department at The 
University of Michigan using either positive-ion or negative-ion mode ESI-MS. Thin 
layer chromatography was performed using Analtech GHLF 250 micron silica gel TLC 
plates. All flash chromatography was performed using grade 60 Å 230-400 mesh silica 
purchased from Fisher. 
 
(4R)-N-(3-hydroxypropyl)-2-(4-methoxyphenyl)-5,5-dimethyl-1,3-dioxane-4-
carboxamide (1) D-panthenol (1.0 g, 5 mmol) was rendered anhydrous by evaporation 
from ethanol stock (5 mL) followed by evaporation from toluene (2 x 5 mL) and 
dissolved in anhydrous DMF (20 mL). Camphor sulfonic acid (CSA) (0.0116 g, 0.05 
mmol) was added and stirred at room temperature for 15 min. p-Methoxybenzaldehyde 
dimethyl acetal (2.55 mL, 15 mmol) was added and the reaction was stirred at room 
temperature for 24 h. The solvents were removed in vacuo and then the resulting syrup 
was purified over silica (100 mL) eluting with 10% EtOAc in hexanes (300 mL), 25% 
EtOAc in hexanes (300 mL), and 50% EtOAc in hexanes yielding a white crystalline 
solid (1.4 g, 86%). Mixture of diastereomers (55%/45%), 1H NMR (DMSO-d6 major 
diastereomer): δ 7.55 (s, 1H), 7.44 (d, J = 7.05 Hz, 2H), 6.93 (d, J = 7.15 Hz, 2H), 5.50 
(s, 1H), 4.52 (t, J = 4.55 Hz, 1H), 4.08 (s, 1H), 3.75 (s, 3H), 3.61 (q, J = 9.74 Hz, 2H), 
3.41 (d, J = 5.40 Hz, 2H), 3.28-3.06 (m, 2H), 1.56 (t, J = 5.75 Hz, 2H), 0.98 (s, 3H), 0.96 
(s, 3H). 13C NMR (DMSO-d6): δ 168.63, 160.01, 130.98, 128.24, 113.79, 100.88, 83.76, 
34 
 
77.87, 59.39, 55.59, 36.34, 32.99, 32.62, 22.05, 19.59. HR-ESI-MS: calcd for [M+Na]+, 
346.1625; found 346.1622. 
Allyl 3-((4R)-2-(4-methoxyphenyl)-5,5-dimethyl-1,3-dioxane-4-carboxamido)propyl 
diisopropyl-phosphoramidite (2) The protected alcohol 1 (3.1 g, 9.59 mmol) and 5- 
(ethylthiol)-1H-tetrazole (0.836 g, 6.42 mmol) were dissolved in anhydrous DCM. Allyl- 
N,N,N,N-tetraisopropylphosphoramidite (5.2 mL, 16.3 mmol) was added dropwise to the 
solution over a period of 5 minutes. The reaction was allowed to stir at room temperature 
for 6 hours, at which time solvents were removed in vacuo. The syrup was then purified 
over silica (150 mL) eluting with 30% EtOAc in hexanes (450 mL), 50% EtOAc in 
hexanes (450 mL), and 100% EtOAc (450 mL). Product eluted in 30% EtOAc and was 
obtained as colorless oil (3.2 g, 65%). 1H NMR (DMSO-d6): δ 7.47-7.42 (ovlp, d,t, 3H), 
6.93 (d, J = 8.75 Hz, 2H), 5.91-5.78 (m, 2H), 5.53 (s, 1H), 5.26 (d, J = 17.15 Hz, 1H), 
5.10 (d, J = 10.20 Hz, 1H), 4.09 (s, 3H), 3.67-3.61 (m, 2H), 3.55-3.47 (m, 4H), 3.27-3.25 
(m, 2H), 3.15-3.12 (m, 2H), 1.70 (t, J = 6.65 Hz, 2H), 1.19 (s, 6H), 1.10 (s, 6H), 1.03 (s, 
3H), 0.95 (s, 3H). 13C NMR (DMSO-d6): δ 168.76, 160.00, 134.39, 130.95, 128.31, 
116.85, 113.73, 100.97, 83.84, 77.88, 63.55, 55.58, 46.53, 45.73, 35.27, 32.98, 30.52, 
22.75, 22.02, 19.60. 31P NMR (DMSO-d6): δ  145.82 (s, 1P). HR-ESI-MS: calcd for 
[M+Na]+, 533.2751; found 533.2764. 
2’-3’-O,N4-Tribenzoyl-5’-O-tert-butyldiphenylsilyl cytidine (3)23 Cytidine (6.0 g, 25 
mmol, 1.0 equiv) and imidazole (4.2 g, 63 mmol) were dissolved in DMF (45 mL). tert-
Butyldiphenylsilyl chloride (7.0 mL, 27 mmol) was added dropwise over 10 min. The 
reaction was stirred at room temperature for 1 h and then quenched by addition of 
methanol (10 mL). The solvents were removed in vacuo and the resulting syrup was 
partitioned between H2O and DCM. The aqueous layer was further washed with DCM 
(2x) and then the organic extracts were combined and upon standing the product 
crystallized out within 10 min. The crystals were dried under vacuum and then dissolved 
in pyridine (40 mL). Benzoic anhydride (56 g, 250 mmol, 10 equiv) was added and the 
reaction was stirred at room temperature for 2 days. The reaction was quenched with H2O 
(20 mL). The solvents were removed in vacuo and the resulting syrup was partitioned 
between water and DCM. The aqueous layer was furthered extracted with DCM (2x), and 
the combined organic extracts were washed with 5% aqueous HCl, saturated aqueous 
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sodium bicarbonate, and brine solution. The organic layer was then dried over Na2SO4 
and then the solvent was removed in vacuo and the product was purified over silica (300 
mL) eluting with 10% EtOAc in hexanes (900 mL), 25% EtOAc in hexanes (900 mL), 
and 50% EtOAc in hexanes (900 mL). The product was obtained as a white solid (15.4 g, 
76%). 1H NMR (DMSO-d6): δ 11.38 (s, 1H), 8.31 (d, J = 6.85 Hz, 1H), 8.02 (d, J = 7.55 
Hz, 2H), 7.87-7.80 (m, 3H), 7.68-7.60 (m, 7H), 7.54-7.30 (m, 14H), 6.28 (d, J = 2.30 Hz, 
1H), 5.93-5.90 (m, 2H), 4.61 (q, J = 4.52 Hz, 1H), 4.11 (dd, J = 3.25, 11.70 Hz, 1H), 3.97 
(dd, J = 4.10, 11.55 Hz, 1H), 1.01 (s, 9H). 13C NMR (DMSO-d6): δ 168.05, 165.07, 
165.02, 164.09, 154.62, 146.22, 135.59, 135.52, 134.41, 134.34, 133.55, 133.31, 132.88, 
132.58, 130.54, 129.84, 129.77, 129.24, 129.00, 128.93, 128.50, 128.41, 97.18, 90.56, 
82.28, 74.67, 70.82, 63.54, 27.07, 19.23. HR-ESI-MS: calcd for [M+Na]+, 816.2712; 
found 816.2740. 
2’-3’-O,N4-Tribenzoyl cytidine (4)23 The protected cytidine derivative 3 (15.5 g, 19.5 
mmol) was dissolved in THF (30 mL). Acetic acid (1.7 mL, 29 mmol) was added 
followed by tetrabutylammonium fluoride solution (1.0 M, 59 mL, 59 mmol). The 
reaction was stirred at room temperature for 1 h and then the solvents were removed in 
vacuo. The resulting syrup was partitioned between saturated aqueous sodium 
bicarbonate and DCM, and the aqueous layer was further extracted using DCM (2x). The 
combined organic extracts were washed with a brine solution, and dried over Na2SO4. 
The product was purified over silica (150 mL) eluting with 50% EtOAc in hexanes (450 
mL), 75% EtOAc in hexanes (450 mL), and 100% EtOAc (450 mL) with the product 
obtained in 100% EtOAc as a white solid (9.9 g, 90%). 1H NMR (DMSO-d6): δ 11.31(1s, 
1H), 8.52 (d, J = 7.00 Hz, 1H), 8.02 (d, J = 7.25 Hz, 2H), 7.93 (d, J = 8.05 Hz, 2H), 7.83 
(d, J = 7.15, 2H), 7.68-7.58 (m, 3H), 7.53-7.39 (m, 7H), 6.38 (d, J = 4.95 Hz, 1H), 5.85 
(t, J = 5.31 Hz, 1H), 5.79 (t, J = 5.64 Hz, 1H), 5.50 (t, J = 5.11 Hz, 1H), 4.53 (q, J = 3.65 
Hz, 1H), 3.88 (m, 1H), 3.81 (m, 1H). 13C NMR (DMSO-d6): δ 167.33, 164.68, 164.43, 
163.54, 154.46, 145.65, 133.82, 133.78, 133.00, 132.74, 129.24, 129.23, 128.76, 128.67, 
128.45, 128.39, 96.82, 88.38, 83.15, 74.39, 71.44, 60.47. HR-ESI-MS: calcd for 






oxopyrimidin-1(2H)-yl)tetrahydro furan-3,4-diyl dibenzoate (5) The tribenzoyl 
cytidine 4 (858 mg, 1.45 mmol) and the p- methoxybenzylidene panthenol 
phosphoramidite 2 (1.26 g, 2.47 mmol) were dissolved in toluene (2 x 5 mL) and 
evaporated, then dissolved in anhydrous acetonitrile (10 mL) along with 3 Å molecular 
sieves (0.5 g). Concurrently, in a separate flask 5-ethylthiol-1H-tetrazole (566 mg, 4.35 
mmol) was dissolved in anhydrous acetonitrile (3 mL) and both flasks were stirred at 
room temperature for 1 hour. The content of the tetrazole and acetonitrile mixture (~ 3.5 
mL) was then added dropwise over 10 minutes to the first flask and the reaction was 
stirred at room temperature for 4 hours. The phosphite was then oxidized in situ upon the 
addition of (1R)-(-)-(8,8-dichloro-10-camphor-sulfonyl) oxaziridine (CSO) (736 mg, 2.47 
mmol) in ethyl acetate (3 mL) dropwise over 5 minutes and then allowed to stir for 2 
hours. The reaction was quenched upon the addition of dimethyl sulfide (0.2 mL), the 
reaction was filtered, and then solvents were removed in vacuo. The reaction was purified 
over silica (50 mL) eluting with 25% EtOAc in hexanes (150 mL), 50% EtOAc in 
hexanes (150 mL), 75% EtOAc in hexanes (150 mL) with the product eluting as white 
crystalline solid (1.43 g, 94%). 1H NMR (DMSO-d6): δ 11.41 (s, 1H), 8.31 (d, J = 7.12, 
1H), 8.03 (d, J = 7.25 Hz, 2H), 7.93 (d, J = 7.55, 2H), 7.87 (d, J = 7.45 Hz, 2H), 7.67-
7.64 (m, 4H), 7.55-7.38 (m, 9H), 6.91 (d, J = 7.60, Hz, 2H), 6.25 (s, 1H), 5.93 (s, 3H), 
5.82 (t, J = 6.08 Hz, 1H), 5.50 (s, 1H), 5.36-5.31 (m, 1H), 5.20 (t, J = 9.45 Hz, 1H), 4.69 
(s, 1H), 4.35 (s, 3H), 4.50-4.42 (m, 1H), 4.40-4.35 (m, 1H), 3.75 (s, 3H), 3.64-3.58 (m, 
2H), 1.80-1.72 (m, 2H), 1.01 (s, 3H), 0.92 (s, 3H). 13C NMR (DMSO-d6): δ 168.82, 
167.88, 165.02, 164.36, 160.02, 154.78, 147.35, 134.42, 134.35, 133.40, 133.35, 130.99, 
130.93, 129.81, 129.22, 129.00, 128.93, 128.23, 118.37, 113.74, 100.97, 97.28, 91.45, 
83.83, 80.63, 77.91, 74.17, 70.95, 68.19, 66.65, 66.17, 55.57, 35.17, 32.96, 30.46, 21.99, 
19.57. 31P NMR (DMSO-d6): δ -0.96 (s, 1P). HR-ESI-MS: calcd for [M+Na]+, 







oxopyrimidin-1(2H)-yl)tetrahydrofuran-3,4-diyl dibenzoate (6) The acetal 5 (710 mg, 
0.72 mmol) was dissolved in 80% acetic acid (8 mL) and was stirred at room temperature 
for 20 hours. The solvents were removed in vacuo and the syrup was partitioned between 
DCM and H2O. The H2O layer was washed with DCM (2 x 20 mL) and then the organic 
extracts were dried (Na2SO4) and evaporated in vacuo. The syrup was purified over silica 
(50 mL) eluting with 50% EtOAc in hexanes (150 mL), 75% EtOAc in hexanes (150 
mL), and 100% EtOAc with the product obtained as white crystalline solid (610 mg, 
95%). 1H NMR (DMSO-d6): δ 11.41 (s, 1H), 8.32 (d, J = 7.40 Hz, 1H), 8.03 (d, J = 7.41 
Hz, 2H), 7.94 (d, J = 7.11 Hz, 2H), 7.94 (d, J = 7.12 Hz, 2H), 7.86 (d, J = 7.15 Hz, 2H), 
7.55-7.44 (m, 9H), 6.25 (s, 1H), 5.96-5.90 (m, 2H), 5.83 (t, J = 6.35 Hz, 1H), 5.38-5.33 
(m, 2H), 5.23-5.19 (m, 1H), 4.70 (s, 1H), 4.56-4.53 (m, 3H), 4.47-4.39 (ovlp, m, 2H) 
4.06-4.01 (m, 2H), 3.71 (d, J = 5.55 Hz, 1H), 3.20-3.11 (m, 4H), 1.80-1.74 (m, 2H), 0.80 
(s, 3H), 0.78 (s, 3H). 13C NMR (DMSO-d6): δ 173.56, 167.89, 165.09, 165.01, 164.39, 
154.81, 147.43, 134.42, 134.36, 133.38, 133.35, 129.82, 129.22, 129.00, 128.93, 128.28, 
118.39, 113.73, 97.25, 83.72, 80.67, 75.56, 74.17, 70.95. 68.49, 68.21, 66.67, 66.10, 
35.05, 30.51, 21.44, 20.80. 31P NMR (DMSO-d6): δ  -0.99 (s, 1P). HR-ESI-MS: calcd for 
[M+Na]+, 885.2719; found 885.2733.  
(2R,3R,4R,5R)-2-((((allyloxy)(3-((R)-4-((bis(2-cyanoethoxy)phosphoryl)oxy)-2-
hydroxy-3,3-dimethylbutanamido)propoxy)phosphoryl)oxy)methyl)-5-(4-
benzamido-2-oxopyrimidin-1(2H)-yl)tetrahydrofuran-3,4-diyl dibenzoate (7) The 
diol 6 (75 mg, 0.087 mmol), O,O-bis(cyanoethyl)-N-diisopropylamine phosphoramidite 
(36 mg, 0.131 mmol), and 3 Å molecular sieves were dissolved in anhydrous pyridine 
(0.5 mL) and cooled to -20°C. Pyridinium HCl (15 mg, 0.131 mmol) was dissolved in 
anhydrous pyridine (1 mL) and then added dropwise to the reaction mixture. The reaction 
was allowed to stir at -20°C for 2 h. At this point CSO (39 mg, 0.131 mmol) in DCM (1 
mL) was added to the reaction and allowed to stir for 1 h. Solvents were removed in 
vacuo and resulting syrup was purified over silica (5 mL) eluting with 50% EtOAc in 
hexanes (25 mL), 75% EtOAc in hexanes (25 mL), 100% EtOAc (25 mL), and 10% 
MeOH in EtOAc (25 mL) to yield 55.6 mg of white crystalline solid (61%). 1H NMR 
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(DMSO-d6): δ 11.40 (s, 1H), 8.31 (d, J = 7.90 Hz, 1H), 8.21-8.19 (m, 1H), 8.03 (d, J = 
7.45 Hz, 2H), 7.93 (d, J = 7.90 Hz, 2H), 7.87 (d, J = 7.50 Hz, 2H), 7.69-7.66 (m, 4H), 
7.55-7.44 (ovlp, m, 6H), 6.25 (s, 1H), 5.97-5.91 (m, 2H), 5.83 (t, J = 6.55, 1H), 5.77 (s, 
1H), 5.71 (d, J = 5.50 Hz, 1H), 5.35 (dd, J = 6.20, 15.90 Hz, 2H), 5.21 (t, J = 9.15 Hz, 
1H), 4.70 (br,s, 1H), 4.54 (s, 2H), 4.44-4.41 (m, 1H), 4.41-4.39 (m, 1H), 4.25-4.18 (m, 
4H), 3.95 (m, 1H), 3.85 (m, 1H), 3.75 (m, 1H), 3.70 (d, J = 5.6 Hz, 1H), 3.60 (t, J = 6.6 
Hz, 1H), 2.92 (t, J = 5.2 Hz, 4H),1.84-1.78 (m, 2H), 1.03 (s, 3H), 0.96 (s, 3H). 13C NMR 
(DMSO-d6): δ 173.12, 167.45, 164.64, 164.57, 163.94, 154.36, 147.02, 133.99, 133.93, 
132.98, 132.89, 129.38, 128.78, 128.57, 128.49, 127.84, 118.47, 117.95, 113.29, 96.83, 
91.22, 80.24, 80.14, 75.09, 73.72, 70.50, 68.03, 67.79, 66.24, 65.68, 60.40, 34.60, 30.08, 




hydroxy-2,2-dimethyl-4-oxobutyl phosphate (8) The protected phosphate 7 (56 mg, 
0.0537 mmol) was dissolved in anhydrous DCM (1 mL). DBU (0.077 mL, 0.429 mmol) 
and TMSCl (0.023 mL, 0.215 mmol) were added dropwise to the solution and allowed to 
stir at rt for 6h. Solvents were removed in vacuo, and then the resulting syrup was 
dissolved in NH4OH (2 mL). β-mercaptoethanol (0.1 mL) was added and the reaction 
was stirred at 55°C for 1 h. The reaction was then placed on a C-18 prep sep column and 
eluted with H2O. The UV active fractions (fractions 3-5) were collected and manually 
loaded onto a 15 mL AMGP anion exchange column. The anion exchange column was 
washed with H2O (30 mL) and then eluted with a 0-60% gradient of 1M NaCl. The 
fractions were monitored at 254 nm and the UV active fractions at 22% 1M NaCl were 
collected and lyophilized. The powder was then dissolved in H2O and purified over a 300 
mL sephadex size exclusion column. The UV active fractions (16-20) were collected and 
lyophilized to yield desired trisodium salt as a fluffy white solid (28.5 mg, 80.8%). 1H 
NMR (D2O-d2): δ 7.84 (d, J = 7.55 Hz, 1H), 6.00 (d, J = 7.65 Hz, 1H), 5.88 (d, J = 3.45 
Hz, 1H), 4.21-4.16 (m, 2H), 4.16 (s, 1H), 4.09 (d, J = 10.10 Hz, 1H), 4.00-3.07 (m, 1H), 
3.94 (s, 1H), 3.85-3.81 (m, 2H), 3.68 (dd, J = 5.32, 9.85 Hz, 1H), 3.40 (dd, J = 4.84, 9.92 
Hz, 1H), 3.23 (t, J = 6.70 Hz, 2H), 1.78 (t, J = 6.52 Hz, 2H), 0.87 (s, 3H), 0.76 (s, 3H). 
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13C NMR (D2O-d2): δ 174.84, 165.99, 157.23, 141.27, 96.35, 89.45, 82.39, 74.54, 74.11, 
70.83, 69.14, 64.07, 63.69, 38.23, 35.69, 29.49, 20.99, 18.25. 31P NMR (D2O-d2): δ 1.78 
(s, 1P), 0.35 (s, 1P). HR-ESI-MS: calcd for [M+H]+, 657.0922; found 657.0936.  
Allyl (((2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-3,4-
dihydroxytetrahydrofuran-2-yl)methyl) (3-((4R)-2-(2-cyanoethoxy)-5,5-dimethyl-2-
oxido-1,3,2-dioxaphosphinane-4-carboxamido)propyl) phosphate (9) The diol 6 (190 
mg, 0.22 mmol) and 5-(ethylthiol)-1H-tetrazole (86 mg, 0.66 mmol) along with 3 Å 
molecular sieves were dissolved in anhydrous CH3CN (5 mL). O,O-bis(cyanoethyl)-N-
diisopropylamine phosphoramidite (119 mg, 0.44 mmol) in anhydrous CH3CN (0.5 mL) 
was added dropwise and the reaction was stirred at rt for 4 h. CSO (131 mg, 0.44 mmol) 
in anhydrous CH3CN (3mL) was added dropwise and allowed to stir for 2 h. The solvents 
were removed in vacuo and the resulting syrup was purified over silica (5 mL) eluting 
with 50% EtOAc in hexanes (25 mL), 75% EtOAc in hexanes (25 mL), 100% EtOAc (25 
mL) to yield 135.6 mg of white crystalline solid (59%). 1H NMR (DMSO-d6): δ 11.41 (s, 
1H), 8.31 (d, J = 7.45 Hz, 1H), 8.21-8.19 (m, 1H), 8.03 (d, J = 7.60 Hz, 2H), 7.93 (d, J = 
7.45 Hz, 2H), 7.88 (d, J = 7.35 Hz, 2H), 7.69-7.64 (m, 4H), 7.54 (t, J = 7.72 Hz, 2H), 
7.47 (ovlp,d,t 6H), 6.26 (d, J = 2.53 Hz, 1H), 5.97-5.91 (m, 2H), 5.35 (dd, J = 5.05, 15.62 
Hz, 2H), 4.72-4.70 (m, 1H), 4.61 (s, 1H), 4.55 (br,s, 3H), 4.47-4.45 (m, 1H), 4.41-4.38 
(m, 1H), 4.18 (q, J = 5.27 Hz, 2H), 4.13 (d, J = 11.35, 1H), 43.95 (m, 1H), 3.85 (m, 1H), 
3.60 (t, J = 6.6 Hz, 1H), 2.97 (t, J = 5 Hz, 2H), 1.82-1.78 (m, 2H), 1.03 (s, 3H), 0.96 (s, 
3H). 13C NMR (DMSO-d6): δ 167.65, 165.83, 165.69, 164.65, 164.58, 163.83, 154.22, 
146.91, 133.99, 133.93, 133.08, 132.97, 132.89, 129.38, 128.78, 128.57, 128.49, 128.03, 
118.42, 117.95, 96.87, 91.16, 84.38, 80.20, 78.00, 73.73, 70.50, 68.06, 67.78, 66.25, 
65.59, 62.75, 61.78, 34.29, 29.78, 26.47, 19.98, 19.14, 19.03, 17.64, 15.02. 31P NMR 
(DMSO-d6): δ -1.01 (s, 1P), -9.44 (s, 1P). HR-ESI-MS: calcd for [M+Na]+, 1000.2542; 
found 1000.2576.  
Disodium ((2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-3,4-
dihydroxytetrahydrofuran-2-yl)methyl (3-((R)-5,5-dimethyl-2,2-dioxido-1,3,2-
dioxaphosphinane-4-carboxamido)propyl) phosphate (10) The protected phosphate 9 
(15 mg, 0.0155 mmol) was dissolved in anhydrous DCM (1 mL). DBU (0.02 mL, 0.115 
mmol) and TMSCl (0.006 mL, 0.057 mmol) were added dropwise to the solution and 
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allowed to stir at rt for 6h. Solvents were removed in vacuo, and then the resulting syrup 
was dissolved in NH4OH (2 mL). β-mercaptoethanol (0.1 mL) was added and the 
reaction was stirred at 55°C for 1 h. The reaction was then placed on a C-18 prep sep 
column and eluted with H2O. The UV active fractions (fractions 3-5) were collected and 
manually loaded onto a 15 mL AGMP1 anion exchange column. The anion exchange 
column was washed with H2O (30 mL) and then eluted with a 0-60% gradient of 1 M 
NaCl. The fractions were monitored at 254 nm and the UV active fractions at 18% 1 M 
NaCl were collected and lyophilized. The powder was then dissolved in H2O and desalted 
over a 300 mL sephadex size exclusion column. The UV active fractions (15-19) were 
collected and lyophilized to yield desired disodium salt as a fluffy white solid (7.6 mg, 
81.1%). 1H NMR (D2O-d2): δ 7.82 (d, J = 7.10 Hz, 1H), 5.99 (d, J = 7.70 Hz, 1H), 5.88 
(s, 1H) 4.40 (s, 1H) 4.23-4.21 (m, 2H) 4.17-4.15 (m, 1H), 4.07 (d, J = 4.15 Hz, 1H) 3.99 
(d, J = 11.50 Hz, 2H), 3.82 (q, J = 6.05 Hz, 2H), 3.63 (dd, J = 11.10, 23.15 Hz, 1H), 3.23 
(dm, 2H), 1.75 (t, J = 6.20 Hz), 0.91 (s, 3H), 0.86 (s, 3H). 13C NMR (D2O-d2): δ 170.48, 
166.07, 157.62, 141.24, 96.34, 89.39, 82.49, 82.42, 76.38, 74.12, 69.144, 64.11, 63.58, 
35.73, 34.54, 29.51, 19.94, 17.38. 31P NMR (D2O-d2): δ -0.367 (s, 1P), -4.21 (s, 1P). HR-
ESI-MS: calcd for [M-H]-, 571.1206, found 571.1213. 
Sulfamoyl chloride30 Chlorosulfonyl isocyanate (1.2 mL, 14.1 mmol) was dissolved in 
anhydrous DCM (7 mL) and cooled to 0°C. 88% Formic acid (0.65 mL, 14.7 mmol) was 
added dropwise and stirred at 0°C for 15 min. The reaction was stirred at rt for 45 min 
and then heated to reflux for 45 min. The reaction mixture was then placed in the -20°C 
freezer overnight. The next day the mixture was cooled to -48°C and the sulfamoyl 
chloride crystallized out. The crystals were vacuumed filtered and washed with DCM to 
yield the desired product (1.6 g, 96%).  
2’-3’-O,N4-Tribenzoyl-5’-O-sulfamoyl cytidine (11)31 Tribenzoyl cytidine 4 (1.54 g, 2.7 
mmol) was dissolved in anhydrous DMA (5 mL). A solution of freshly made sulfamoyl 
chloride (940 mg, 8.11 mmol) dissolved in anhydrous DMA (2 mL) was added dropwise 
at 0°C. The ice bath was removed and the reaction was stirred at rt for 3 h. The reaction 
was quenched with H2O (1 mL) and the solvents were removed in vacuo. The resulting 
syrup was partitioned between EtOAc (250 mL) and brine (50 mL). The brine layer was 
washed with EtOAc (2 x 50 mL) and then the organic extracts were combined, dried 
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(Na2SO4), and concentrated in vacuo. The crude mixture was then purified over silica (50 
mL) eluting with 50% EtOAc in hexanes to yield the desired product as a white solid 
(1.32 g, 77%). 1H NMR (DMSO-d6): δ 11.41 (s, 1H), 8.29 (d, J = 7.50 Hz, 1H), 7.87 (d, J 
= 8.10 Hz, 2H) 8.03 (d, J = 8.00 Hz, 2H), 7.95 (d, J = 8.20 Hz, 2H), 7.75 (s, 2H), 7.70-
7.65 (m, 3H), 7.52-7.40 (m, ovlp, 7H), 6.27 (d, J = 3.65 Hz, 1H), 5.91 (t, J = 5.05 Hz, 
1H) 5.81 (t, J = 6.10 Hz, 1H), 4.77 (s, 1H), 4.50-4.44 (m, 1H), 4.43-4.41 (m, 1H). 13C 
NMR (DMSO-d6): δ 167.53, 164.57, 164.47, 163.70, 154.19, 146.54, 133.91, 133.87, 
133.00, 132.80, 129.30, 128.72, 128.70, 128.47, 128.41, 128.36, 96.93, 90.66, 79.46, 
73.64, 70.64, 67.88. HR-ESI-MS: calcd for [M-H]-, 635.1448, found 635.1445. 
2,5-Dioxopyrrolidin-1-yl-3-((4R)-2-(4-methoxyphenyl)-5,5-dimethyl-1,3-dioxane-4-
carboxamido)propanoate (13)29 Pantothenic acid hemicalcium salt (5 g, 20.98 mmol) 
was dissolved in anhydrous DMF (50 mL). Concentrated H2SO4 (0.65 mL, 20.98 mmol) 
was added dropwise and stirred for 30 min. p-Anisaldehyde dimethyl acetal (3.6 mL, 
20.98 mmol) and CSA (244 mg, 1.05 mmol) were added and the reaction was stirred for 
16 h. Solvents were removed in vacuo and the resulting syrup was portioned between 
EtOAc (500 mL) and H2O (50 mL). The organic layer was washed with H2O (2 x 50 
mL). The organic layer is then dried (Na2SO4) and evaporated. The resulting white solid 
is then washed with DCM to remove any remaining p-anisaldehyde dimethyl acetal to 
yield the desired product as a white crystalline product (5.1 g, 72%).  
The PMB protected pantothenic acid (750 mg, 2.10 mmol) and N-hydroxysuccinimide 
(242 mg, 2.10 mmol) were dissolved in anhydrous THF (5 mL). A solution of DCC (433 
mg, 2.10 mmol) in anhydrous THF (3 mL) was added dropwise and the reaction was 
stirred for 6h. The reaction mixture was then filtered over celite to remove the white 
precipitate. The white precipitate was then washed with EtOAc (10 mL). The organic 
filtrate was then concentrated in vacuo to yield the desired product as a glassy clear solid 
(885 mg, 93%). 1H NMR (DMSO-d6): δ 7.59 (s, 1H), 7.45 (d, J = 8.40 Hz, 2H), 6.94 (d, J 
= 8.80 Hz, 2H), 5.53 (s, 1H), 4.12 (s, 1H), 3.76 (s, 1H), 3.33 (s, 3H), 2.88 (t, J = 7.10 Hz, 
2H), 2.81 (s, 4H), 2.42-2.40 (m, ovlp, 2H), 1.00 (s, 3H), 0.96 (s, 3H). 13C NMR (DMSO-
d6): δ 170.59, 169.07, 167.84, 160.00, 130.95, 128.27, 113.80, 100.91, 83.63, 77.85, 
55.61, 34.30, 33.02, 30.94, 25.90, 21.97, 19.50. HR-ESI-MS: calcd for [M+Na]+, 




carboxamido)propanoyl) sulfamoyl)-2’,3’-O,N4-tribenzoylcytidine (14)15 NHS ester 
13 (442 mg, 0.97 mmol) was dissolved in anhydrous DMF (8 mL). Sulfamoyl cytidine 11 
(307 mg, 0.485 mmol) was added and the solution was cooled to 0°C. Cs2CO3 (316 mg, 
0.97 mmol) was added and stirred at 0°C for 30 min. The ice bath was removed and the 
reaction was stirred at rt for 16 h. The solvents were removed in vacuo and the resulting 
paste was taken up in EtOAc (50 mL) and filtered. The white precipitate was washed 
thoroughly with EtOAc (100 mL). The combined filtrate was purified over silica (25 mL) 
eluting with 75% EtOAc in hexanes (100 mL), 100% EtOAc (100 mL), and 10% MeOH 
in EtOAc (100 mL) to yield the desired product as a white solid (270 mg, 58%). 1H NMR 
(DMSO-d6): δ 11.33 (s, 1H), 8.02 (d, J = 7.20 Hz, 2H), 7.94 (d, J = 7.20 Hz, 2H), 7.83 (d, 
J = 7.10 Hz, 2H), 7.64 (t, J = 7.55 Hz, 3H), 7.55-7.41 (m, ovlp, 12H), 6.90 (d, J = 8.81 
Hz, 2H), 6.30 (d, J = 4.30 Hz, 1H), 5.83 (t, J = 5.15 Hz, 1H), 5.75 (t, J = 5.49 Hz, 1H), 
5.48 (s, 1H), 4.69 (m, 1H), 4.47-4.38 (m, 2H), 4.12-3.96 (m, ovlp, 1H), 4.05 (s, 1H), 3.73 
(s, 3H), 3.59 (d, J = 2.72 Hz, 1H), 3.29-3.26 (m, 2H), 2.39-2.84 (m, 2H), 0.98 (s, 3H), 
0.92 (s, 3H). 13C NMR (DMSO-d6): δ 167.92, 167.23, 164.49, 164.31, 163.63, 159.39, 
154.35, 146.33, 133.80, 133.76, 132.96, 132.68, 130.32, 129.23, 128.67, 128.63, 128.52, 
128.40, 128.33, 127.61, 113.21, 100.26, 96.83, 83.08, 80.00, 77.29, 73.94, 71.04, 54.96, 
34.48, 32.40, 21.43, 18.91. HR-ESI-MS: calcd for [M+H]+, 954.2863; found 954.2906.  
5’-O-(N-(3-((R)-2,4-Dihydroxy-3,3-dimethylbutanamido)propanoyl)sulfamoyl)-2’,3’-
O,N4-tribenzoylcytidine (15) The p-methoxy benzyl acetal 14 (92.5 mg, 0.097 mmol) 
was dissolved in 80% AcOH (5 mL) and stirred at rt for 12 h. Solvents were removed in 
vacuo and the resulting syrup was purified over silica (10 mL) eluting with 75% EtOAc 
in hexanes (25 mL), 100% EtOAc (25 mL), and 10% MeOH in EtOAc (25 mL) to yield 
the desired product as a white solid (65 mg, 80%). 1H NMR (DMSO-d6): δ 11.33 (s, 1H), 
8.50 (s, 1H), 8.02 (d, J = 7.53 Hz, 2H), 7.95 (d, J = 7.29 Hz, 2H), 7.83 (d, J = 7.65 Hz, 
2H), 7.67-7.61 (m, 5H), 7.55-7.41 (m, 8H), 6.32 (s, 1H), 5.84-5.82 (m, 1H), 5.75 (t, J = 
5.52 Hz, 1H), 5.35 (d, J = 5.61 Hz, 1H), 4.74-4.70 (m, 1H), 4.44-4.31 (m, 2H), 4.10 (d, J 
= 5.22 Hz, 1H), 3.67 (d, J = 5.52 Hz, 1H), 3.30-3.26 (m, 2H), 2.30-2.27 (m, 2H), 0.77 (s, 
3H), 0.75 (s, 3H). 13C NMR (DMSO-d6): δ 176.72, 173.03, 165.10, 164.84, 147.23, 
147.00, 134.39, 134.34, 133.62, 133.24, 129.82, 129.31, 129.22, 129.00, 128.92, 97.50, 
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88.70, 81.15, 75.50, 74.77, 72.05, 68.58, 66.71, 66.16, 39.27, 35.75, 21.27, 20.96. HR-
ESI-MS: calcd for [M+Na]+, 858.2263; found 858.2286. 
5’-O-(N-((((R)-Bis(2-cyanoethyl) 3-hydroxy-4-(3-oxopropylamino)-2,2-dimethyl-4-
oxobutyl) phosphoryl)oxy)sulfamoyl)-2’,3’-O,N4-tribenzoylcytidine (16) The diol 15 
(65 mg, 0.077 mmol), O,O-bis(cyanoethyl)-N-diisopropylamine phosphoramidite (32 mg, 
0.117 mmol), and 3 Å molecular sieves were dissolved in anhydrous pyridine (0.5 mL) 
and cooled to -20°C. Pyridinium HCl (13.5 mg, 0.117 mmol) was dissolved in anhydrous 
pyridine (1 mL) and then added dropwise to the reaction mixture. The reaction was 
allowed to stir at -20°C for 2 h. At this point CSO (35 mg, 0.117 mmol) in DCM (1 mL) 
was added to the reaction and allowed to stir for 1 h. Solvents were removed in vacuo and 
resulting syrup was purified over silica (5 mL) eluting with 50% EtOAc in hexanes (25 
mL), 75% EtOAc in hexanes (25 mL), 100% EtOAc (25 mL), and 10% MeOH in EtOAc 
(25 mL) to yield 38 mg of white solid (50%). 1H NMR (DMSO-d6): δ 11.34 (s, 1H), 8.46 
(s, 1H), 8.04 (d, J = 7.20 Hz, 2H), 7.96 (d, J = 7.17 Hz, 2H), 7.86 (d, J = 7.14 Hz, 2H), 
7.66 (t, J = 7.53 Hz, 3H), 7.57-7.43 (m, 8H), 6.34 (d, J = 6.30 Hz, 1H), 5.86-5.81 (m, 
1H), 5.79-5.70 (ovlp, m, 2H), 4.75 (s, 1H), 4.46-4.40 (m, 2H), 4.28-4.21 (m, 4H), 4.04 (q, 
J = 11.92, 1H), 3.94-3.92 (m, 1H), 3.88-3.86 (m, 1H), 3.29-3.26 (m, 2H), 2.95 (t, J = 8.74 
Hz, 4H), 2.28-2.23 (m, 2H), 0.89 (s, 3H), 0.85 (s, 3H). 13C NMR (DMSO-d6):  δ 176.42, 
174.02, 165.12, 161.98, 134.36, 133.25, 129.81, 129.21, 128.90, 103.80, 97.52, 75.49, 
74.65, 68.56, 62.89, 60.87, 30.65, 26.95, 23.87, 21.28, 20.91, 19.61. 31P NMR (DMSO-
d6): δ -2.13 (s, 1P). HR-ESI-MS: calcd for [M+Na]+, 1044.2458; found 1044.2482.  
5’-O-(N-((((R)-3-hydroxy-4-(3-oxopropylamino)-2,2-dimethyl-4-
oxobutyl)phosphoryl)oxy) sulfamoyl) cytidine disodium salt (17) The protected 
phosphate 16 (61 mg, 0.0597 mmol) was dissolved in anhydrous DCM (1 mL). DBU 
(0.086 mL, 0.478 mmol) and TMSCl (0.026 mL, 0.239 mmol) were added dropwise to 
the solution and allowed to stir at rt for 6h. Solvents were removed in vacuo, and then the 
resulting syrup was dissolved in NH4OH (2 mL). β-mercaptoethanol (0.1 mL) was added 
and the reaction was stirred at 55°C for 1 h. The reaction was then placed on a C-18 prep 
sep column and eluted with H2O. The UV active fractions (fractions 3-5) were collected 
and manually loaded onto a 15 mL AGMP1 anion exchange column. The anion exchange 
column was washed with H2O (30 mL) and then eluted with a 0-60% gradient of 1M 
44 
 
NaCl. The fractions were monitored at 254 nm and the UV active fractions at 58% 1M 
NaCl were collected and lyophilized. The powder was then dissolved in H2O and desalted 
over a 300 mL sephadex size exclusion column. The UV active fractions (15-20) were 
collected and lyophilized to yield desired trisodium salt as a fluffy white solid (36 mg, 
95%). 1H NMR (D2O-d2): δ 7.75 (d, J = 7.10 Hz, 1H), 5.99 (d, J = 7.70 Hz, 1H), 5.86 (s, 
1H), 4.31 (d, J = 9.60 Hz, 1H), 4.23-4.21 (m, 2H), 4.15 (s, 1H), 3.67-3.64 (m, 1H), 3.37 
(t, J = 6.80 Hz, 2H), 3.30 (dd, J = 4.00, 9.20 Hz, 1H), 2.38 (t, J = 6.58 Hz, 2H), 0.88 (s, 
3H), 0.72 (s, 3H). 13C NMR (D2O-d2): δ 180.70, 174.99, 166.14, 157.66, 141.25, 96.38, 
89.51, 81.35, 74.62, 73.99, 70.70, 69.22, 67.57, 38.38, 37.97, 35.70, 21.34, 17.96. 31P 
NMR (D2O-d2): δ 1.42 (s, 1P). HR-ESI-MS: calcd for [M+Na]+, 670.0779; found 
670.0780.  
5’-O-(N-(((R)-2-(2-cyanoethoxy)-5,5-dimethyl-N-(3-oxopropyl)-1,3,2-
dioxaphosphinane-4-carboxamide 2-oxy)sulfamoyl)-2’,3’-O,N4-tribenzoyl cytidine 
(18) The diol 15 (115 mg, 0.14 mmol) and 5-(ethylthiol)-1H-tetrazole (54 mg, 0.411 
mmol) along with 3 Å molecular sieves were dissolved in anhydrous CH3CN (5 mL). 
O,O-bis(cyanoethyl)-N-diisopropylamine phosphoramidite (75 mg, 0.275 mmol) in 
anhydrous CH3CN (0.5 mL) was added dropwise and the reaction was stirred at rt for 4 h. 
CSO (82 mg, 0.275 mmol) in anhydrous CH3CN (3mL) was added dropwise and allowed 
to stir for 2 h. The solvents were removed in vacuo and the resulting syrup was purified 
over silica (5 mL) eluting with 50% EtOAc in hexanes (25 mL), 75% EtOAc in hexanes 
(25 mL), 100% EtOAc (25 mL), and 10% MeOH in EtOAc (25 mL) to yield the desired 
product as a white solid (68 mg, 52%). 1H NMR (DMSO-d6): δ 11.34 (s, 1H), 8.55 (s, 
1H), 8.20 (s, 1H), 8.03 (d, J = 7.25 Hz, 2H), 7.96 (d, J = 7.15 Hz, 2H), 7.84 (d, J = 8.0 
Hz, 2H), 7.69 (t, J = 7.35 Hz, 2H), 7.65 (t, J = 7.35 Hz, 2H), 7.52 (q, J = 8.15 Hz, 4H), 
7.45 (t, J = 7.90 Hz, 3H), 6.35 (d, J = 4.50 Hz, 1H), 5.83 (t, J = 5.40 Hz, 1H) 5.76 
(ovlp,m, 2H), 4.73 (s, 1H), 4.51 (d, J = 7.75 Hz, 1H), 4.37-4.31 (m, 2H), 4.23-4.18 (m, 
2H), 3.88 (t, J = 4.65 Hz, 1H), 3.18 (m, 1H), 3.15 (q, J = 7.35 Hz, 1H), 2.94 (t, J = 
4.30Hz, 2H), 2.28-2.23 (m, 2H), 1.02 (s, 3H), 0.95 (s, 3H). 13C NMR (DMSO-d6):  
δ 186.17, 165.12, 164.88, 164.00, 154.90, 146.31, 134.35, 133.24, 129.80, 129.22, 
129.00, 128.92, 128.31, 119.28, 118.71, 95.78, 89.01, 82.35, 74.32, 73.23, 65.71, 63.22, 
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60.88, 26.91, 19.62, 15.50.31P NMR (DMSO-d6): δ -9.46 (s, 1P). HR-ESI-MS: calcd for 
[M+Na]+, 973.2087; found 973.2098.  
Sodium 5’-O-(N-(((R)-5,5-dimethyl-4-((3-oxopropyl)carbamoyl)-1,3,2-
dioxaphosphinan-2-olate 2-oxy)sulfamoyl) cytidine (19) The protected phosphate 18 
(38 mg, 0.0402 mmol) was dissolved in anhydrous DCM (1 mL). DBU (0.058 mL, 0.322 
mmol) and TMSCl (0.015 mL, 0.16 mmol) were added dropwise to the solution and 
allowed to stir at rt for 6h. Solvents were removed in vacuo, and then the resulting syrup 
was dissolved in NH4OH (2 mL). β-mercaptoethanol (0.1 mL) was added and the 
reaction was stirred at 55°C for 1 h. The reaction was then placed on a C-18 prep sep 
column and eluted with H2O. The UV active fractions (fractions 3-5) were collected and 
manually loaded onto a 15 mL AMGP anion exchange column. The anion exchange 
column was washed with H2O (30 mL) and then eluted with a 0-60% gradient of 1M 
NaCl. The fractions were monitored at 254 nm and the UV active fractions at 54% 1M 
NaCl were collected and lyophilized. The powder was then dissolved in H2O and 
purified over a 300 mL sephadex size exclusion column. The UV active fractions (15-20) 
were collected and lyophilized to yield desired trisodium salt as a fluffy white solid (21 
mg, 86%). 1H NMR (D2O-d2): δ 8.61 (s, 1H), 7.82 (d, J = 7.70 Hz, 1H), 6.03 (d, J = 7.70 
Hz, 1H), 5.85 (d, J = 3.35 Hz, 1H), 4.40 (s, 1H), 4.31 (d, J = 10.10 Hz, 1H), 4.23 (s, 2H), 
4.21-4.17 (m, 2H), 3.98 (d, J = 11.20 Hz, 1H), 3.62 (dd, J = 11.42, 22.83 Hz, 1H), 3.45-
3.35 (m, 2H), 2.40 (t, J = 6.70 Hz, 2H), 0.93 (s, 3H), 0.87 (s, 3H). 13C NMR (D2O-d2): δ 
180.55, 174.77, 166.12, 160.40, 141.23, 96.36, 89.54, 82.26, 81.30, 74.66, 73.92, 69.23, 
67.65, 39.23, 38.31, 37.94, 35.66, 21.44, 17.85. 31P NMR (D2O-d2): δ -4.26 (s, 1P). HR-
ESI-MS: calcd for [M-H]-, 606.0883; found 606.0901. 
Purification of E. faecalis PPCS: E. coli BL21 AI/pUMGD1 was used to express E. 
faecalis PPCS and the enzyme purified by previously published methods.12 
Purification of C-terminal Hexa-Histidine Tagged Human PPCS: E. coli BL21 
(DE3)/pUMJY120ho was used to express human PPCS and the enzyme purified by 
previously published methods.33  
Cloning, Overexpression, and Purification of E. coli PPCS: The coaB coding region 
of the dfp gene (encoding ser181-arg406 of the E. coli CoaBC protein)4, 34 was PCR 
amplified using E. coli MG1655 genomic DNA as a template, and the primers, 
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coabec1(forward primer), 5’ – CGCGCATA 
TGTCGCCCGTCAACGACCTGAAACATCTG-3’ and dfp3 (reverse primer), 5’-
GCGCCTCGAGACGTCGATTTTTTTCATCATAACGGG-3’. The forward primer 
introduces an NdeI site (shown underlined) to provide a start codon for the coaB coding 
region, and the reverse primer creates a XhoI site (shown underlined) downstream of the 
stop codon of the open reading frame. The PCR products were digested with NdeI and 
XhoI, and ligated into pET23a(+) (Novagen) cut with NdeI and XhoI. The resulting 
plasmid was designated pUMDOT3 and the insert was confirmed by DNA sequencing.  
E. coli BL21 AI (Invitrogen) harboring the plasmid pUMDOT3 were grown in 500 mL 
LB-ampicillin media (5 g of NaCl, 5 g of yeast extract, 10 g of tryptone, and 100 mg of 
ampicillin per L) at 37°C and 250 rpm to a OD600 of 0.6. The cells were then cooled by 
shaking at 16°C for 10-15 min, induced with 0.07% L-arabinose, and continued to grow 
at 16°C and 250 rpm for 12-16 hours. The cells were harvested at 6000 x g for 10 
minutes at 4°C, washed, and then suspended in 12 ml of 20 mM HEPES pH 8.0. Cells 
were lysed by French Press and crude cytosol obtained by centrifugation at 20,000 x g for 
25 minutes at 4°C.  
 ecPPCS was purified using a tandem anion exchange column (Source 15Q (GE 
Healthcare); 20 mL) and cation exchange column (Source 15S (GE Healthcare); 8 mL). 
The 12 mL of crude cytosol was loaded onto the tandem chromatography columns which 
had been pre-equilibrated with 20 mM HEPES pH 8.0. The columns were then washed 
with another 40 mL of equilibration buffer and the anion exchange column was removed. 
Under these conditions the ecPPCS does not bind to the anion exchange resin, but does 
bind to the cation exchange resin. The cation exchange column was eluted with a linear 
gradient of 0-0.4 M NaCl in 20 mM HEPES pH 8.0, with a total gradient volume of 100 
mL. ecPPCS eludes as a single peak at 75 mM NaCl and was greater than 98 % pure as 
determined by SDS-PAGE.  
Cloning, Overexpression, and Purification of the C-terminal Hexa-Histidine Tagged 
Streptococcus pneumoniae PPCS: The coaB gene was amplified from S. pneumonia 
TIGR4 genomic DNA via PCR, using the forward primer 
CATATGAAAATTTTAGTTACATC and reverse primer 
CTCGAGAGAATGATAGGCTTGAATTTTTTC to introduce a NdeI site before and 
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XhoI site after the gene. The PCR product from the amplification was digested with NdeI 
and XhoI, and then ligated into pET23a(+) (Novagen) also digested with NdeI and XhoI. 
The desired plasmid was designated pUMJY140h, and the sequence of the inserted coaB 
gene was confirmed by DNA sequencing. Since the reverse primer was designed to 
exclude the stop codon of the gene, the linker and hexa-histidine tag encoded by the 
pET23a(+) vector is expressed with the gene to generate the C-terminal hexa-histidine 
tagged PPCS.  
 E. coli strain BL21 AI, transformed with plasmid pUMJY140h, was incubated in 
four 1 L flasks containing 250 ml each of LB-ampicillin media at 37ºC and 250 rpm to an 
OD600 of 0.6-0.8. Then, the culture was cooled to 16ºC and induced with L-arabinose 
(0.065% w/v final concentration). Incubation at 16ºC and 250 rpm shaking was continued 
for 16 hours. Cells from 1 L of culture were harvested via centrifugation at 6,000 x g, 
washed with 20 mM HEPES pH 8.0, and resuspended in 60 ml of 20 mM HEPES pH 8.0. 
The harvested cells were lysed via French Press, and the lysed mixture was centrifuged at 
20,000 x g for 30 minutes to spin down the cellular debris as the pellet.  
 The resulting supernatant was shaken gently with Ni-NTA resin (4 mL per 1 L 
culture) in a solution of 10 mM imidazole and 20 mM HEPES pH 8.0 for 10 minutes. 
Then, the mixture was poured into a 20 mL column and the resin was collected in the 
column. The column was washed with 5 column volumes of 50 mM imidazole, 20 mM 
HEPES pH 8.0, followed by 5 column volumes of 50 mM imidazole, 500 mM NaCl, 20 
mM HEPES pH 8.0. The column was pre-equilibrated prior to elution by flowing through 
2 column volumes of 50 mM imidazole, 20 mM HEPES pH 8.0, and then eluted with a 
250 mM imidazole, 20 mM HEPES pH 8.0 solution. The elution was collected as 1 mL 
fractions, until proteins were no longer eluted. The fractions containing protein were 
collected, diluted 4 fold with 20 mM HEPES pH 8.0, and chromotographed on a Mono Q 
5/50 GL column pre-equilibrated with 20 mM HEPES pH 8.0 buffer. The column was 
eluted over a 10 column volume linear gradient of 0 – 0.5 M NaCl buffered with 20 mM 
HEPES pH 8.0. Approximately 30 mg of spPPCS was purified per liter of culture.  
PPCS inhibition assays: The PPCS reaction was observed in the forward reaction via an 
enzyme coupled assay.12, 33 The coupled assay measured production of pyrophosphate 
from PPCS activity via the oxidation of NADH, which could be monitored as a 
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disappearance of absorption at 340 nm. For each mole of pyrophosphate produced, two 
moles of NADH are oxidized. The commercially available Pyrophosphate Reagent (PR) 
from Sigma-Aldrich was used as the pyrophosphate detection system and each vial of the 
PR was initially suspended in 4.5 mL of 100 mM Tris-HCl pH 7.6. Assays were 
performed on a SpectraMax M5 (Molecular Devices) microplate reader using 96-well 
half-area plates (Costar UV), with a final assay volume of 100 µL. The pre-incubation 
mixture consisted of 30 µL PR, 20 µL PPCS (20-400 nM final assay concentration), and 
20 µL of varying concentrations of inhibitor in a total volume of 70 µL. These solutions 
were preincubated at 37°C for 15 minutes. The enzymatic reaction was initiated by 
addition of the substrates (also pre-incubated at 37°C for 15 minutes) to the assay 
mixture, to a final concentration of 0.6 mM MgCTP (or MgATP with the human 
enzyme), 1.0 mM L-cysteine, and 0.6 mM PPA. The oxidation of NADH, monitored by a 
decreasing UV absorbance at 340 nm (ε= 6.22 mM-1 cm-1), is monitored over the course 
of the assay. Assays were run in triplicate with the average IC50 being reported. As a 
control, pre-incubation of the PR (in the absence of PPCS) with the highest 
concentrations of inhibitors (1000 nM) showed no inhibition of the coupling enzymes 
when assayed as above with the addition of magnesium pyrophosphate (0.1 mM). 
Ki Determination35: Assays were performed on a SpectraMax M5 (Molecular Devices) 
microplate reader using 96-well half-area plates (Costar UV), with a final assay volume 
of 100 µL. The assay mixture consisted of 30 µL of PR, 0.86 mM MgCTP, 0.86 mM 
PPA, 1.43 mM L-cysteine, 14 mM DTT, and 19 µL of varying concentrations of inhibitor 
in a total volume of 70 µL. The assay mixture was preincubated at 37°C for 15 minutes. 
The enzymatic reaction was initiated by addition of 30 µL of efPPCS (also pre-incubated 
at 37°C for 15 minutes) to the assay mixture, to a final concentration of 27 nM. The 
oxidation of NADH, monitored by a decreasing UV absorbance at 340 nm (ε = 6.22 mM-
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Co-Crystallization of Intermediate Mimics with E. coli PPCS 
 
Introduction 
 The crystal structures of Human PPCS and a mutant (Asn210Asp) E. coli PPCS 
domain containing a N-terminal hexa-His tag, have been published.1, 2 Both mammalian 
and bacterial PPCS are dimers in solution.  Their structures contain a Rossmann fold, 
which is typical of nucleotide binding enzymes.1, 2 Dimerization of the two subunits is via 
interactions between the four stranded antiparallel β sheets, one contributed from each 
monomer.  In addition to dimerization functions, the β sheet is also positioned over the 
active site of the partner subunit, suggesting cooperativity between the two subunits for 
both the eukaryotic and the prokaryotic enzymes. The eukaryotic PPCS protein has an 
additional dimerization domain, consisting of a helix-βstrand-helix motif. The 
significance of this extra dimerization domain is unclear.  
 The structures of the E. coli PPCS in complex with CTP, phosphopantothenoyl 
cytidylate, and CMP have been determined.1  From the CTP bound structure, the protein 
interacts with the phosphates of the CTP via a bound divalent metal ligand, which is 
common for many enzymes that bind NTP.  Interaction with the ribose and nucleotide 
ring is primarily through hydrogen bonds with the protein backbone, involving the 
residues Ala98, Pro128, and Val131 for the cytidine as well as Phe147 and Ala95 for the 
ribose.  Upon soaking the crystals with both CTP and phosphopantothenate, 
phosphopantothenoyl cytidylate is bound to the active site of the enzyme.  The 
pantothenate chain extends through a grove formed from two β strands and binds to the 
protein mostly via charged and hydrogen bond interactions.   
 The cysteine binding pocket of the second half reaction has been hypothesized to 
involve binding contacts with Asn210, Arg206, and Ala276 based upon mutagenesis 
studies. However, no one has confirmed these binding contacts and the cysteine binding 
pocket has not been explored or used in inhibitor design. Identification of the cysteine 
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binding site and the orientation of cysteine binding to the PPCS-acyl cytidylate complex, 
also has mechanistic implications toward the ability of PPCS to discriminate between 
cysteine and serine.  This discrimination has critical biological implications, since 
incorporation of serine would lead to the production of potentially toxic CoA 
antimetabolites.3   
 Having successfully synthesized the first selective inhibitors of PPCS (Figure 
3.1), we were interested in using these chemical probes to glean more information about 
the active site of the native E. coli PPCS domain.4  The purpose of this study was to 
further explore the binding contacts within the active site of PPCS by elucidating the 
differences in the binding contacts made by the cyclic terminal phosphate of compound 
10 versus the non-cyclic phosphate of compound 8 and the internal sulfamate linkage of 
compound 17 versus the phosphodiester of compound 8, and exploring the cysteine 
binding pocket. 
 
Figure 3.1: First Inhibitors of PPCS 
Co-Crystallization of E. coli PPCS Domain with Phosphodiester Inhibitor 
 The IC50 values of the intermediate mimics 8, 10, and 17, indicated that the 
terminal and bridging phosphates were important for potency and that changing either 
resulted in a reduction in potency.4 The loss in potency of intermediate mimics 10 and 17, 
in comparison to that of the phosphodiester mimic, are most likely due to loss of key 
binding contacts in the phosphate binding sites of PPCS. As well, intermediate mimics 10 
and 17 could also be making unique binding contacts due to their differences in geometry 
and electronics. Such differences may point the way to new avenues for structure-based 
drug design of PPCS inhibitors. 
 Based upon the crystallization conditions reported in literature, an initial 96 well 
PEG sitting drop screen was set up.1 The commercially available Nextall 96 well PEG 
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screen allows for screening different PEGs starting at low molecular weight PEGs (200 
amu) all the way up to high molecular weight PEGs of 4000 amu while varying pH, 
buffer system, and salts. The initial screen was conducted using E. coli 1) apo PPCS, 2) 
PPCS with inhibitor 8, and 3) PPCS with inhibitor 8, and cysteine. Within 7 days, several 
different sets of conditions out of the initial screen afforded diffraction quality crystals 
(Figure 3.2).  
 
Figure 3.2: Co-crystals of PPCS [15 mg/mL] and Inhibitor 8 from Nextall PEG screen. 
Crystallization conditions as follows: (A) 0.2 M Ammonium chloride 20% PEG 3350 (B)  
0.2 M K/Na tartrate 20% PEG 3350 (C) 0.1 M Sodium acetate pH 4.6 30% PEG 300 (D) 
0.2 M Potassium thiocyanate 20% PEG 3350  
 
 The crystallization conditions were then further optimized using a focused grid 
hanging drop screen of 24 wells varying the pH and buffer concentration around the 
conditions of 0.1 M sodium acetate pH 4.6 30% PEG 300 and 0.2 M potassium 
thiocyanate 20% PEG 3350..  
 Diffractable crystals of PPCS and phosphodiester 8 were harvested within 14 
days. Upon harvesting the crystals, the cryo-protective conditions were explored using 
the well solution, the well solution plus 40% PEG 400, the well solution plus 10% 
glycerol, and paraffin oil. Once cryoprotected, the crystals were flash frozen using liquid 
N2, and stored in liquid N2. X-ray diffraction data was taken at the advanced photon 
source (APS) in Argonne National Laboratory. Due to the size of the asymmetric unit of 
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the crystal of the PPCS domain with phosphodiester 8, the x-ray detector had to be 
moved back to a distance of 250 mm and offset 150 mm in order to resolve the very close 
together spots of the diffraction pattern. While offsetting the detector allowed for the 
diffraction pattern to be resolved, moving the x-ray detector away from the x-ray source 
led to the higher resolution diffraction data being lost. Despite this obstacle, several data 
sets were obtained of sufficient quality to be processed. 
Data Collection  
Space Group C222(1) 
Unit Cell 45.615,  141.081, 
240.799 
 90, 90, 90 
Wave length (Å) 1.1271 
Resolution (Å) 2.45-2.37 
Rsym  (%) 6.6      (31.4) 
<I/σI> 20           (2) 
Completeness 
(%) 
98.5      (94.6) 
Redundancy 3.3        (2.6) 
  
Table 3.1:  Data collection statistics for structure of phosphodiester 8 bound PPCS  
 
 The diffraction data was indexed, integrated, and scaled using HKL2000.5 The 
best data set came from crystals grown using 0.1 M NaOAc, pH 5.5, and 24% PEG 400 
using paraffin oil as the cryoprotective solution, gaving a resolution of 2.37 Å and a 
redundancy of 3.1 (Table 3.1). The crystals were of space group C222(1) and contained 3 
monomers in the asymmetric unit. This data set has been solved using molecular 
replacement using ccp4 software suite with the published activated intermediate bound 
mutant (1u7z) as the model (Figure 3.3).1, 6  The structure of PPCS with phosphodiester 8 
was overlaid with the structure of the PPCS mutant with the activated intermediate to 
confirm the validity of the structure and the binding mode of the intermediate-based 
inhibitor (Figure 3.4). The overlay reveals that the intermediate mimic binds to PPCS 
similar to the activated intermediate, as designed. The most notable difference between 
the two structures is the lack of a carbonyl on phosphodiester 8 leading to the loss of a 




Both the N- and C-terminal amino acids are solvent exposed with the first three 
N-terminal amino acids and the C-terminal arginine unresolved.  The N-terminal region 
of the PPCS domain in its native form would be attached to the PPCDC domain.  
 
Figure 3.3: Phosphodiester mimic 8 bound to PPCS domain 
  
 
Figure 3.4: Overlay of phosphodiester 8 and PPCS (blue) with 1U7Z (yellow) 
 
 A closer look at phosphodiester 8 in the active site of PPCS shows that the 
molecule takes advantage of almost all of the binding contacts of the activated 
intermediate in PPCS (Figure 3.5). Within the nucleotide binding pocket, the cytidine 
portion of inhibitor 8 forms hydrogen bond contacts with Pro308, Ile310, and Val311.  
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The ring oxygen of the ribose ring forms a hydrogen bond with lysine 345 while the 2’ 
and 3’ alcohols form a hydrogen bonding network with the backbone of Ala275, Ala273, 
and Phe327.  The internal phosphate forms a salt bridge with Lys341 and has a hydrogen 
bond to the backbone of Ala329. The internal phosphate also forms a binding contact 
with Lys289 from the other monomer. This binding contact is important because it was 
shown in previous site directed mutagenesis studies that Lys289 was critical for 
enzymatic catalysis of PPCS. Lys289 from the other monomer binding to the internal 
phosphate of the bound molecule is similar in the structure of the mutant; however, this 
contact is only briefly mentioned in the crystallographic study and there is no mention of 
the implications this contact may have on dimerization based upon the molecule bound in 
the active site. One subtle difference between the phosphodiester 8 bound structure and 
the activated intermediate bound PPCS mutant is the orientation of the side chain on 
Val205. Val205 is important because it is believed that the Val205 of one monomer 
interacts at the active site of the other monomer and helps to create the cysteine binding 
pocket. In literature, the side chain of Val205 adopts different conformation within the  
 
 
Figure 3.5: Nucleotide binding pocket of PPCS with phosphodiester 8 
different monomers of the dimer with the different conformations being responsible for 
allowing access of the cysteine into the active site to react with the intermediate by either 
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allowing space for its side chain in one conformation or creating a steric hinderence and 
disallowing entrance in the other conformation. In our structure both Val205 of the dimer 
adopt the same conformation and form an open binding cavity that should allow for 
unhindered access to the bound molecule in the active site. The other difference between 
the structure of the intermediate bound PPCS mutant and our current structure is the 
mutation from Asn210 to Asp210 in the mutant enzyme. In the mutant structure, Asp210  
 
Figure 3.6: Asn210Asp mutation in the active site 
 




adopts a different conformation than the Asn210 in our native PPCS structure, and forms 
a hydrogen bond with a water molecule not present in our structure. It has been 
speculated that this mutation either causes a perturbation to the oxyanion hole of the 
enzyme or forms an undesirable salt bridge with substrate cysteine, resulting in a 
decreased rate in the second half reaction of the mutant PPCS.1 
 The phosphopantothenol binding pocket is a long narrow channel that is covered 
by a flexible binding clamp that extends from Asp354 to Ala368 (Figure 3.7). Within the 
binding pocket, the 4’ phosphate of the inhibitor extends into the phosphate cradle 
composed of residues Ser212, Ser213, Gly214, Met216, and a water molecule.  This 
phosphate binding pocket forms an elaborate hydrogen bonding network to the negatively 
charged terminal phosphate and constitutes the majority of the binding contacts in the 
phosphopantothenate binding pocket. Asn353 is an important residue in the binding 
pocket because it is responsible for hydrogen bonding to both the carbonyl of the amide 
bond in panthenol and the secondary alcohol of the pantoyl portion of the molecule. 
Phosphodiester 8 lacks a hydrogen bond from the amide nitrogen to the backbone 
carbonyl of Cys274. As can be seen from the overlay of the two molecules, 
phosphodiester 8 does not possess the carbonyl present in the active intermediate which 
due to its sp2 hybridization is not as easily rotatable as the methylene of mimic 8 and 
most likely responsible for the differences in location and orientation of the amide 
nitrogen. 
Co-Crystallization of E. coli PPCS Domain with Sulfamate Inhibitor 
 The hanging drop conditions used for the co-crystallization of PPCS and 
phosphodiester 8 were then used as the basis for the co-crystallography study of 
inhibitors 10 and 17.  Co-crystals of both compounds 10 and 17 had formed within two 
weeks. These crystals were of a lesser quality than the co-crystals of PPCS and 8 (Figure 
3.8). From Figure 3.8, it can be seen that the co-crystals with both 10 and 17 are not of 
uniform width with thicker portions and softer edges. Nevertheless, the crystals were 
harvested, cryoprotected, and flash frozen. These crystals produced low quality and low 




Figure 3.8: Crystals of PPCS and 10 (left) and PPCS and 17 (right) 
 To improve the quality of the co-crystals with inhibitors 10 and 17, a Nextall 96 
well PEG screen and an Emerald 96 well wizard screen were performed incubating with 
2.5 mM of the appropriate inhibitor overnight. The Emerald wizard screen produced a 
new set of crystallization conditions very similar to the original crystallization conditions 
but with Ca(OAc)2 as additive (Figure 3.9). All crystals from these conditions were 
harvested and the cryoprotective solution was varied from no cryoprotection, 15% 
glycerol in the well solution, and 40% PEG 400.  
 
Figure 3.9: Emerald Wizard Screen. Conditions: (left ) 0.1 M Sodium acetate pH 4.5, 0.1 
M Ca(OAc)2 30% PEG 300 and 2.5 mM 10 (right) 0.1 M Sodium acetate pH 4.5, 0.1 M 
























Table 3.2: Data collection statistics for structure of sulfamate 17 bound PPCS 
 
 The best data set for the co-crystal of PPCS and sulfamate 17 was obtained from 
32% PEG 300 0.1M sodium acetate pH 5.2 with the well solution plus 40% PEG 300 as 
the cryoprotectant. The data was collected at APS shifting the X-ray detector back 250 
mm and offsetting it by 150 mm. The crystal gave a resolution of 2.11 Å, and belonged to 
space group P6122 with one monomer in the asymmetric unit (Table 3.2). This data set 
has been solved using molecular replacement using the ccp4 software suite with the 
structure of phosphodiester 8 bound PPCS as the model  and the dimer being generated 
from the symmetry related molecule along the crystallographic 2 fold axis (Figure 
3.10).1, 6 It is known that the native domain of E. coli PPCS is a dimer in solution, but it 
should be noted that both the structure of the PPCS Asn210Asp mutant from literature 
and the structure of sulfamate 17 bound PPCS, crystallized as monomers with residues 
Thr284 to 299 being disordered.1 This is significant because within this loop is Lys289, 
which as previously mentioned is crucial for PPCS catalysis and forms a binding contact 
with the internal phosphate of either the bound intermediate or phosphodiester 8.  
 
 
Data Collection  
Space Group P6122 
Unit Cell 44.038,  44.038, 
390.47 
 
 90, 90, 120 
Wave length (Å) 1.1271 
Resolution (Å) 2.15-2.11 
Rsym  (%) 7.3         (33.3) 
<I/σI> >20        (5) 
Completeness 
(%) 
99.7       (100) 





Figure 3.10: Sulfamate mimic 17 bound to PPCS domain 
 
Figure 3.11: Overlay of phosphodiester 8 and sulfamate 17 
 An overlay of the structure of PPCS and phosphodiester 8 (the model) and PPCS 
and the sulfamate mimic 17 was generated (Figure 3.11).  From this overlay, it is 
apparent that the phosphodiester 8 and sulfamate 17 bind in an almost identical manner 
and that the difference in potency must be explained by very subtle differences in the 
binding contacts. 
 Investigating the nucleotide binding pocket, the majority of the binding contacts 
for the sulfamate 17 are the same as the phosphodiester inhibitor 8 (Figure 3.12). The 
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exocyclic amine on the cytidine ring forms a hydrogen bond with Pro308 while the 
carbonyl on the cytidine ring forms hydrogen bonds with Ile310 and Val311. The 2’ and 
3’ hydroxyl groups on the ribose ring form a hydrogen bond with Ala275 and Ala273 
 
Figure 3.12: Nucleotide binding pocket of PPCS with sulfamate 17 
 
Figure 3.13: Phosphopantothenate binding pocket of PPCS with sulfamate 17 
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and Phe327, respectively. The ring oxygen in sulfamate 17 does not form a hydrogen 
bond with Lys345, as is the case with both the activated intermediate and phosphodiester 
inhibitor 8. Also, the sulfamate makes a hydrogen bond with Lys341 as opposed to the 
salt bridge that the negatively charged phosphate of the phosphodiester 8 makes.  
 Within the phosphopantothenate binding pocket, sulfamate 17 binds very 
similarly to phosphodiester 8. The 4’ phosphate of the sulfamate extends into the 
phosphate cradle consisting of Ser212 and 213, Gly214, and Met216. The secondary 
alcohol and the carbonyl of the amide bond, both form a hydrogen bond to Asn263. The 
geometry of the sulfamate twists the β-alanine portion of the molecule in order for the 
nitrogen of the amide bond to hydrogen bond with the backbone carbonyl of Cys274.  
The sulfamate oxygen forms a hydrogen bond with Ala329 along with the hydrogen bond 
to Lys345. 
 Phosphodiester 8 and sulfamate 17 have IC50s within 4 fold of each other with 
phosphodiester 8 having an IC50 of 68 nM and sulfamate 17 having an IC50 of 270 nM 
which explains their very similar mode of binding and common binding contacts. There 
are several differences in the binding that can explain the differences in the IC50s of the 
two compounds. The main difference in the binding of the two compounds is how the 
two compounds bind at the edge of the ribose binding pocket through the internal linkage 
of the molecule, and at the carbonyl of the amide bond in the panthenol arm. The 
sulfamate cannot form an ionic interaction with Lys341 and does not form a hydrogen 
bond with its ribose ring oxygen with Lys345. Despite the carbonyl in the sulfamate 
being able to form a hydrogen bond and the nitrogen in the amide bond forming a 
hydrogen bond with Cys274, these added binding contacts are not able to counteract the 
loss of the ionic interaction of the negatively charged phosphate. 
Co-Crystallization of E. coli PPCS Domain with Cyclic Phosphodiester Inhibitor 
 The best data set for the co-crystal of PPCS and cyclic phosphodiester 10 was 
obtained from 30% PEG 400 0.1 M sodium acetate pH 4.5 0.2 M calcium acetate with 
the well solution pus 40% PEG 400 as the cryoprotectant. The data was collected at APS 
shifting the X-ray detector back 250mm and offsetting it by 150 mm. The crystal gave a 
resolution of 2.30 Å, and belonged to space group P6122 with one monomer in the 
asymmetric unit (Table 3.3). This data set has been solved using molecular replacement 
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using the ccp4 software suite with the structure of PPCS and phosphodiester 8 as the 
model (Figure 3.14).6 A brief investigation of this structure shows that there is a major 
difference in the structure of PPCS when the cyclic phosphodiester 10 is bound in the 
active site as compared to the non-cyclic inhibitors 8 and 17. Looking at the yellow 
monomer in Figure 3.14, one can see that the flexible binding clamp composed of the 
residues Asp354 to Ala368 is disordered and not making contact with the PPA binding 
pocket. An overlay of cyclic phosphodiester 10 and the non-cyclic phosphodiester 8 show 
that there is also a difference in the orientation of the panthenol arm within the binding 
pocket (Figure 3.15). 
 
Data Collection  
Space Group P6122 
Unit Cell 43.891, 43.891, 
386.951 
 
 90, 90, 120 
Wave length (Å) 1.1271 
Resolution (Å) 2.34-2.30 
Rsym  (%) 8.4           (49.7) 
<I/σI> >20          (5) 
Completeness (%) 99.6         (99.6) 
Redundancy 17.6         (18.2) 
  
 
Table 3.3: Data collection statistics for structure of phosphodiester 10 bound PPCS 
 















Figure 3.17: Phosphopantothenate binding pocket with cyclic phosphodiester 10 
 Within the nucleotide binding pocket, the cytidine nucleobase is bound in the 
same fashion as the other inhibitors with a hydrogen bonding network to Pro308, Ile310, 
and Val311. The 2’ and 3’ alcohols form hydrogen bonds with Ala275, Ala273 and 
Phe327. However, it can be seen that the internal phosphate does not form a salt bridge 
with Lys341 and there is no binding contact with the ring oxygen on the ribose ring. 
 The most drastic difference in the binding of the cyclic phosphodiester mimic 17 
with PPCS can be seen within the PPA binding pocket (Figure 3.17). In order for the 
terminal cyclic phosphate to reach into the phosphate cradle, the panthenol arm must 
twist and place the gem dimethyl group toward Asn353. Despite this adjustment the 
terminal cyclic phosphate cannot reach into the phosphate cradle very well and only 
makes a few hydrogen bonds in the cradle. This orientation of the gem dimethyl group 
does not allow for a hydrogen bond to form to Asn353 and more importantly the gem 
dimethyl creates a large steric clash which keeps the Asp354 to Ala368 binding flap from 
closing on the PPA binding pocket.  
 There is an interesting trend between the crystal structures that form a dimer in 
the asymmetric unit and the ability of the molecule within the active site in these 
structures to interact with Lys289. Both phosphodiester 8 bound to native PPCS and the 
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activated intermediate bound to the mutant PPCS are able to interact with Lys289 and 
form crystallographic dimers. Whereas the apo form of the Asn210Asp mutant and native 
PPCS structures with inhibitors 10 and 17 do not have molecules that interact with 
Lys289 and form monomers in the asymmetric unit. Site directed mutagenesis studies 
have shown that mutation of  certain residues such as Asn210, Thr194 and 198, Ala275 
diminish the ability of PPCS to form a dimer and in these cases PPCS elutes as a 
monomer in gel filtration experiments.7 In the structures with the activated intermediate 
or phosphodiester 8 bound to the active site, Lys289 is able to interact with the internal 
phosphate of the two molecules keeping the monomers of the dimer closer together 
increasing the overlap of the dimerization domain thus stabilizing the dimer. Mutation of 
Lys289 did not cause PPCS to run as a monomer in the literature report most likely due 
to the fact that the dimerization domain was not mutated and there was no molecule in the 
active site to perturb the protein.7 It was determined in the mutagenesis study that the 
Asn210Asp mutant ran closer to the monomer, so it is not surprising that its crystal 
structure was a monomer in the asymmetric unit.7 The structure of PPCS with sulfamate 
17 may have been a monomer because sulfamate 17 has no phosphate to interact with 
Lys289. Without the added stability of the Lys289 contact to counteract the disturbance 
to the dimerization domain due to the molecule bound in the active site the overlap of the 
dimerization domain may not have been sufficient to keep the dimer. The cyclic 
phosphate 10 has the necessary phosphate for binding to Lys289, but due to the binding 
mode of the cyclic phosphate moiety, the active site and protein are so perturbed that 
Lys289 cannot form a binding contact and the dimerization domain does not have the 
necessary overlap to give a dimer. To test if PPCS is really a monomer in solution when 
bound to mimics 10 and 17 and a dimer when bound to mimic 8, a set of gel filtration 
experiments should be run. 
 Based upon the differences in the three structures it is possible to use this 
information to design 2nd generation inhibitors. The nucleotide binding pocket showed 
very little difference among the three structures, except that phosphodiester 8 could form 
an extra hydrogen bond between the ring oxygen of the ribose ring and Lys345. This 
difference does not seem to account for a large difference in potency. However if taking 
advantage of this contact is the goal, then the cytidine portion of the molecule should be 
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replaced with isosteres of the same size or smaller. The internal phosphate linkage and its 
ability to form an ionic interaction with Lys341 and Lys289 from the other monomer are 
quite important and it will be difficult to replace. The sulfamate in inhibitor 17 does an 
adequate job as a geometric and electronic isostere in the E. coli PPCS structure; 
however, the sulfamate does not interact with Lys289. This replacement is better 
tolerated in E. coli PPCS as compared to the other PPCSs tested in vitro.4 If the sulfamate 
linkage is taken forward as the isosteric replacement for the phosphate then it will be 
necessary to take advantage of other binding contacts within the active site to increase 
inhibitor potency. 
 The PPA binding pocket and the binding contacts made by the intermediate 
mimics 8, 10, and 17 provide an opportunity for more chemical diversity in inhibitor 
design. The amine on Asn353 is a hydrogen bond donor to the amide carbonyl on the 
pantothenate arm, while the carbonyl on Asn353 is hydrogen bond acceptor to the 
secondary alcohol. The other important binding contact in this region of the binding 
pocket is the carbonyl oxygen of Cys274, which forms a hydrogen bond with the 
hydrogen on the nitrogen of the amide. These contacts should be accessible to any 
carbonyl compound such as an amide, ester, urea, or a ketone with either an alcohol or an 
amine in the α position. An α hydroxy ketone should be an interesting isostere. The α 
hydroxy ketone would not contact Cys274, but neither does phosphodiester 8, which is 
the most potent molecule to date.  However, it is essential that there be little steric bulk 
on this side of the PPA binding pocket. While it should be easy to take advantage of 
Asn353, it must be done with a linear molecule. A non-linear molecule will cause a steric 
clash with the binding clamp in the same manner that the gem dimethyl of cyclic 
phosphodiester 10 and cause a drastic drop in potency. 
 The final binding pocket is the phosphate cradle consisting of amino acids Ser212 
through Met216. The terminal phosphate is crucial for binding to PPCS. Both 
phosphodiester 8 and sulfamate 17 bind very tightly within this binding pocket. However, 
cyclic phosphate 10 cannot fully extend into the phosphate cradle due to steric hindrance 
and the effective shortening of the panthenol arm due to the cyclized phosphate. The 
cyclized phosphate moiety still forms hydrogen bonds with Ser213, Gly214, and Met216, 
which shows the potential for a cyclic phosphate isostere to bind within the phosphate 
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cradle as long as there is a long enough linker that does not contain sterically bulky 
groups on the edge of the phosphate binding cradle. A neutral isostere such as triazole or 
a tetrazole attached with at least one or two methylene groups between it and any other 
functional groups would be ideal for fitting into the phosphate cradle.  
Co-Crystallization of E. coli PPCS Domain with Phosphodiester 8 and Cysteine 
 To complete the second goal of the structural study and investigate the cysteine 
binding pocket, the crystallographic conditions obtained from the Nextall 96 well PEG 
screen and explored using focused hanging drop screens. Unfortunately the cro-
crystallographic study with PPCS, phosphodiester 8, and cysteine did not yield a crystal 
structure that included cysteine in the active site. Initial attempts involving the focused 
hanging drop screens focused around 0.1 M sodium acetate pH 4.6 30% PEG 300 and 0.2 
M potassium thiocyanate 20% PEG 3350 with 15 mg/ml PPCS, 0.93 mM inhibitor 8, and 
2mM cysteine yielded less crystals and crystals of a poorer quality than drops without 
cysteine. These crystals were harvested, cryoprotected, and flash frozen using liquid N2. 
Most of the crystals did not diffract beyond 4Å resolution and those that had a higher 
resolution did not give quality diffraction patterns that could be indexed and integrated 
using HKL2000.  
 To overcome the poor quality of the crystals with cysteine, co-crystals of PPCS 
and phosphodiester 8 were grown without cysteine according to the focused screen and 
cysteine was soaked into the pre-established crystal. At first, 1, 10, or 100 mM cysteine 
was place in the cryoprotective solution used during the flash freezing process. Low 
resolution screening of these crystals revealed quality diffraction patterns, but when the 
data was processed there was no cysteine in the active site. The study was continued by 
extending the soaking time of the co-crystals of PPCS and phosphodiester 8 with the 
cryoprotective solution containing 1, 10, and 100 mM cysteine to 1 min, 15 min, 1 hour, 
2 hours, and 24 hours. The concentration of the cysteine in the solution had no effect on 
the crystals, however, longer incubation times tended to crack and dissolve the pre-grown 
crystals containing PPCS and phosphodiester 8. Despite this exhaustive screen, no 
structures with phosphodiester 8 and cysteine were obtained. 
 Unfortunately, phosphodiester 8 is not able to stabilize the PPCS active site 
enough to allow cysteine to bind to PPCS on the timescale that is visible by 
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crystallography. It is possible that the cysteine is able to enter the active site of PPCS and 
with no electrophile present; the cysteine diffuses back out into the solution. Stanitzek et 
al. observed catalytic turnover when the PPCS mutant with the activated intermediate in 
the active site showing that cysteine is free to enter the active site and react with the 
activated intermediate on the crystallographic timescale.1  In order to crystallize cysteine 
with PPCS and explore its binding pocket, it is necessary to employ a mechanistic trap 
with an electrophilic functionality such as a Michael acceptor or an epoxide. 
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Materials and Methods 
Cloning, Overexpression, and Purification of E. coli PPCS: The coaB coding region 
of the dfp gene (encoding ser181-arg406 of the E. coli CoaBC protein)1, 8 was PCR 
amplified using E. coli MG1655 genomic DNA as a template, and the primers, 
coabec1(forward primer), 5’ – CGCGCATA 
TGTCGCCCGTCAACGACCTGAAACATCTG-3’ and dfp3 (reverse primer), 5’-
GCGCCTCGAGACGTCGATTTTTTTCATCATAACGGG-3’. The forward primer 
introduces an NdeI site (shown underlined) to provide a start codon for the coaB coding 
region, and the reverse primer creates a XhoI site (shown underlined) downstream of the 
stop codon of the open reading frame. The PCR products were digested with NdeI and 
XhoI, and ligated into pET23a(+) (Novagen) cut with NdeI and XhoI. The resulting 
plasmid was designated pUMDOT3 and the insert was confirmed by DNA sequencing.  
E. coli BL21 AI (Invitrogen) harboring the plasmid pUMDOT3 were grown in 500 mL 
LB-ampicillin media (5 g of NaCl, 5 g of yeast extract, 10 g of tryptone, and 100 mg of 
ampicillin per L) at 37°C and 250 rpm to a OD600 of 0.6. The cells were then cooled by 
shaking at 16°C for 10-15 min, induced with 0.07% L-arabinose, and continued to grow 
at 16°C and 250 rpm for 12-16 hours. The cells were harvested at 6000 x g for 10 
minutes at 4°C, washed, and then suspended in 12 ml of 20 mM HEPES pH 8.0. Cells 
were lysed by French Press and crude cytosol obtained by centrifugation at 20,000 x g for 
25 minutes at 4°C.  
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 ecPPCS was purified using a tandem anion exchange column (Source 15Q (GE 
Healthcare); 20 mL) and cation exchange column (Source 15S (GE Healthcare); 8 mL). 
The 12 mL of crude cytosol was loaded onto the tandem chromatography columns which 
had been pre-equilibrated with 20 mM HEPES pH 8.0. The columns were then washed 
with another 40 mL of equilibration buffer and the anion exchange column was removed. 
Under these conditions the ecPPCS does not bind to the anion exchange resin, but does 
bind to the cation exchange resin. The cation exchange column was eluted with a linear 
gradient of 0-0.4 M NaCl in 20 mM HEPES pH 8.0, with a total gradient volume of 100 
mL. ecPPCS eludes as a single peak at 75 mM NaCl and was greater than 98 % pure as 
determined by SDS-PAGE.  The fractions were combined and diluted with 20 mM 
TrisHCl pH 8.0 with 10 mM NaCl to a total volume of 15 mL. The solution was 
concentrated to a volume of 1 mL using a Centricon 10,000 MW cutoff centrifugal filter 
device. This process was repeated and the buffer exchange was complete. The 
concentration of PPCS was adjusted to 15 mg/mL. 
 
Synthesis of compounds 8, 10, and 17: Compounds 8, 10, and 17 were synthesized as 
previously described. 
 
96 Well sitting drop robotic screens: 96 Well crystallization screens with three 
crystallization wells per each of the 96 reservoir wells. The Nextall PEG and Emerald 
Wizard screens were set up using Honeybee 961 crystallization robot. The crystal trays 
were incubated at 20°C for 3-14 days until crystals were mature and ready for harvest. 
 
24 Well focused hanging drop screens: Focused hanging drop screens were set up using 
Hampton 1.5 mL capacity hanging drop trays. The drops contained 15 mg/mL PPCS and 
the appropriate compound. The pH was varied across the row and concentration of PEG 
was varied down the columns. The trays were set up and incubated at 20°C for 3-14 days 
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Probes of the individual half reactions of PPCS 
 
Introduction 
 In the first half reaction catalyzed by PPCS, CTP binds and then PPA enters the 
active site. The carboxylate of PPA then attacks the α phosphate on CTP to generate an 
activated intermediate and release pyrophosphate (Figure 4.1).1, 2  The second half 
reaction involves cysteine entering the active site and initiating amide bond formation via 
nucleophilic attack on the carbonyl of the mixed anhydride of the activated cytidylate 
intermediate. With this mechanistic information, it should be possible to design probes 
that will mimic the PPA substrate to probe and exploit the first half reaction. Likewise,  
 
Figure 4.1: Mechanism of both half reactions of PPCS. A) Mechanism of first half 
reaction B) Mechanism of second half reaction
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intermediate mimics containing an electrophilic functionality could be used to exploit the 
mechanism of the second half reaction and trap substrate cysteine in the active site. 
 
Figure 4.2: Known inhibitors of bacterial and malarial growth 
  Several pantothenate analogs are known to inhibit both malarial and bacterial 
growth in vitro and are thought to inhibit and/or serve as alternate substrates for 
pantothenate kinase (Figure 4.2).3 Panthenol is commercially available and the thiol and 
disulfide molecules can be readily made from pantolactone and cystamine. Unfortunately, 
due to a lack of commercial availability, there are no pantothenate or PPA mimics with a 
three carbon unit to mimic the β-alanine portion of the molecule other than panthenol. 
Herein, we have constructed PPA and pantothenate based probes which keep the three  
 
Figure 4.3: Proposed PPA analogs 
carbon unit of β-alanine, but replace the carboxylate with a nucleophilic thiol or amine 
(Figure 4.3).  The PPA mimics should either act as competitive inhibitors with regard to 
PPA or act as mechanism-based inhibitors that are able to utilize PPCS and CTP to form 
an intermediate mimic in situ. If the mechanism of inhibition conforms to the latter, then 
pre-incubating these substrate analogs with CTP and PPCS would allow the thiol or 
amine to attack the α phosphate of CTP and synthesize a cytidylate mimic analog within 




Figure 4.4: Mechanism of proposed PPA analog inhibitors 
 The second class of probes was designed to be an intermediate mimic mechanism 
based probe with a vinyl sulfone built into the pantothenate portion of the molecule. 
Vinyl sulfones have found great utility in the study of enzyme mechanisms and 
interactions because of their ability to act as Michael acceptors and crosslink the 
mechanism-based probe to the enzyme being studied, usually via cysteine attack on the 
vinyl sulfone.4-7 It has been shown that various vinyl sulfones react with the active site 
cysteine of cysteine proteases, such as Cruzain, ketosynthases, such as KASI and KASII, 
as well as the cystamine functionality of the phosphopantetheine arm of carrier proteins 
(Figure 4.5). The carrier protein mechanism-based probe was shown to specifically 
irreversibly label an acyl carrier protein from Mycobacterium tuberculosis as shown by 
mass spectrometry, and the ketosynthase mechanism-based probe was able to crosslink 
acyl carrier protein and KASI as analyzed by SDS-PAGE analysis (Figure 4.5).5, 7   
 
Figure 4.5: Examples of vinyl sulfones in literature. A) Carrier protein mechanism-based 




 Based upon the ability of these vinyl sulfones to act as Michael acceptors and the 
ability to characterize the resulting irreversibly labeled product, an intermediate mimic 
was designed with a vinyl sulfone functionality in place of the electrophilic carbonyl of 
the activated intermediate. The vinyl sulfone intermediate mimic would be attacked by 
the cysteine that enters PPCS as the third substrate rather than by a cysteine embedded 
within the enzyme of interest. Once cysteine attacks the vinyl sulfone it should be 
possible to isolate and characterize the ternary complex and identify whether the amine or 




Figure 4.6: Mechanism of vinyl sulfone intermediate mimic 
 
Phosphopantothenate and pantothenate based probes 
 The synthesis of the proposed thiol analog of PPA begins with the nucleophilic 
displacement of the bromide on 3-bromopropylamine hydrobromide with trityl thiol in 
58%. The propyl amine 21 was used to open pantolactone to yield the desired diol 22.8 
The choice of the protecting groups on the phosphate proved to be very important as the 
deprotection was more difficult than initially anticipated. Originally, ethyl protecting 
groups were used based upon the commercial availability of chlorodiethyl phosphate and 
ease of the phosphorylation which proceeded in 87% yield.9 All attempts to deprotect the 
ethyl groups with TMSBr or under acidic conditions resulted in degradation of the 
molecule with only 1.6 mg of the desired phosphate ever recovered. Alternatively, the 
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diol was then phosphitylated with pyridinium HCl as the activator at -20°C to yield the 
protected phosphodiester. Phosphodiester 23 was deprotected by oxidatively cleaving the 
trityl group to yield the disulfide followed by deprotecting the phosphodiester by treating 
with DBU and TMSCl. After purification by anion exchange column and P2 sizing 
column, the disulfide 24 was obtained in 27% yield as the tetrasodium salt.9, 10 The non-
phosphorylated analog of the desired mimic was synthesized from the protected diol 22 
by oxidatively deprotected the thiol group to give diol 25. 
 
 
Scheme 4.1: Synthesis of proposed thiol PPA analog 
 The synthesis of the proposed amine analog of PPA is similar to thiol mimic and 
begins with the opening of pantolactone with tert-butyl (3-aminopropyl)carbamate 
(Scheme 4.2). The phosphitylation and oxidation of diol 26 was not as straightforward as 
initially anticipated. Standard phosphitylation and oxidation conditions led to no reaction 
in the case of diol 26. In order to get the desired β-cyanoethyl protected phosphate, diol 
26 was treated with bis(β-cyanoethyl) diisopropylphosphoramidite and pyridinium HCl 
as the activator at -5°C in DMF. The protected phosphate 27 was deprotected in two steps 
to yield the desired phosphate 28; however, the phosphorylated compound was not 
recovered after anion exchange chromatography. The non-phosphorylated analog 29 was 





Scheme 4.2: Synthesis of amine PPA analog 
 The first assay performed was to test whether the non-phosphorylated analogs 25 
and 29 would be substrates for the kinase PanK, the first enzymatic step in CoA 
synthesis. The kinase assay consists of coupling PanK to pyruvate kinase (PK) and lactate 
dehydrogenase (LDH), and following the oxidation of NADH to NAD, which can be 
monitored by the disappearance of UV absorbance at 340 nm (Figure 4.7). The disulfide 
25 had a Km of 500 µM and the amine compound 29 showed no phosphorylation (Figure 
4.8). It is known that the carbonyl group of the carboxylate of vitamin B5 is important for 
binding to the kinase. Despite not possessing a carbonyl functionality at this position, the 
oxidized and reduced forms of 25 were still able to be phosphorylated by E. coli PanK. 
The amine 29, however, does not only lack the carbonyl, but also possesses a positive 
charge on the amine. This positive charge probably forms unfavorable interactions in the 





Figure 4.7: Kinase assay 
 
Figure 4.8: Kinase assay results 
 The phosphorylated disulfide 24 was then tested for time dependent PPCS 
inactivation using the pyrophosphate reagent coupled PPCS assay. Compound 24 was 
pre-incubated with one equivalent of dithiothreitol (DTT) at 37°C for one hour. The 
reduced version of compound 24 was then incubated with PPCS and CTP for various 
times. The other substrates were then added to the assay mixture and PPCS activity was 
monitored. Unfortunately, compound 24 did not display any inhibition of PPCS activity 
in this manner and as such compound 24 was not a time dependent mechanism-based 
inhibitor. This result maybe due to the thiol not being placed at the proper geometry in 
relation to the α phosphate of CTP in the active site of PPCS. To try and increase the 
nucleophilicity of the thiol by biasing the equilibrium towards the thiolate, the pH of the 
pre-incubation solution was varied from 7.5 to 8.5. Even at the elevated pHs the thiol 
mimic did not display any time dependent inhibition. 
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 Disulfide 24 was then tested as a competitive inhibitor of PPCS with respect to 
PPA. The inhibitor concentration was varied along with the concentration of PPA while 
the other substrate concentrations were fixed. The velocity of the reaction was plotted 
against PPA concentration for the different disulfide concentrations (Figure 4.9). 
 
Figure 4.9: Velocity versus PPA concentration 
The curves from Figure 4.9 were fit using the following equation: 
 
and solving for Kmapp. The Kmapp values were then replotted against disulfide 
concentration to give a straight line with an x intercept equal to negative Ki, which in this 




Figure 4.10: Kmapp versus [I] 
 
Vinyl Sulfone mechanism-based probes 
 Retrosynthetic analysis of the vinyl sulfone mimic reveals that the first 
disconnection is the terminal phosphate on the 1,3 diol of the panthenol portion (Figure 
4.9). This phosphate will be installed last in the synthetic sequence using the 
phosphitylation/oxidation methodology previously used on intermediate mimic 8. The 
second disconnection was the nitrogen sulfur bond of the vinyl sulfonate dissecting the 
molecule into two halves consisting of an amino cytidine portion and the panthenol 
portion with the vinyl sulfone. The vinyl sulfone can be installed via a Horner 
Wadsworth Emmons (HWE) reaction using ethyl methanesulfonate and an aldehyde 




Figure 4.11: Retrosynthetic analysis of vinyl sulfone intermediate mimic 
 In the forward direction, several aldehydes were constructed in order to probe 
which aldehyde was most suited for the HWE reaction and subsequent coupling to the 
amino cytidine molecule. The synthesis of the boc protected vinyl sulfone begins with the 
selective protection of the amine on 3-aminopropanol with boc anhydride in 80% 
(Scheme 4.3).11 The alcohol is then subjected to standard Swern oxidation to yield the 
aldehyde 32. The aldehyde is then converted to the vinyl sulfone by coupling compound 
32 to the sulfone 30 via a HWE reaction in 75% yield.4 The phthalate protected vinyl 
sulfone is synthesized in a similar fashion as vinyl sulfone 33 (Scheme 4.4). The amine 
on 3-aminopropanol was selectively protected using phthalic anhydride in 90% yield.12-14  
 




Alcohol 34 was then subjected to standard Swern oxidation conditions to yield aldehyde 
35.13, 15 The vinyl sulfone was then obtained by coupling aldehyde 35 to sulfone 30 via a 
HWE reaction in 65%. The third vinyl sulfone synthesized was the PMB acetal vinyl 
sulfone derived from the PMB acetal of panthenol (Scheme 4.5). The previously 
synthesized PMB protected panthenol 1 was oxidized to the aldehyde in 82% yield. The 
aldehyde was then coupled to sulfone 30 under standard HWE conditions to yield the 
desired vinyl sulfone 38. 
 
Scheme 4.4: Synthesis of phthaloyl protected vinyl sulfone 
 
 
Scheme 4.5: Synthesis of PMB protected vinyl sulfone 
 The amine group was installed on the cytidine portion of the molecule starting 
from the previously synthesized tribenzoyl cytidine. Tribenzoyl cytidine 5 was treated 
with mesyl chloride to yield the mesylated tribenzoyl cytidine 39. Displacement of the 
mesylate of compound 39 was accomplished using excess sodium azide to give 
tribenzoyl cytidine azide 40 in 93%.16 Reduction of the azide to the amine was 
accomplished by either Staudinger reduction or transfer hydrogenation to afford the 




Scheme 4.6: Synthesis of tribenzoyl cytidine amine 
 With the tribenzoyl cytidine amine 41 and the protected vinyl sulfonate esters 33, 
36, and 38 in hand, the next step was to couple the two fragments. The ethyl ester of the 
vinyl sulfone was deprotected using tetrabutylammonium iodide (TBAI).4, 6, 17, 18 In the 
case of the phthaloyl protected sulfonate and the PMB protected sulfonate the resulting 
tetrabutylammonium (TBA) salt were chromatographable via silica column, however, the 
boc protected TBA salt was used without further purification. Initial attempts involved 
subjected the TBA salt to the chlorination conditions of triphenylphosphine and sulfuryl 
chloride to generate the sulfonyl chloride in situ and then addition of the tribenzoyl 
cytidine amine 41 or tribenzoyl cytidine 4. Under these conditions, the tribenzoyl cytidine 
analogs 41 and 4 were recovered in 80% or greater and no productive coupling was 
detected whether the boc, phthaloyl, or PMB vinyl sulfonate was used.  
 
 
Scheme 4.7: Coupling of two fragments 
 The Boc protected sulfonate was used in model reactions for probing the 
chlorination and coupling conditions because it was most analogous to molecules 
successfully coupled in literature.17 The Boc protected sulfonate TBA salt was exposed to 
one to ten equivalents of freshly distilled sulfuryl chloride and one to three equivalents of 
triphenylphosphine. Based upon literature precedent, the reaction mixture was purified 
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over oven dried silica gel.4, 17 However, the desired sulfonyl chloride was not recovered. 
Triphenylphosphine oxide and TBA were recovered off the column, but no species 
containing the Boc protecting group and the vinyl group were recovered. The 
chlorination conditions were then varied using Oxalyl chloride, thionyl chloride, and 
phosphorous trichloride; however, the sulfonyl chloride was not isolatable. Investigating 
the PMB protected sulfonate TBA salt using the various chlorinating conditions resulted 
in up to 50% deprotection of the PMB acetal and no chlorinated product. 
 
Scheme 4.8: Synthesis of N-Boc sulfones 
 Based upon literature reports that N-Boc protected mesylates and tosylates can be 
coupled to various alcohols through the Mitsunobu reaction, an alternative route utilizing 
a Mitsunobu reaction to install either the vinyl sulfone or the sulfonyl phosphonate was 
also explored.19 Methanesulfonamide is protected with Boc anhydride in the presence of 
catalytic DMAP (Scheme 4.8).20 Treating sulfone 42 with two equivalents of n-butyl 
lithium and diethyl chlorophosphate yielded the desired phosphonate smoothly in 60%.20 
The Boc protected phosphonate was then coupled via a HWE reaction to the PMB 
protected aldehyde 37. The Mitsunobu reaction conditions were explored treating 
triphenylphosphine with diisopropyl azodicarboxylate (DIAD) to pre-form the betaine 
and then tribenzoyl cytidine 4 and the various N-Boc sulfones 42-44 were added and 
allowed to stir for 24 hrs.  Under these conditions only sulfone 42 was successful in 
forming the cytidine sulfone in 53% by NMR. Numerous attempts to isolate the desired 
cytidine sulfone via column chromatography, inseparable mixtures contaminated with 
tribenzoyl cytidine and triphenylphosphine oxide were obtained. Varying the reaction 
conditions did not allow for the successful addition of either sulfone 43 or 44 with 
tribenzoyl cytidine being isolated as the major product in all cases. The optimized 
conditions of pre-forming the betaine and accelerating the reaction using sonication 
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allowed for the reaction time of sulfone 42 to be reduced to 15 min, but there was no 
improvement in yield or purification. 
 The final attempt to install the desired vinyl sulfone on the intermediate mimic 
was to build the sulfonyl phosphonate required for the HWE reaction off of the cytidine 
portion of the molecule. Mesyl tribenzoyl cytidine 39 was treated with either two or three 
equivalents of sodium hydride, LDA, or n-BuLi at -78°C for thirty minutes and diethyl 
chlorophosphate was added. Upon workup and purification greater than 75% of the 
starting mesylate was recovered along with 10% tribenzoyl cytidine but none of the 
desired product. The stir time was extended and the reaction was allowed to warm to 
room temperature, 0°C, and -48°C with the same results. 
 Installing the vinyl sulfone in an intermediate mimic of PPCS proved more 
difficult than initially anticipated due to the inability to link the two fragments of the 
intermediate mimic. The vinyl sulfone moiety was readily installed in a PMB protected 
panthenol molecule and in both a Boc and phthaloyl protected β-alanine molecule. 
However, converting these molecules to the necessary sulfonyl chlorides was never 
accomplished. This reaction was difficult due to the inability to properly monitor the 
reaction as TLC was inconclusive at best. Crude 1H NMRs conclusively showed 
decomposition products during some reactions, but did not conclusively show conversion 
to the desired product under any circumstances. The phthaloyl protected β-alanine was 
the most promising based on the fact that despite not yielding the sulfonyl chloride the 
phthaloyl protecting group was never deprotected in situ under the chlorination 
conditions and the phthaloyl protected β-alanine was converted successfully to the acid 
chloride. 
 The alternative route of installing the vinyl sulfone on the cytidine portion of the 
molecule was promising because it eliminated the need to generate the sulfonyl chloride 
and utilized previously made intermediates.  Installing the sulfonyl phosphonate required 
for the HWE reaction on the cytidine portion via the Mitsunobu reaction was 
unsuccessful using the desired phosphonate nucleophile. Tribenzoyl cytidine had proven 
to be an efficient nucleophile under all other reaction conditions, but its steric hindrance 
may have prevented its activation under the Mitsunobu conditions or once activated may 
have been too sterically hindered to allow nucleophilic attack by the phosphonate. 
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Deprotonation of mesyl tribenzoyl cytidine and subsequent nucleophilic attack of diethyl 
chlorophosphate was also surprisingly unsuccessful. Extra equivalents of base were 
employed due to the acidic amide proton on the benzoyl protecting group of the exocyclic 
amine, but the reaction was still unsuccessful. The recovered starting material means that 
the deprotonated mesylate was not nucleophilic enough to attack the chlorophosphate or 
the mesylate was not properly deprotonated. While unsuccessful to this point, the route of 
installing the sulfonyl phosphonate on the cytidine portion of the molecule is promising 
and more straightforward to monitor and thus troubleshoot as compared to the sulfonyl 
chloride route. 
 
Scheme 4.9: Synthesis of vinyl sulfone PPA analog 
 An alternative smaller vinyl sulfone based upon the PPA portion of the 
intermediate mimic was also pursued. The PMB acetal of the ethyl sulfonate 38 can be 
cleanly removed by passing the molecule through a Dowex 100 H+ anion exchange 
column. The primary alcohol is the selectively phosphitylated using pyridinium HCl in 
DMF at -5°C and oxidized in situ using hydrogen peroxide to give the crude protected 
phosphate 45. The crude protected phosphate 45 was deprotected in a two step sequence 
using DBU and TMSCl to deprotect the terminal phosphate, followed by potassium 
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iodide to remove the ethyl ester. Crude NMR after passing the reaction mixture through a 
C18 sep prep column revealed pantolactone and other degradation products. The non-
phosphorylated analog 48 was obtained by simply treating ethyl ester 38 with tetrabutyl 
ammonium iodide followed by passing the crude reaction mixture through a Dowex 100 
column followed by a C18 sep prep column. 
Conclusion 
 Disulfide 24 was the first PPA mimic synthesized and evaluated as an inhibitor of 
PPCS. Compound 24 was synthesized as the tetrasodium salt in four steps from 
commercially available material. Deprotection of the final product proved to be the most 
difficult step due to decomposition of the final product under the deprotection conditions. 
The disulfide in compound 24 was reduced prior to pre-incubation with PPCS and CTP. 
Under these conditions, the sulfur analog of PPA did not display time dependent 
inactivation of PPCS. The reduced form of disulfide 24 was shown to be a competitive 
inhibitor with respect to PPA of PPCS with an initial Ki of 12 µM. This molecule was the 
first PPA competitive inhibitor of PPCS and proved low micromolar inhibition could be 
achieved with a low molecular weight molecule. In order to take the PPA mimic 24 
forward, the terminal phosphate must either be replaced by a neutral isostere or masked 
as a labile phosphodiester prodrug. 
 The mechanistic probe designed with a vinyl sulfone installed in an intermediate 
mimic to trap cysteine in the second half reaction of PPCS was not synthesized due to the 
difficulty of linking the cytidine portion and the vinyl sulfone installed within the β-
alanine portion of the molecule. The first route consisted of installing the vinyl sulfone on 
the β-alanine portion of panthenol and then generating a sulfonyl chloride to be linked to 
tribenzoyl cytidine. This strategy was hampered by the inability to monitor the 
chlorination of the vinyl sulfone. Alternatively, installing the prerequisite sulfonyl 
phosphonate for the HWE reaction on the cytidine portion of the molecule was much 
more straightforward to monitor, but was as yet unsuccessful. The PMB protected vinyl 
sulfone 38 was successfully deprotected to yield both the ethyl ester and the sulfonic 
acid. Current attempts to chemically phosphorylate the diol on the ethyl ester 45 were 
successful, but it was not possible to purify the product. The PMB protected vinyl sulfone 
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Materials and Methods 
General Methods: All chemicals were used as purchased from Acros, Fisher, Fluka, 
Sigma-Aldrich, or Specialty Chemicals Ltd. and used without further purification unless 
otherwise noted. 1H NMR, 13C NMR, and 31P NMR spectra were recorded on a Bruker 
Avance DRX 500MHz spectrometer or Bruker Avance DPX 300MHz spectrometer. 
Proton assignments are reported in ppm from an internal standard of TMS (0.0ppm), and 
phosphorous assignments are reported relative to an external standard of 85% H3PO4 
(0.0ppm). Proton chemical data are reported as follows: chemical shift, multiplicity (ovlp 
= overlapping, s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, m = multiplet, 
br = broad), coupling constant in Hz, and integration. All high resolution mass spectra 
were acquired from the Mass Spectrometry facility in the Chemistry Department at The 
University of Michigan using either positive-ion or negative-ion mode ESI-MS. Thin 
layer chromatography was performed using Analtech GHLF 250 micron silica gel TLC 
plates. All flash chromatography was performed using grade 60 Å 230-400 mesh silica 
purchased from Fisher. 
 
3-(tritylthio)propan-1-amine (21) 3-bromopropan-1-amine hydrobromide (2.38 g, 10.85 
mmol) was dissolved in anhydrous THF (8 mL). DBU (5.83 mL, 32.56 mmol) was added 
dropwise and stirred for 15 min. Trityl thiol (3 g, 10.85 mmol) was added and stirred at 
room temperature for 24 hrs. The solvents were removed in vacuo and the resulting syrup 
was purified over silica (50 mL) eluting with 25% EtOAc in hexanes (150 mL), 50% 
EtOAc in hexanes (150 mL), 75% EtOAc in hexanes (150 mL), and 100% EtOAc to 
yield desired product as a yellow oil (2.12g, 58%).  1H NMR (DMSO-d6) δ 7.92 (s, 1H), 
7.37 – 7.29 (m, 12H), 7.25 (t, J = 6.7, 3H), 2.98 (dd, J = 12.9, 6.4, 2H), 2.10 (t, J = 7.4, 
2H), 1.47 – 1.38 (m, 2H). 13C NMR (DMSO-d6): δ 145.07, 129.57, 128.45, 127.11, 




(tritylthio)propan-1-amine 1 (1.40 g, 4.19 mmol) was dissolved in ethanol (10 mL). 
Triethylamine (1.75 mL, 12.57 mmol) was added and stirred for 10 min. Pantolactone 
(1.60 g, 12.57 mmol) was added and the reaction was heated to 120°C and stirred 
overnight. Solvents were removed in vacuo and the resulting syrup was purified over 
silica (75 mL) eluting with DCM (300 mL), 1% MeOH in DCM (225 mL), 2% MeOH in 
DCM (300 mL) to yield desired product as a clear oil (1.59 g, 82%). 1H NMR (DMSO-
d6) δ 7.64 (t, J = 5.7 Hz, 1 H), 7.36 – 7.14 (m, 15H), 5.29 (d, J = 5.5, 1H), 4.46 (t, J = 5.6, 
1H), 3.65 (d, J = 5.6, 1H), 3.28-3.23 (m, 2H), 3.10 – 3.02 (m, 1H), 3.01-2.92 (m, 1H), 
2.07 (t, J = 7.44 Hz, 2H), 1.44 (t, J = 7.05 Hz, 2H), 0.74 (s, 3H) , 0.72 (s, 3H). 13C NMR 
(DMSO-d6) δ 173.30, 144.95, 129.51, 128.47, 127.14, 75.45, 68.48, 66.38, 49.06, 37.99, 
29.49, 28.61, 21.44, 20.79. HR-ESI-MS: calcd for [M+Na]+, 486.2074; found 486.2080. 
 (R)-biscyanoethyl (3-hydroxy-2,2-dimethyl-4-oxo-4-((3-
(tritylthio)propyl)amino)butyl) phosphate (23) The protected thiol 2 (200 mg, 0.432 
mmol) and O,O-bis(cyanoethyl)-N-diisopropylamine phosphoramidite (178 mg, 0.648 
mmol) was dissolved in anhydrous pyridine (2 mL) and cooled to -20°C. Pyridinium HCl 
(78 mg, 0.648 mmol) was added and stirred at -20°C for 2 hrs.5 M t-butyl hyperperoxide 
(130 mL, 0.648 mmol) was added dropwise and stirred for 2 hrs. Solvents were removed 
in vacuo and the resulting syrup was purified over silica (25 mL) eluting with 50% 
EtOAc in hexanes (75 mL), 75% EtOAc in hexanes (150 mL), and 100% EtOAc, and 
10% MeOH in EtOAc (75 mL) to yield desired product as a clear oil (154 mg, 55%). 1H 
NMR (DMSO-d6) δ 7.72 (s, 1H), 7.40 – 7.27 (m, 12H), 7.25 (d, J = 7.5, 3H), 5.64 (d, J = 
5.8, 1H), 4.01 (m, 4H), 3.84-3.80 (m, 1H), 3.95-3.93 (m, 2H), 3.63 (d, J = 5.46 Hz, 1H), 
3.47-3.40 (m, 2H), 2.94-2.87 (m, 4H), 2.07 (t, J = 7.35 Hz, 2H), 1.45 (t, J = 2.7, 2H), 
0.83 (s, 3H), 0.80 (s, 3H). 13C NMR (DMSO-d6) δ 172.30, 144.94, 129.51, 128.48, 
127.14, 118.17, 74.33, 66.41, 62.81, 60.83, 38.87, 38.02, 29.48, 28.60, 21.00, 20.19, 
19.57. 31P NMR (DMSO-d6): δ -2.11 (s, 1P).   
(3R,3'R)-((disulfanediylbis(propane-3,1-diyl))bis(azanediyl))bis(3-hydroxy-2,2-
dimethyl-4-oxobutane-4,1-diyl) bis(phosphate) tetrasodium salt (24) The protected 
phosphate 23 (65 mg, 0.099 mmol) was dissolved in MeOH (5 mL)  and the  solution was 
cooled to 0°C. I2 (25 mg, 0.10 mmol) was added and the reaction was stirred at 0°C for 
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15 min. The reaction was then diluted to a volume of 15 mL of MeOH and passed 
through AGMP anion exchange column (12 mL). The solvents were removed in vacuo. 
The resulting paste was taken up in anhydrous THF (3 mL). DBU (0.120 mL, 0.80 mmol) 
was added followed by TMSCl (0.065 mL, 0.50 mmol) and allowed to stir for 6 hrs. The 
solvents were removed in vacuo and the resulting paste was taken up in 1:1 pyridine:H2O 
(5 mL) and stirred for 3 hrs. The reaction was partitioned between DCM and H2O. The 
H2O layer was washed with DCM (2x) and the loaded onto a 15 mL AMGP anion 
exchange resin. The column was eluted with a gradient of 1M NaCl with the UV active 
fractions at 420 mM NaCl collected and passed through a P2 sizing column eluting with 
H2O. The UV active fractions (16-20) were pooled and lyophilized to yield the desired 
compound as a fluffy white solid (18.5 mg, 27%). 1H NMR (D2O-d2) δ 3.94 (s, 1H), 3.70 
(dd, J = 2.2, 6.9 Hz, 1H), 3.45 (dd, J = 4.74, 9.09 Hz, 1H), 3.22 (t, J = 6.51 Hz, 2H), 2.63 
(t, J = 7.0 Hz, 2H), 1.81 (t, J = 6.50 Hz, 2H), 0.87 (s, 3H), 0.79 (s, 3H). 13C NMR (D2O-
d2) δ 174.80, 74.36, 70.97, 38.27, 38.17, 37.41, 35.10, 28.00, 20.75, 18.42. 31P NMR 
(DMSO-d6) δ 0.51 (s, 1P). ESI-MS calcd for [M+3Na]- 665.07; found 665.1. 
(2R,2'R)-N,N'-(disulfanediylbis(propane-3,1-diyl))bis(2,4-dihydroxy-3,3-
dimethylbutanamide) (25) The protected thiol 22 (50 mg, 0.108 mmol) was dissolved in 
MeOH (5 mL). The solution was cooled to 0°C and I2 (27 mg, 0.108 mmol) was added 
and the reaction was stirred at 0°C for 15 min. The reaction was diluted with DCM and 
then washed with H2O. The H2O layer was then passed through a 12 mL AMGP anion 
exchange column. The eluent was collected and lyophilized to give the desired compound 
as a white solid (41 mg, 87%). 1H NMR (D2O-d2) δ 3.85 (s, 1H), 3.48 (d, J = 11.25 Hz, 
1H), 3.25 (d, ovlp, 1H), 3.23-3.15 (m, ovlp, 2H), 2.62 (t, J = 7.13 Hz, 2H), 1.79 (t, J = 
7.13 Hz, 2H),  0.80 (s, 3H), 0.77 (s, 3H). 13CNMR (D2O-d2) δ 174.97, 75.73, 68.38, 
38.60, 37.48, 36.27, 28.20, 20.57, 19.16. ESI-MS: calcd for [M+H]+, 440.21; found 
440.2. 
(R)-tert-butyl (3-(2,4-dihydroxy-3,3-dimethylbutanamido)propyl)carbamate (26) 
tert-Butyl (3-aminopropyl)carbamate (500 mg, 2.87 mmol) was dissolved in ethanol (10 
mL). Triethylamine (1.20 mL, 8.61 mmol) was added and stirred for 10 min. 
Pantolactone (1.12 g, 8.61 mmol) was added and the reaction was heated to 120°C and 
stirred overnight. Solvents were removed in vacuo and the resulting syrup was purified 
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over silica (75 mL) eluting with DCM (300 mL), 1% MeOH in DCM (225 mL), 2% 
MeOH in DCM (300 mL), 4%MeOH in DCM (300 mL) to yield desired product as a 
clear oil (786 mg, 90%). 1H NMR (DMSO-d6) δ 7.75 (t, J = 5.7, 1H), 6.79 (t, J = 5.6, 
1H), 5.37 (d, J = 5.5, 1H), 4.48 (t, J = 5.6, 1H), 3.69 (d, J = 5.5, 1H), 3.34 (s, 1H), 3.30 
(dd, J = 10.4, 5.8, 1H), 3.17 (dd, J = 10.4, 5.4, 1H), 3.09 (dd, J = 11.7, 5.3, 1H), 3.02 (dt, 
J = 13.2, 6.6, 1H), 2.91 (dd, J = 12.7, 6.4, 2H), 1.48 (dt, J = 12.7, 6.2, 2H), 1.37 (s, 9H), 
0.80 (s, 3H), 0.79 (s, 3H). 13C NMR (DMSO-d6) δ 173.41, 156.08, 77.91, 75.57, 68.49, 
39.47, 37.78, 36.06, 30.17, 28.70, 21.43, 20.88. HR-ESI-MS: calcd for [M+Na]+, 
327.1891; found 327.1887. 
(R)-tert-butyl (3-(4-((bis(2-cyanoethoxy)phosphoryl)oxy)-2-hydroxy-3,3-
dimethylbutanamido)propyl)carbamate (27)  The protected amine 26 (80 mg, 0.432 
mmol) and O,O-bis(cyanoethyl)-N-diisopropylamine phosphoramidite (178 mg, .648 
mmol) was dissolved in anhydrous DMF (2 mL) and cooled to -5°C. Pyridinium HCl (78 
mg, .648 mmol) was added and stirred at -5°C for 4 hrs.5 M t-butyl hyperperoxide (0.130 
mL, 0.648 mmol) was added dropwise and stirred for 2 hrs. Solvents were removed in 
vacuo and the resulting syrup was purified over silica (15 mL) eluting with EtOAc (50 
mL), 5% MeOH in EtOAc (50 mL) to yield desired product as a clear oil (64 mg, 50%). 
1H NMR (DMSO-d6) δ 7.84 (t, J = 5.64 Hz, 1H), 6.79 (t, J = 5.58 Hz, 1H), 5.71 (d, J = 
5.13 Hz, 1H),  4.19-4.15 (m, 4H), 3.98-3.94 (m, 1H), 3.88-3.83 (m, 1H), 3.70 (d, J = 4.80 
Hz, 1H), 2.96-2.92 (m, 4H), 1.47 (t, J = 6.48 Hz, 2H), 1.37 (s, 9H), 3.17-3.05 (m, 4H), 
0.91 (s, 3H), 0.88 (s, 3H). 13C NMR (DMSO-d6) δ 172.41, 162.77, 156.09, 118.71, 77.93, 
74.18, 73.89, 62.82, 60.83, 37.79, 36.13, 31.22, 28.70, 20.87, 20.19, 19.57. 31P NMR 
(DMSO-d6) δ -2.11 (s, 1P). 
sodium (R)-4-((3-ammoniopropyl)amino)-3-hydroxy-2,2-dimethyl-4-oxobutyl 
phosphate chloride (28)  The protected phosphorylated amine 27 (45 mg, 0.092 mmol) 
was dissolved in anhydrous DCM (2 mL). DBU (0.11 mL, 0.736 mmol) was added 
followed by TMSCl (0.60 mL, 0.50 mmol). The reaction was stirred for 6 hrs. The 
solvents were removed in vacuo. The resulting residue was dissolved in 1:1 pyridine:H2O 
(5 mL) and stirred at rt for 4 hrs. The solvents were removed in vacuo. The resulting 
residue was dissolved in 1M HCl (5 mL) and stirred for 12 hrs. The solvents were 
removed in vacuo and the resulting paste was dissolved in water and passed through a 
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C18 sep prep column. Fractions 3-5, which were positive by I2 staining, were combined 
and solvents were removed in vacuo. Crude NMR and mass spectrometry revealed 
desired product contamiated with pyridine and another undetermined contaminent. Crude 
1H NMR (D2O- d2) δ 3.81 (s, 1H), 3.69-3.67 (m, 1H), 3.55 -3.53 (m, 1H), 2.83 (t, J = 
7.26 Hz, 2H), 1.72-1.67 (m, ovlp, 2H), 0.78 (s, 3H), 0.73 (s, 3H). 31P NMR (DMSO-d6) 
δ −0.34 (s, 1P). ESI-MS: calcd for [2M+H]-, 567.22; found 567.2. 
(R)-N-(3-aminopropyl)-2,4-dihydroxy-3,3-dimethylbutanamide hydorchloride salt 
(29)  The protected amine 26 (15 mg, 0.049 mmol) was dissolved in 1.25 M MeOH:HCl 
(5 mL) and stirred at rt for 8 h. Solvents were removed in vacuo and desired product was 
dried on high vac overnight to yield the desired product as white crystaline solid (10 mg, 
88%). 1H NMR (D2O- d2) δ 3.85 (s, 1H), 3.37 (d, J = 11.3, 1H), 3.25 (d, J = 11.2, 1H), 
3.19 (t, J = 6.9, 2H), 2.87 (t, J = 7.6, 2H), 1.76 (dd, J = 14.6, 7.2, 2H), 0.79 (s, 3H), 0.75 
(s, 3H). 13C NMR (D2O- d2): δ 175.58, 75.69, 68.20, 38.55, 36.99, 35.56, 26.66, 20.46, 
19.08. 
ethyl (diethoxyphosphoryl)methanesulfonate (30) Ethyl methane sulfonate (1 mL, 9.6 
mmol) was dissolved in anhydrous THF (5 mL). The solution was cooled to -78°C for 30 
min. 1.6 M n-BuLi (6.2 mL, 10.12 mmol) was added dropwise and the solution was 
stirred for 15 min. Diethyl chlorophosphate (0.775 mL, 5.34 mmol) was added dropwise 
and stirred at -78°C. This reaction was then warmed up to -48°C and stirred for 1.5 hrs. 
The reaction was quenched with saturated ammonium chloride and allowed to warm to rt. 
The solvents were removed in vacuo and the resulting syrup was purified over silica (50 
mL) eluting with 25% EtOAc in hexanes (150 mL), 50% EtOAc in hexanes (150 mL), 
and EtOAc (150 mL) to yield the desired phosphonate as a clear oil (776 mg, 55%). 1H 
NMR (DMSO-d6): δ 4.43 (d, J = 18 Hz, 2H), 4.32 (q, J = 6.0 Hz, 2H), 4.09 (q, J = 7.02 
Hz, 4H), 1.25 (t, J = 7.05 Hz, 6Hz). 13C NMR (DMSO-d6): δ 68.54, 63.11, 47.03, 45.25, 
16.54, 15.13. 31P NMR (DMSO-d6): δ 12.43 (s, 1P). 
tert-butyl (3-hydroxypropyl)carbamate (31) Boc anhydride (6.15 g, 28.18 mmol) was 
dissolved in anhydrous THF (50 mL). The solution was cooled to 0°C and 3-
aminopropanol (1.95 mL) was added slowly and stirred for 15 min. Triethylamine (8.9 
mL, 64 mmol) was added and the reaction was allowed to warm to rt and stirred 
overnight. Solvents were removed in vacuo and the resulting syrup was partitioned 
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between DCM and H2O. The DCM layer was dried (Na2SO4) and concentrated in vacuo 
to give the desired product as a clear oil (3.63 g, 80%). 1H NMR (DMSO-d6): δ 4.39 (t, J 
= 3.09 Hz, 1 H), 3.38 (q, J = 3.66 Hz, 2 H), 2.95 (q, J = 3.96 Hz, 2 H), 1.51 (p, J = 4.05 
Hz, 2 H), 1.37 (s, 9 H). 13C NMR (DMSO-d6): δ 156.08, 77.83, 58.96, 37.62, 33.20, 
28.83. . HR-ESI-MS: calcd for [M+Na]+, 198.1101; found 198.1117. 
tert-butyl (3-oxopropyl)carbamate (32) Oxalyl chloride (0.91 mL, 10.4 mmol) was 
dissolved in anhydrous DCM (7 mL) and cooled to -78°C. A solution of DMSO (1.6 mL, 
22.8 mmol) in anhydrous DCM (3 mL) was added dropwise and then stirred at -78°C for 
15 min. A solution of the protected alcohol 31 (1 g, 5.7 mmol) in anhydrous DCM (3 mL) 
was added dropwise and stirred at -78°C for 4 hr. Triethylamine (3 mL, 22.8 mmol) was 
added and the reaction was warmed to rt over 2 hr. The reaction was diluted using DCM 
and washed with H2O (3x).  Solvents were removed in vacuo and the resulting syrup was 
purified over silica (75 mL) eluting with 25% EtOAc in hexanes (250 mL) and 50% 
EtOAc in hexanes to yield 891 mg of the desired product as a pale yellow oil (90%). 1H 
NMR (DMSO-d6): δ 9.62 (s, 1 H), 3.21 (q, J = 3.77 Hz, 2 H), 2.52 (m, ovlp, 2 H), 1.37 
(s, 9 H). 13C NMR (DMSO-d6): δ 202.88, 155.99, 78.17, 53.00, 34.44, 28.65. 
(E)-ethyl 4-((tert-butoxycarbonyl)amino)but-1-ene-1-sulfonate (33) Ethyl 
(diethoxyphosphoryl)methanesulfonate (499 mg, 1.87 mmol) was dissolved in anhydrous 
THF (4 mL) and cooled to -78°C. n-BuLi (1.6M, 1.25 mL, 2 mmol) was added dropwise 
and stirred for 30 min. The aldehyde 32 (270 mg, 1.55 mmol) in anhydrous THF (2 mL) 
was added dropwise and stirred at -78°C for 2h and then warmed to rt and stirred for 48h. 
Solvents were removed in vacuo and the resulting syrup was purified over silica (50 mL) 
and eluted with 25% EtOAc in hexanes (150 mL), 50% EtOAc in hexanes (150 mL), 
75% EtOAc in hexanes (150 mL) to yield the desired product as a pale yellow oil (325 
mg, 75%). 1H NMR (DMSO-d6): δ 7.12 (t, J = 5.52, 1 H), 5.85 (dt, J = 5.25, 20.52 Hz, 1 
H), 5.48 (dt, J = 5.25, 15.36 Hz, 1 H), 4.24 (q, J = 7.08 Hz, 2 H), 4.10 (d, J = 7.20 Hz, 2 
H), 3.57 (t, J = 5.10 Hz, 2 H), 1.38 (s, 9 H), 1.27 (t, J = 7.02 Hz, 3 H). 13C NMR (DMSO-
d6): δ 156.10, 137.58, 117.34, 78.19, 67.91, 52.50, 41.50, 28.68, 15.30. HR-ESI-MS: 
calcd for [M+Na]+, 302.1033; found 302.1034. 
2-(3-hydroxypropyl)isoindoline-1,3-dione (34) 3-aminopropanol (10g, 131 mmol) and 
phthalic anhydride (19.46g, 131 mmol) were placed in an open flask with a magnetic stir 
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bar. The two solids were heated to 150°C for 2 hrs. The reaction was cooled to rt and 
H2O was added. The reaction was filtered and dried under vacuum to yield the desired 
product as a white crystalline solid (23.77g, 90%). 1H NMR (DMSO-d6): δ 7.79 (s, 4H), 
4.53 (t, J = 5.04 Hz, 1H), 3.61 (t, J = 7.20 Hz, 2H), 3.43 (q, J = 6.06 Hz, 2H), 1.73 (p, J = 
6.21 Hz, 2H). 13C NMR (DMSO-d6): δ 168.31, 162.33, 134.67, 132.07, 123.31, 59.02, 
35.61, 31.64. 
3-(1,3-dioxoisoindolin-2-yl)propanal (35) Oxalyl chloride (1.75 mL, 20 mmol) was 
dissolved in anhydrous DCM (30 mL) and cooled to -78°C. A solution of DMSO (2.84 
mL, 40 mmol) in anhydrous DCM (5 mL) was added dropwise and then stirred at -78°C 
for 15 min. A solution of the protected alcohol 34 (2.05 g, 10 mmol) in anhydrous DCM 
(10 mL) was added dropwise and stirred at -78°C for 4 hr. Triethylamine (3.17 mL, 22.8 
mmol) was added and the reaction was warmed to rt over 2 hr. The reaction was diluted 
using DCM and washed with H2O (3x).  Solvents were removed in vacuo and the 
resulting syrup was purified over silica (75 mL) eluting with 25% EtOAc in hexanes (250 
mL) and 50% EtOAc in hexanes to yield 1.70 g of the desired product as a pale yellow 
oil (84%). 1H NMR (DMSO-d6): δ 9.84 (s, 1H), 7.89-7.84 (m, 2H), 7.77-7.72 (m, 2H), 
4.06 (t, J = 6.90 Hz, 2H), 2.90 (td, J = 6.96, 1.26 Hz, 2H). 13C NMR (DMSO-d6): 
δ 199.41, 134.13, 131.97, 42.38, 31.68. 
(E)-ethyl 4-(1,3-dioxoisoindolin-2-yl)but-1-ene-1-sulfonate (36) Ethyl 
(diethoxyphosphoryl)methanesulfonate (98 mg, 0.378 mmol) was dissolved in anhydrous 
THF (2.5 mL) and cooled to -78°C. n-BuLi (1.6M, 0.225 mL, 0.41 mmol) was added 
dropwise and stirred for 30 min. The aldehyde 35 (64 mg, 0.315 mmol) in anhydrous 
THF (2 mL) was added dropwise and stirred at -78°C for 2h and then warmed to rt and 
stirred for 48h. Solvents were removed in vacuo and the resulting syrup was purified over 
silica (25 mL) and eluted with 25% EtOAc in hexanes (75 mL), 50% EtOAc in hexanes 
(75 mL), 75% EtOAc in hexanes (75 mL) to yield the desired product as a pale yellow oil 
(75 mg, 76%). 1H NMR (DMSO-d6): δ 7.89-7.84 (m, 2H), 7.78-7.73 (m, 2H), 6.90 (dt, J 
= 7.08, 15.24 Hz, 1H), 6.33 (dt, J = 1.44, 15.24 Hz, 1H), 4.16 (q, J = 2.9 Hz), 3.90 (t, J = 
6.87 Hz, 2H), 2.71 (qd, J = 1.38, 6.93 Hz, 2H), 1.33 (t, J = 6.12 Hz, 3H). 13C NMR 





(37) Oxalyl chloride (1.08 mL, 12.38 mmol) was dissolved in anhydrous DCM (10 mL) 
and cooled to -78°C. A solution of DMSO (1.76 mL, 24.75 mmol) in anhydrous DCM (5 
mL) was added dropwise and then stirred at -78°C for 15 min. A solution of the protected 
alcohol 1 (2.0 g, 6.19 mmol) in anhydrous DCM (10 mL) was added dropwise and stirred 
at -78°C for 4 hr. Triethylamine (3.5 mL, 24.75 mmol) was added and the reaction was 
warmed to rt over 2 hr. The reaction was diluted using DCM and washed with H2O (3x).  
Solvents were removed in vacuo and the resulting syrup was purified over silica (75 mL) 
eluting with 25% EtOAc in hexanes (250 mL), 50% EtOAc in hexanes (250 mL), and 
75% EtOAc (250 mL) to yield 1.63 g of the desired product as a pale yellow oil (82%). 
1H NMR (DMSO-d6): δ 9.62 (s, 1H), 7.57 (t, J = 5.25 Hz, 1H), 7.44 (d, J = 8.61 Hz, 2H), 
6.93 (d, J = 8.64 Hz, 2H), 5.51 (s, 1H), 4.08 (s, 1H), 3.76 (s, 3H), 3.67-3.62 (m, 2H), 
3.58-3.44 (m, 1H), 3.38-3.29 (m, 1H), 2.57 (t, J = 6.45 Hz, 2H), 0.97 (s, 3H), 0.93 (s, 
3H). 13C NMR (DMSO-d6): δ 203.00, 168.89, 128.24, 113.78, 83.69, 77.83, 60.22, 55.59, 
43.95, 32.88, 21.96, 19.47, 14.55. 
(E)-ethyl 4-((4R)-2-(4-methoxybenzyl)-5,5-dimethyl-1,3-dioxane-4-
carboxamido)but-1-ene-1-sulfonate (38) Ethyl (diethoxyphosphoryl)methanesulfonate 
(250 mg, 0.964 mmol) was dissolved in anhydrous THF (5 mL) and cooled to -78°C. n-
BuLi (1.6M, 0.625 mL, 1 mmol) was added dropwise and stirred for 30 min. The 
aldehyde 37 (311 mg, 0.964 mmol) in anhydrous THF (3 mL) was added dropwise and 
stirred at -78°C for 2h and then warmed to rt and stirred for 48h. Solvents were removed 
in vacuo and the resulting syrup was purified over silica (25 mL) and eluted with 25% 
EtOAc in hexanes (75 mL), 50% EtOAc in hexanes (75 mL), 75% EtOAc in hexanes (75 
mL) to yield the desired product as a pale yellow oil (292 mg, 71%). 1H NMR (DMSO-
d6): δ 7.44 (d, J = 8.52 Hz, 2H), 6.93 (d, J = 8.50 Hz, 2H), 5.86 (dt, J = 6.10, 15.20 Hz, 
1H), 5.53 (s, 1H), 5.50-5.45 (m, ovlo, 1H), 4.23 (m, 2H), 4.13-4.07 (m, 2H), 3.76 (s, 3H), 
3.66-3.58 (m, 2H), 1.24 (td, J = 2.2, 7.0 Hz, 3H), 1.03 (s, 3H), 0.95 (s, 3H). 
O-Mesyl-tribenzoyl cytidine (39) Tribenzoyl cytidine (1.29 g, 2.25 mmol) was 
dissolved in anhydrous pyridine (8 mL) and cooled to 0°C. Mesyl chloride (0.261 mL, 
3.38 mmol) was added dropwise and stirred at 0°C for 2 h. The reaction was allowed to 
warm to rt and then stirred overnight. The solvents were removed in vacuo and the 
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resulting syrup was purified over silica (100 mL) eluting with 25% EtOAc in hexanes 
(300 mL), 50% EtOAc in hexanes (300 mL), 75% EtOAc in hexanes (300 mL), and 
100% EtOAc (300 mL) to yield 1.23 g of the desired compound as a white solid (84%). 
1H NMR (DMSO-d6): δ 11.43 (s, 1 H), 8.31 (d, J = 4.50 Hz, 1 H), 8.03 (d, J = 4.86 Hz, 2 
H), 7.94 (d, J = 4.80 Hz, 2 H), 7.88 (d, J = 4.77 Hz, 2H), 7.69-7.65 (m, 3 H), 7.55-7.44 
(m, 6 H), 6.26 (d, J = 2.13 Hz, 1 H), 5.97 (t, J = 2.99 Hz, 1 H), 5.83 (t, J = 3.65 Hz, 1 H), 
4.77 (s, 1 H), 4.65 (t, ovlp, 1 H), 4.63 (m, 1 H), 3.28 (s, 3 H). 13C NMR (DMSO-d6): 
δ 165.09, 165.00, 164.42, 154.80, 147.66, 134.44, 134.44, 134.38, 133.45, 133.34, 
129.84, 129.22, 128.99, 128.94, 97.33, 91.83, 79.81, 73.96, 70.90, 69.30, 37.35. HR-ESI-
MS: calcd for [M+Na]+, 656.1309; found 656.1332. 
5’-Azido-5’-deoxy-tribenzoyl cytidine (40) The mesylate 39 (850 mg, 1.3 mmol) was 
dissolved in anhydrous DMF (7 mL). Sodium azide (425 mg, 6.5 mmol) was added and 
the reaction was heated to 60°C and stirred for 16h. Solvents were removed in vacuo and 
the resulting paste was purified over silica (50 mL) eluting with 25% EtOAc in hexanes 
(150 mL), 50% EtOAc in hexanes (150 mL) to yield the desired product as a white solid 
(702 mg, 93%). 1H NMR (DMSO-d6): δ 11.42 (s, 1 H), 8.34 (d, J = 6.63 Hz, 1 H), 8.02 
(d, , J = 7.77 Hz, 2 H), 7.92 (d, , J = 8.07 Hz, 2 H), 7.87 (d, , J = 7.92 Hz, 2 H), 7.68-7.63 
(m, 3 H), 7.55-7.44 (m, 6 H),  6.21 (s, 1 H), 5.99 (s, 1 H), 5.76 (t, , J = 7.32 Hz, 1 H),  
4.68-4.63 (m, 1 H), 3.90-3.84 (m, 2 H). 13C NMR (DMSO-d6): δ 165.13, 165.05, 162.76, 
147.85, 134.41, 134.33, 133.56, 133.30, 129.82, 129.20, 129.06, 129.00, 128.92, 97.37, 
91.89, 80.80, 73.95, 71.53, 51.38. 1H NMR (DMSO-d6): δ 1HR-ESI-MS: calcd for 
[M+H]+, 581.1785; found 581.1785. 
5’-Amino-5’-deoxy-tribenzoyl cytidine (41) The azide 40 (100 mg, 0.172 mmol) was 
dissolved in anhydrous THF (2 mL) and degassed with Ar. Pd/C (10%, 53 mg, 0.05 
mmol) was added followed by 1,4 cyclohexadiene (0.2 mL, 1.72 mmol). The reaction 
was heated to 60°C and stirred overnight. The reaction was filtered through a celite plug. 
The solvents were removed in vacuo. The resulting residue was purified over silica (25 
mL) eluting with 50% EtOAc in hexanes (50 mL), 75% EtOAc in hexanes (50 mL), 
EtOAc (50 mL), 10% MeOH in EtOAc (50 mL), and 20% MeOH in EtOAc (100 mL) to 
yield the desired product as a white solid (81 mg , 85%). 1H NMR (DMSO-d6): δ 11.52 
(1s, 1H), 8.52 (d, J = 7.00 Hz, 1H), 8.02 (d, J = 7.25 Hz, 2H), 7.93 (d, J = 8.05 Hz, 2H), 
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7.83 (d, J = 7.15, 2H), 7.68-7.58 (m, 3H), 7.53-7.39 (m, 7H), 5.98 (m, br,  2H), 5.71 (m, 
br, 1H), 4.53 (q, J = 3.65 Hz, 1H), 3.64-3.59 (m, 1H), 3.51-3.45 (m, 1H). 13C NMR 
(DMSO-d6): δ 167.243, 164.65, 164.40, 163.54, 154.46, 145.65, 133.97, 133.68, 133.00, 
132.71, 129.27 129.26, 128.76, 128.63, 128.45, 128.32, 96.82, 88.38, 83.15, 74.39, 71.44, 
50.11.HR-ESI-MS: calcd for [M+H]+, 555.1874; found 555.1891. 
Representative TBAI deprotection 
 tetrabutylammonium (E)-4-((4R)-2-(4-methoxybenzyl)-5,5-
dimethyl-1,3-dioxane-4-carboxamido)but-1-ene-1-sulfonate The PMB protected vinyl 
sulfonate 38 (200 mg, 0.45 mmol) was dissolved in anhydrous acetone (5 mL). TBAI 
(251 mg, 0.679 mmol) was added and the reaction was heated to 55°C for 12 hrs. The 
solvents were removed in vacuo and the resulting residue was purified over silica (30 
mL) eluting with 50% EtOAc in hexanes (100 mL), 75% EtOAc in hexanes (100 mL), 
EtOAc (100 mL), 10% MeOH in EtOAc (100 mL), and 20% MeOH in EtOAc (100 mL) 
to yield the desired product as a extremely hygroscopic white solid (250 mg, 85%). 1H 
NMR (CDCl3-d1): δ 7.37-7.34 (m, 2H), 6.85-6.82 (m, 2H),  5.80-5.73 (m, 1H), 5.52-5.45 
(m, 1H), 5.35 (s, 1H), 3.70 (t, J = 2.67 Hz, 2H), 3.56 (t, J = 6.60 Hz, 2H), 3.43 (d, J = 
3.90 Hz, 1H), 3.18 (t, J = 4.86 Hz, 9H), 1.57-1.51 (m, 8H), 1.38-1.32 (m, 8H), 1.01 (s, 
3H), 0.98 (s, 3H), 0.91 (t, J = 4.41 Hz, 12H). 13C NMR (CDCl3-d1): δ 171.07, 160.05, 
130.17, 127.59, 113.64, 101.30, 83.81, 78.40, 60.30, 58.55, 55.25, 33.04, 23.88, 21.83, 
20.99, 19.64, 19.14, 14.13, 13.65. 
tert-butyl methylsulfonylcarbamate (42) Methanesulfonamide (3.80 g, 40 mmol) was 
suspended in anhydrous DCM (50 mL). Triethylamine (6.06 mL, 44 mmol) and DMAP 
(0.49 g, 4.0 mmol) were added and stirred for 15 min. Di-(t-butyl)dicarbonate (10 g, 46 
mmol) in anhydrous DCM (50 mL) was added dropwise over 10 min. The reaction was 
stirred for 6 hrs. The solvents were removed in vacuo and the resulting syrup was 
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dissolved in EtOAc. The EtOAc was washed with 1 M HCl, water, and brine. The 
organic layer was then dried (Na2SO4) and concentrated in vacuo leave a white solid. 1H 
NMR (DMSO-d6): δ 11.23 (s, 1H), 3.20 (s, 3H), 1.43 (s, 9H). 13C NMR (DMSO-d6): 
δ 151.16, 82.53, 41.20, 28.12. 
tert-butyl ((diethoxyphosphoryl)methyl)sulfonylcarbamate (43) Diisopropylamine 
(4.48 mL, 31.76 mmol) was dissolved in anhydrous THF (30 mL) and cooled to -78°C 
for 15 min. n-BuLi (12.30 mL, 30.73 mmol) was added dropwise and stirred at -78°C for 
30 min. tert-butyl methylsulfonylcarbamate 42 (2.00 g, 10.24 mmol) in anhydrous THF 
(20 mL0 was added dropwise over 10 min and the reaction was stirred at 78°C for 30 
min. The reaction was then warmed to -48°C and stirred for 1 hr. The reaction was 
quenched with saturated ammonium chloride and warmed to rt. The solvents were 
removed in vacuo. The resulting syrup was purified over silica (50 mL) eluting with 50% 
EtOAc in hexanes (150 mL), 75% EtOAc in hexanes (150 mL), EtOAc (150 mL), 10% 
MeOH in EtOAc (150 mL), and 20% MeOH in EtOAc (150 mL) to yield the desired 
product as a white solid (2.04 g , 60%). 1H NMR (DMSO-d6): δ 11.57 (s, 1H), 4.23 (d, J 
= 16.74 Hz, 2H), 4.08 (p, J = 7.11 Hz, 4H), 1.43 (s, 9H), 1.25 (t, J = 6.99 Hz, 6H). 13C 
NMR (DMSO-d6): δ 151.50, 82.51, 63.05, 62.97, 28.18, 16.59. 31P NMR (DMSO-d6): 
δ 12.43 (s, 1P). 
tert-butyl ((E)-4-((4R)-2-(4-methoxybenzyl)-5,5-dimethyl-1,3-dioxane-4-
carboxamido)but-1-en-1-yl)sulfonylcarbamate (44) tert-butyl 
((diethoxyphosphoryl)methyl)sulfonylcarbamate 43 (331 mg, 1.0 mmol) was dissolved in 
anhydrous THF (3 mL) and cooled to -78°C. n-BuLi (1.6M, 0.625 mL, 1 mmol) was 
added dropwise and stirred for 30 min. The aldehyde 37 (323 mg, 1.0 mmol) in 
anhydrous THF (2 mL) was added dropwise and stirred at -78°C for 2h and then warmed 
to rt and stirred for 48h. Solvents were removed in vacuo and the resulting syrup was 
purified over silica (50 mL) and eluted with 25% EtOAc in hexanes (150 mL), 50% 
EtOAc in hexanes (150 mL), 75% EtOAc in hexanes (150 mL) to yield the desired 
product as a wax (313 mg, 71%). 1H NMR (CDCl3-d1): δ  7.42 (dd, J = 5.51, 8.64 Hz, 
2H), 6.92 (d, J = 6.78 Hz, 2H), 6.70 (dt, J = 5.61, 18.45 Hz, 1H), 6.52-6.47 (m, 1H), 5.45 
(d, J = 4.38 Hz, 1H), 3.81 (s, 3H), 3.71 (d, J = 4.80 Hz, 2H), 3.48-3.39 (m, 2H), 3.25 (s, 
1H), 3.02-2.95 (m, 1H), 2.85-2.77 (m, 1H), 1.48-1.45 (m, 9H), 1.10 (s, 3H), 1.09 (s, 
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3H).13C NMR (DMSO-d6): δ 171.62, 160.02, 130.92, 128.26, 113.78, 100.97, 83.76, 
82.27, 78.01, 55.64, 33.17, 28.12, 22.07, 19.58. 
(R,E)-ethyl 4-(2,4-dihydroxy-3,3-dimethylbutanamido)but-1-ene-1-sulfonate (45)  
The PMB acetal 38 (50 mg, 0.097 mmol) was dissolved in 1:1 MeOH:H2O (10 mL) and 
passed through a Dowex 100 (H+ form) anion exchange column (12 mL). The first 12 mL 
of eluent was collected and combined. The volume was reduced in vacuo to ~2 mL and 
passed through a C18 Sep prep column. Fractions 3-5, which tested positive by I2 
staining, were combined and lyophilized to yield the desired product as a hygroscopic 
white solid (27 mg, 90%). 1H NMR (D2O- d2) δ 5.87 (dt, J = 5.88, 15.30 Hz, 1H), 5.57-
5.50 (m, 1H), 4.28-4.21 (m, 2H), 3.95 (d, J =  7.14 Hz, 2H), 3.89 (s, 1H), 3.78-3.72 (m, 
2H), 3.39 (d, J = 11.25 Hz, 1H), 3.27 (d, J = 11.13 Hz, 1H), 1.24 (t, J = 6.87 Hz, 3H), 
0.81 (s, 3H), 0.78 (s, 3H). 13C NMR (D2O-d2) δ 175.09, 136.26, 117.00, 75.70, 69.38, 
68.34, 52.39, 39.88, 38.61, 20.49, 19.08, 14.32. 
(R,E)-ethyl 4-(4-((bis(2-cyanoethoxy)phosphoryl)oxy)-2-hydroxy-3,3-
dimethylbutanamido)but-1-ene-1-sulfonate (46) The diol 45 (75 mg, 0.242 mmol) and 
O,O-bis(cyanoethyl)-N-diisopropylamine phosphoramidite (100 mg, 0.363 mmol) was 
dissolved in anhydrous DMF (2 mL) and cooled to -5°C. Pyridinium HCl (43 mg, 0.363 
mmol) was added and stirred at -5°C for 4 hrs. 5 M t-butyl hyperperoxide (0.075 mL, 
0.363 mmol) was added dropwise and stirred for 2 hrs. Solvents were removed in vacuo 
and the resulting syrup (62 mg, 52%) was taken forward.  
(R,E)-4-(2,4-dihydroxy-3,3-dimethylbutanamido)but-1-ene-1-sulfonic acid (48) The 
PMB acetal 38 (50 mg, 0.117 mmol) was dissolved in anhydrous acetone (5 mL). TBAI 
(65 mg, 0.176 mmol) was added and the reaction was heated to 55°C for 12 hrs. The 
solvents were removed in vacuo and the resulting residue was purified over silica (30 
mL) eluting with 50% EtOAc in hexanes (60 mL), 75% EtOAc in hexanes (60 mL), 
EtOAc (60 mL), 10% MeOH in EtOAc (100 mL), and 20% MeOH in EtOAc (100 mL) to 
yield the desired product as a extremely hygroscopic white solid. The white solid was 
then dissolved in 1:1 MeOH:H2O (10 mL) and passed through a Dowex 100 (H+ form) 
anion exchange column (12 mL). The first 12 mL of eluent was collected and combined. 
The volume was reduced in vacuo to ~2 mL and passed through a C18 Sep prep column. 
Fractions 3-5, which tested positive by I2 staining, were combined and lyophilized to 
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yield the desired product as a wax (26 mg, 81%). 1H NMR (D2O- d2) δ 6.41-6.24 (m, 
ovlp, 2H), 3.84 (s, 1H), 3.35 (d, J = 6.81 Hz, 1H), 3.29-3.21 (m, ovlp, 3H), 2.30 (q, J = 
6.51 Hz, 2H), 0.88 (s, 3H), 0.80(s, 3H). 
Growing and Culturing of Cells  
Escherichia coli BL21-AI/pUMDOT2 was used for the expression of E. coli PanK.  The 
construct contains the coaA gene of E. coli under the control of viral T7 RNA promoter 
and overall expression controlled by L-arabinose induction. Cell cultures were grown in 
250 ml LB broth containing ampicillin (50 µg/ml) at 37° C until it reached an optical 
density of 0.6 – 0.8 at 600 nm.  One mL of 20% (w/v) L-arabinose was added to the 
culture to induce protein expression.  The induced culture was allowed to grow at 37° C 
for 3 hours post induction. The cells were harvested by centrifuged for 10 minutes at 
10,000 x g.  The cells were then washed and suspended in 10 ml of 20 mM HEPES pH 
8.0 buffer, and subsequently lysed by French Press.  The resulting suspension was 
centrifuged at 4° C and 20,000 rpm for 30 minutes.  The lysate containing soluble protein 
was collected and purified through a 2 ml Ni+2-NTA column.  All fractions containing the 
protein of interest were pooled together and desalted using Bio-Gel P-2 resin.  The 
purified proteins were stored in aliquots at -80° C. 
PanK Assays 
Continuous spectrophotometric measurements of the conversion of NADH to NAD+ were 
performed in a pyruvate kinase/lactate dehydrogenase coupled assay.  The oxidation of 
NADH was monitored by the decreasing absorbance at 340 nm at 10 second intervals 
over 5 minutes.  Assays were performed in a 96 well plate in a final volume of 100 µl (80 
µl from assay mix + 10 µl of enzyme + 10 µl of PA or PA analogs).  PanK was at a 
concentration of 50 mg/mL and PA analog concentrations varied from 3 µM to 3 mM.  
The reactions were started by adding the enzyme and substrate to the assay mix.  The 
assay mix contained a final concentration of 50 mM HEPES pH 8.0, 2 mM MgCl2, 1 mM 
ATP, 1 mM PEP, 0.4 mM NADH, 100 units/ml pyruvate kinase, 80 units/ml of lactic 
dehydrogenase, and H2O to a final volume of 100 µL.  
Cloning, Overexpression, and Purification of E. coli PPCS 
 The coaB coding region of the dfp gene (encoding ser181-arg406 of the E. coli CoaBC 
protein)21, 22 was PCR amplified using E. coli MG1655 genomic DNA as a template, and 
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the primers, coabec1(forward primer), 5’ – CGCGCATA 
TGTCGCCCGTCAACGACCTGAAACATCTG-3’ and dfp3 (reverse primer), 5’-
GCGCCTCGAGACGTCGATTTTTTTCATCATAACGGG-3’. The forward primer 
introduces an NdeI site (shown underlined) to provide a start codon for the coaB coding 
region, and the reverse primer creates a XhoI site (shown underlined) downstream of the 
stop codon of the open reading frame. The PCR products were digested with NdeI and 
XhoI, and ligated into pET23a(+) (Novagen) cut with NdeI and XhoI. The resulting 
plasmid was designated pUMDOT3 and the insert was confirmed by DNA sequencing.  
E. coli BL21 AI (Invitrogen) harboring the plasmid pUMDOT3 were grown in 500 mL 
LB-ampicillin media (5 g of NaCl, 5 g of yeast extract, 10 g of tryptone, and 100 mg of 
ampicillin per L) at 37°C and 250 rpm to a OD600 of 0.6. The cells were then cooled by 
shaking at 16°C for 10-15 min, induced with 0.07% L-arabinose, and continued to grow 
at 16°C and 250 rpm for 12-16 hours. The cells were harvested at 6000 x g for 10 
minutes at 4°C, washed, and then suspended in 12 ml of 20 mM HEPES pH 8.0. Cells 
were lysed by French Press and crude cytosol obtained by centrifugation at 20,000 x g for 
25 minutes at 4°C.  
 ecPPCS was purified using a tandem anion exchange column (Source 15Q (GE 
Healthcare); 20 mL) and cation exchange column (Source 15S (GE Healthcare); 8 mL). 
The 12 mL of crude cytosol was loaded onto the tandem chromatography columns which 
had been pre-equilibrated with 20 mM HEPES pH 8.0. The columns were then washed 
with another 40 mL of equilibration buffer and the anion exchange column was removed. 
Under these conditions the ecPPCS does not bind to the anion exchange resin, but does 
bind to the cation exchange resin. The cation exchange column was eluted with a linear 
gradient of 0-0.4 M NaCl in 20 mM HEPES pH 8.0, with a total gradient volume of 100 
mL. ecPPCS eludes as a single peak at 75 mM NaCl and was greater than 98 % pure as 
determined by SDS-PAGE.  
Time Dependence Assay 
The disulfide 24 (1mM stock) was preincubated with equimolar DTT for 1h at 37°C. 
Assays were performed in a 96 well plate in a final volume of 100 µl. ecPPCS (12.9 µL 
of 310nM stock), the reduced thiol mimic (4.5 µL of 1 mM stock), of MgCTP (2.7 µL of 
20mM stock), and water (9.9 µL) were preincubated at time intervals ranging from 15 
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min-4hrs. A solution containing Pyrophosphate reagent (40 µL), PDK (5 µL), DTT (14 
µL of 100mM stock), cysteine (1.4 µL of 100 mM stock), PPA (2 µL, of 30 mM stock), 
and water (7.6 µL) was added to the pre-incubated PPCS/inhibitor solution and then 
continuous spectrophotometric measurements of the conversion of NADH to NAD+ were 
performed via the Pyrophosphate reagent coupled assay.  The oxidation of NADH was 
monitored by the decreasing absorbance at 340 nm at 10 second intervals over 10 
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Difluorophosphonate Mechanistic Probe 
 
Introduction 
 Phosphonates have become increasingly useful as chemically stable isosteres for 
phosphates in medicinal chemistry. It has been shown that due to the increased 
electronegativity of fluorine, α,α difluorophosphonates more closely mimic the 
electronics of the oxygen atom in the naturally occurring phosphate as compared to the 
methylene of a non-fluorinated phosphonate.1-3 Difluorophosphonates also have lower 
pKa values for the phosphonic acid protons, which are more in line with a phosphate.1-3 
Recently, a difluorophosphonate analog of diaminopelic acid (DAP) was designed to 
react with an active site cysteine of aspartate semi-aldehyde dehydrogenase (ASA-DH) 
(Figure 5.1).4, 5 The difluorophosphonate was shown to be a time dependent slow binding 
inhibitor most likely due to covalent linkage of cysteine to the molecule.4, 5  
 
 
Figure 5.1: Difluorophosphonate inhibitor of ASA-DH 
 It can be reasoned from these results that a difluorophosphonate analog designed 
to mimic the activated intermediate of PPCS should behave in a similar fashion. Pre-
incubating PPCS, cysteine, and the difluorophosphonate intermediate mimic should allow 
for binding of the intermediate mimic followed by cysteine entering the active site of 
PPCS, attacking the carbonyl of the mimic, and forming a tetrahedral ternary complex 
(Figure A.2). Forming a ternary complex with cysteine would allow the proposed 
compound to be a potent inhibitor because it would be able to take advantage of the 
binding contacts in the binding pockets of all three enzyme substrates. Beyond being a 
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potent inhibitor, the proposed molecule having trapped cysteine during the second half 
reaction would allow us to study the yet unexplored cysteine binding pocket by co-
crystallizing PPCS, the difluorophosphonate mimic, and cysteine. 
 
Figure 5.2: Proposed difluorophosphonate electrophilic trap and its mechanism of action 
 Aside from studying the binding pocket, the proposed difluorophosphonate 
inhibitor would allow for the elucidation of the mechanism of the second half reaction. 
To date, the mechanism of the second half reaction has not been proven. When entering 
the active site, cysteine can either attack via the more nucleophilic thiol or less 
nucleophilic amine. The proposed difluorophosphonate trap can be attacked by either of 
the two nucleophilic functional groups of cysteine (Figure 5.2). Upon attack and trapping 
of cysteine, the ternary complex can be studied by crystallography within the active site 
or isolated and characterized by 2D NMR studies.  
 
Synthesis of difluorophosphonate probe 
 A retrosynthetic analysis shows that the 4’ terminal phosphate on the pantothenic 
acid portion of the proposed difluorophosphonate is the first disconnection and can be 
installed last via phosphitylation and in situ oxidation (Figure 5.3). The disconnection 
that dissects the molecule in two halves consists of a DCC coupling between an 
appropriately protected cytidine fragment and a pantothenate fragment with a 
difluorophosphonate moiety. The pantothenate portion of the molecule can be further 
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Figure 5.3: Retrosynthetic analysis of proposed difluorophosphonate mimic    
 The synthesis of the difluorophosphonate mimic begins with the protonation of 
pantothenate followed by protection of the 1,3 diol as an acetonide (Scheme 5.1). The 
acetonide was then activated as the NHS ester. Due to a lack of literature precedent for 
coupling of this type, the coupling of the difluorophosphonate to tribenzoyl cytidine 
before attempting the C-C bond formation involving the difluoronated 
methylphosphonate.6-9 The commercially available diethyl difluoromethyl phosphonate is 
treated with 4 equivalents of TMSBr for 18h followed by stirring in a 1:1 mixture of 
pyridine and water for 1h (Scheme 5.2). The resulting mixture was  
 
Scheme 5.1: Synthesis of NHS ester 
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azeotropically distilled with toluene (3 x 10mL).8 The deprotected phosphonate was then 
treated with tribenzoyl cytidine 5 and DCC in refluxing pyridine for 72 h.6 While the 
crude product was not isolated, the desired product was confirmed by 2D 31P, 1H HMBC 
by the presence of a phosphorous signal that showed cross peaks with both the α proton 
of the phosphonate and the two 5’ protons on the ribose ring of tribenzoyl cytidine 
 
Scheme 5.2: Model reaction of DCC coupling 
 Having shown that a model difluorophosphonate could be coupled to tribenzoyl 
cytidine, the next goal was to form the C-C bond between the protected pantothenate 
molecule and the difluorophosphonate. The initial attempts to form the C-C bond, 
involved generating the lithium anion of the difluorophosphonate at -78°C and then 
dropwise addition of the electrophilic NHS ester.1-3, 5, 10-20 Anion generation with n-BuLi 
resulted in phosphonate degradation as seen by 31P NMR. However, anion generation at   
-78°C or -100°C followed by addition of the electrophile resulted in starting phosphonate 
by 31P NMR and the free acid on the pantothenate electrophile from the aqueous quench 
(Scheme 5.3). The base used to generate the difluorophosphonate anion was varied using 
LDA, n-BuLi, NaH, LiH, KHMDS, and Cs2CO3 along with the stir time of both the anion 
generation and nucleophilic attack, but none of these attempts were successful. The 
protecting group on the 1,3 diol was changed to a PMB acetal and the activated ester was 
changed to a pentafluorophenol ester. This electrophile was also unsuccessful. 
 





Scheme 5.4: Model reaction of phosphonate linkage 
 In order to more systematically evaluate synthetic viability of this reaction, a very 
simplified model reaction employing methyl benzoate as the electrophilic ester and both 
the difluoronated and non-fluorinated diethyl methyl phosphonate (Scheme 5.4). Using 
this model system, I was able to link the non-fluorinated diethyl methyl phosphonate to 
methyl benzoate in 49.8% isolated yield, but was unable to link the difluorinated diethyl 
methyl phosphonate to methyl benzoate in any detectable amount.21 The 
phenylethylphosphonate was then taken forward and treated with two equivalents of 
LDA and 2 equivalents of Selectfluor for 2 h at room temperature yielding 10% of the 
desired difluorinated model phosphonate.21 
 
Figure 5.4: Alternative esters 
 Based upon the results from the model study, smaller and less functionalized 
esters of β-alanine were chosen to move forward with as the electrophile in the C-C bond 
forming reaction (Figure 5.4).  The various β-alanine derivatives in Figure 5.4 were 
synthesized from the appropriate starting materials (Scheme 5.5). Treating azetidinone 
with NaH and TESCl yielded the protected β-lactam 49.22 3-Bromopropionic acid was 
converted to methyl ester 51 by displacement of the bromide by dibenzylamine followed 




Scheme 5.5: Synthesis of β-alanine fragments 
were made simply by protecting β-alanine methyl ester with 1,2-
Bis(chlorodimethylsilyl)ethane and boc anhydride respectively.24, 25 Treating β-alanine 
with phthalic anhydride at 150°C and oxalyl chloride yielded the protected acyl chloride 
55.26 
 Three equivalents of the lithium anion of methyl diethylphosphonate was 
generated at -78°C and then treated with the protected β-alanine derivatives 49, 51, 52, 
53, and 55. Compounds 49 and 55 did not yield the desired phosphonates under these 
conditions with 49 not reacting and 55 showing degradation of starting material. Methyl 
ester 51 provided less than 10% yield under the standard conditions, however, replacing 
the methyl ester with an activated pentafluorophenol (pfp) gave a 22% yield (Figure 5.5). 
The boc protected 53 gave a modest 52% yield of the desired phosphonate. Methyl ester 
52 reacted smoothly under these conditions and upon the acidic work up of the reaction 




Figure 5.5: Synthesis of phosphonates 
 With the phosphonates in hand, the next step was the installation of the α diflouro 
functionality. In the case of phosphonate 56, the primary amine had to be protected after 
the protecting group was lost during the acidic workup. Attempts to protect phosphonate 
A8 with either the original silyl protecting group or a boc group failed and resulted in 
degradation of the starting material. Alternatively, phosphonate 56 was taken forward and 
used to open pantolactone with intention of then protecting the diol. However, due to the 
acidic nature of the α protons and the electron withdrawing capability of the phosphonate 
the desired diol was only produced in less than 10%.  
 At this point focus was shifted to working with the already protected 
phosphonates 57 and 58. Phosphonates 57 and 58 were treated with two equivalents of 
base and two equivalents of Selectfluor and N-fluorobenzenesulfonimide as the 
electrophilic source of fluorine (Table 5.1). The reactions were monitored by 31P and 19F 
NMR.  None of the conditions tested yielded the desired difluorophosphonate. Treating 
both the boc protected and dibenzyl protected phosphonates 57 and 58 with the bases 
listed in Table 5.1 with Selectfluor yielded no reaction by both 31P and 19F NMR and the 
starting phosphonate was recoverable. Exposing phosphonates 57 and 58 to similar 
reaction conditions except with N-fluorobenzenesulfonimide as the electrophilic source 
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of fluorine and DBU as the base, NMR showed no reaction had occurred.27 However, 
when the stronger bases were employed the reaction conditions led to decomposition of 
the starting material. 31P NMR showed the disappearance of the starting phosphonate and 
the appearance of a new phosphorous peak that was not split into a triplet indicative of 
the phosphorous being coupled to fluorine. 19F NMR showed the starting material and 
several other fluorinated species. The only species that was isolated after column 
chromatography was the N-fluorobenzenesulfonimide. Attempts to shorten the reaction 
time or use only one equivalent of base in the fluorination were unsuccessful and led to 
no reaction with recovery of starting materials. 
 
Table 5.1: Attempts to install electrophilic fluorine 
   
 
Scheme 5.6: Alternative difluorophosphonate strategy 
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 An alternative strategy was explored in which magnesium was inserted into 
carbon bromine bond of diethyl (bromodifluoromethyl)phosphonate and this species can 
be used as a nucleophile (Scheme 5.5). 28 According to the literature procedure, the silyl 
phosphonate was made in 92% yield.28 This method was advantageous because of the 
ability to monitor the reaction progress by 19F NMR. The starting diethyl 
(bromodifluoromethyl)phosphonate gives a 19F doublet at -60 ppm while the quenched 
protonated difluorophosphonate gives a doublet at -130 ppm, and the 
difluorophosphonate a to a carbonyl gives a doublet at approximately -110 ppm. Two 
equivalents of the magnesium phosphonate species was generated in situ at -78°C for five 
minutes and then methyl esters 51-53 and acyl chloride 55 were added dropwise. 19F 
NMR revealed the protonated quenched phosphonates in all cases. This result could have 
been due to acidic protons on the β-alanine derivatives such as the benzylic protons on 51 
or the amide proton on the boc protecting group on 53, but the silyl derivative 52 and the 
acyl chloride 55 do not have these acidic protons.  
 To ascertain if the protonation event was caused by the β-alanine derivatives, a 
control reaction was run in which the magnesium phosphonate species was generated and 
then quenched using D2O.  In this case if the magnesium species was generated and 
sustained for five minutes and then quenched with D2O, then the 19F NMR would have 
shown a doublet of triplets caused by the deuterium splitting the fluorine signal. 
However, the 19F NMR revealed only approximately 10% of the deuterated species and 
90% of the protonated phosphonate. This result coupled with the fact that the magnesium 
phosphonate species should be stable at -78°C for several hours according to the 
literature report points to the fact that the reaction is being quenched before the addition 
of the electrophile presumably by a proton most likely due to moisture.28 Great care was 
taken in an attempt to exclude moisture from the reaction, but I was not able to improve 
upon the amount of deuterated phosphonate generated and based upon the inability to 
generate the stable magnesium phosphonate species this synthetic strategy was 
abandoned. 
 Since the magnesium phosphonate species was not stable in our hands, the less 
reactive but more stable zinc phosphonate was explored as a more suitable nucleophile. 
In this methodology, zinc is inserted in the carbon bromide bond and this species is then 
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treated with an acyl chloride. This method has the advantage that the zinc inserted species 
is stable at room temperature for days.29, 30 31, 32 The zinc phosphonate species was 
generated in diglyme and then treated with freshly distilled acetyl chloride for 24 hrs. 19F 
NMR revealed a complex mixture of fluorinated species of which approximately 30% 
was the desired acylated difluorophosphonate. The desired product was not separable 
from the rest of the complicated mixture. The reaction was repeated with acyl chloride 
55. In this case, 19F NMR revealed a mixture of the starting diethyl 
(bromodifluoromethyl)phosphonate, the protonated difluorophosphonate, and several 
other fluorinated species that were not α to a carbonyl based upon the chemical shift.  
 
Figure 5.6: TBAF method of installing difluorophosphonate 
 The final attempt to install the α difluorophosphonate functionality was to use 
catalytic TBAF and the silyl difluorophosphonate (Figure 5.6). In this strategy, the TMS 
group on the difluorophosphonate is deprotected by the 10% TBAF. The generated anion 
can then attack the aldehyde and produce an oxyanion. The oxyanion can then attack the 
TMS group on another molecule of the silyl difluorophosphonate and allow the  
phosphonate to attack another molecule of the aldehyde. This method was attempted 
using both the PMB protected aldehyde 37 and the phthaloyl protected β-alanine 
derivative 35. In both cases the reaction was stirred from 24 hrs to 72 hrs and the TBAF 
was varied from 10% up to 50%. Monitoring the reaction by 1H NMR showed that the 
aldehyde signal persisted and thus no reaction had taken place.  
 At this point, the difluorophosphonate was abandoned due to the difficulty 
encountered installing the desired functionality. The difluorophosphonate is still an 
attractive target for a mechanism-based probe; however, installing the functionality was 
not feasible at this time. Using isopropyl magnesium chloride and forming the 
magnesium phosphonate species was the method that displayed the most success and was 
easily monitored by 19F NMR. This method may still be optimized in the future if the 
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magnesium phosphonate species can be generated and persist at -78°C. Conducting the 
reaction in a glove box may provide a more anhydrous environment and thus allow for 
the magnesium insertion and productive bond formation. 
 
Materials & Methods 
General Methods: All chemicals were used as purchased from Acros, Fisher, Fluka, 
Sigma-Aldrich, or Specialty Chemicals Ltd. and used without further purification unless 
otherwise noted. 1H NMR, 13C NMR, and 31P NMR spectra were recorded on a Bruker 
Avance DRX 500MHz spectrometer or Bruker Avance DPX 300MHz spectrometer. 
Proton assignments are reported in ppm from an internal standard of TMS (0.0ppm), and 
phosphorous assignments are reported relative to an external standard of 85% H3PO4 
(0.0ppm). Proton chemical data are reported as follows: chemical shift, multiplicity (ovlp 
= overlapping, s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, m = multiplet, 
br = broad), coupling constant in Hz, and integration. All high resolution mass spectra 
were acquired from the Mass Spectrometry facility in the Chemistry Department at The 
University of Michigan using either positive-ion or negative-ion mode ESI-MS. Thin 
layer chromatography was performed using Analtech GHLF 250 micron silica gel TLC 
plates. All flash chromatography was performed using grade 60 Å 230-400 mesh silica 
purchased from Fisher. 
1-(triethylsilyl)azetidin-2-one (49) 60% NaH (80 mg, 2 mmol) was suspended in 
anhydrous THF (2 mL). Azetidinone (142 mg, 2 mmol) in anhydrous THF (2 mL) was 
added dropwise and stirred for 5 min. TESCl (0.352 mL, 2.1 mmol) was added dropwise 
and the reaction was stirred for 4 hrs. The reaction was quenched with water (1 mL) and 
then solvents were removed in vacuo. The resulting yellow syrup was purified over silica 
(25 mL) eluting with 25% EtOAc in hexanes (100 mL) and 50% EtOAc in hexanes (100 
mL) to yield the desired product as a clear oil (214 mg, 42%). 1H NMR (DMSO-d6): δ 
3.32 (t, J = 5.10 Hz, 2H), 3.06 (t, J = 5.10 Hz, 2H), 1.09 (t, J = 6.10 Hz, 6H), 0.88 (q, J = 
6.10 Hz, 9H).  
3-(dibenzylamino)propanoic acid (50) Dibenzylamine (0.961 mL, 5mmol) was 
dissolved in anhydrous toluene (7 mL). Triethylamine (1.4 mL, 10 mmol) was added and 
stirred for 15 min. 3-Bromopropionic acid (765 mg, 5 mmol) was added and the reaction 
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was heated to reflux for 12 hrs. The reaction was cooled to rt and then filtered. The 
solvents were removed in vacuo and the resulting syrup was purified over silica (50 mL) 
eluting with 25% EtOAc in hexanes (150 mL), 50% EtOAc in hexanes (50 mL), and 
EtOAc (150 mL) to yield the desired product as an oil (1.17 g, 87%). 1H NMR (DMSO-
d6): δ 7.36-7.31 (m, 6H), 7.25 (t, J = 6.50 Hz, 2H), 3.34 (s, 4H), 2.65 (t, J = 7.40 Hz, 2H), 
2.43 (t, J = 7.30 Hz, 2H). 13C NMR (DMSO-d6): δ 174.13, 139.59, 128.98, 128.64, 
127.33, 57.54, 49.00, 32.39, 14.55. 
methyl 3-(dibenzylamino)propanoate (51) 3-(dibenzylamino)propanoic acid (50) (383 
mg, 1.42 mmol) was dissolved in anhydrous THF (5 mL). DCC (293 mg, 1.42 mmol) 
was added and stirred for 15 min. Anhydrous MeOH (0.18 mL, 4.27 mmol) was added 
and the reaction was allowed to stir for 4 hrs. The reaction was filtered and the solvents 
were removed in vacuo to yield the desired product (381 mg, 95%).1H NMR (DMSO-d6): 
δ 7.35-7.29 (m, 6H), 7.26-7.23 (m, 2H), 3.57 (s, 3H), 3.34 (s, 4H), 2.65 (t, J = 7.40 Hz, 
2H), 2.43 (t, J = 7.30 Hz, 2H). 13C NMR (DMSO-d6): δ 174.13, 139.59, 128.98, 128.64, 
127.33, 57.54, 55.41, 49.00, 32.39, 14.55. ESI-MS: calcd for [M+H]+, 284.15; found 
284.1. 
methyl 3-(2,2,5,5-tetramethyl-1,2,5-azadisilolidin-1-yl)propanoate (52)  β-alanine 
methyl ester was dissolved in anhydrous DCM (10 mL). Triethylamine (4.17 mL) was 
added and stirred at rt for 30 min. The solution was cooled to 0°C for 30 min. 1,2-
Bis(chlorodimethylsilyl)ethane (2.15g, 10 mmol) in anhydrous DCM (10 mL) was added 
dropwise. The reaction was stirred at 0°C for 2 hrs and then warmed to rt for 1 hr. The 
reaction was diluted into 125 mL DCM and then washed with H2O) (2 x 25 mL). The 
organic layer was dried (Na2SO4) and evaporated in vacuo to yield the desired product as 
2.28 g of a clear oil (88%). 1H NMR (DMSO-d6): δ 3.59 (s, 3H), 3.06 (t, J = 4.5 Hz, 2H), 
2.37 t, J = 7.1 Hz, 2H), 0.65 (s, 4H), 0.04 (s, 12H). 13C NMR (DMSO-d6): δ 172.55, 
51.61, 39.06, 38.24, 8.16, 0.29. 
methyl 3-((tert-butoxycarbonyl)amino)propanoate (53) β-Alanine methyl ester (1g, 
7.16 mmol) was dissolved in anhydrous DCM (15mL). Triethylamine (3.0 mL, 21.48 
mmol) was added and allowed to stir for 15 min. Boc anhydride (1.72g, 7.88 mmol) was 
added and the reaction was allowed to stir overnight. The reaction was partitioned 
between DCM and H2O. The DCM layer was dried (Na2SO4) and evaporated in vacuo 
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to yield the desired product as a clear oil (1.15g, 80%). 1H NMR (DMSO-d6): δ 6.87 (s, 
1H), 3.58 (s, 3H), 3.14 (q, J = 5.65, 7.00 Hz, 2H), 2.42 (t, J = 6.95 Hz, 2H), 1.37 (s, 9H). 
13C NMR (DMSO-d6): δ 172.16, 155.92, 78.15, 51.80, 36.54, 34.55, 28.67. 
3-(1,3-dioxoisoindolin-2-yl)propanoic acid (54) β-Alanine (4.49g, 52.16 mmol) and 
phthalic anhydride (7.4g, 52.16 mmol) were placed in an open flask with a magnetic stir 
bar. The two solids were heated to 150°C for 2 hrs. The reaction was cooled to rt and 
H2O was added. The reaction was filtered and dried under vacuum to yield the desired 
product as a white crystalline solid (9.1g, 80%). 1H NMR (DMSO-d6): δ 12.39 (s, 1H) 
7.80 (s, 4H), 3.77 (d, J = 7.26 Hz, 2H), 2.60 (d, J = 7.26 Hz, 2H). 13C NMR (DMSO-d6): 
δ 172.61, 168.00, 162.34, 134.76, 131.99, 123.39, 32.99, 32.79. 
3-(1,3-dioxoisoindolin-2-yl)propanoyl chloride (55) Phthathoyl β-alanine (1g, 4.58 
mmol) was dissolved in anhydrous DCM (10 mL). To this heterogeneous mixture was 
added anhydrous dioxane (2 drops). Oxalyl chloride (0.52 mL, 5.96 mmol) was added 
and the reaction was stirred overnight. The solvents were removed in vacuo to yield the 
desired acyl chloride as a white solid (quantitative). 1H NMR (DMSO-d6): δ 7.90-7.86 
(m, 2H), 7.79-7.75 (m, 2H), 4.06 (t, J = 6.96 Hz, 2H), 3.36 (t, J = 6.96 Hz, 2H). 13C NMR 
(DMSO-d6): δ 1171.43, 167.70, 134.31, 131.80, 123.56, 44.96, 33.21. 
diethyl (4-amino-2-oxobutyl)phosphonate hydrochloride (56) Diethyl 
methylphosphonate (1.07 mL, 7.1 mmol) and 3Å molecular sieves were dissolved in 
anhydrous THF (2 mL) and the solution was cooled to -78°C. n-BuLi (4.4 mL, 7.1 mmol) 
was added dropwise and allowed to stir for 45 min. Methyl ester 52 (580 mg, 2.37 mmol) 
in anhydrous THF (2 mL) was added dropwise and the reaction was stirred for 2 hrs. The 
reaction was quenched with saturated ammonium chloride. The reaction was diluted with 
ether and portioned between ether and saturated ammonium chloride. The ethereal extract 
was then washed with 1M HCl (2.4 mL). The water layer was then concentrated in vacuo 
to yield the HCl salt of the desired product. 1H NMR (DMSO-d6): δ 7.99 (s, br, 3H), 4.05 
(p, J = 7.20 Hz, 4H), 3.35 (d, J = 22.20 Hz, 2H), 2.98 (d, J = 6.1 Hz, 2H), 2.94 (t, J = 
5.70 Hz, 2H), 1.25 (t, J = 7.0 Hz, 6H). 31PNMR (DMSO-d6): δ 20.12 (s, 1P). 
diethyl (4-(dibenzylamino)-2-oxobutyl)phosphonate (57) Diethyl methylphosphonate 
(1.65 mL, 11.27 mmol) and 3Å molecular sieves were dissolved in anhydrous THF (3 
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mL) and the solution was cooled to -78°C. n-BuLi (7.0 mL, 11.27 mmol) was added 
dropwise and allowed to stir for 45 min. The pfp ester of 3-(dibenzylamino)propanoic 
acid (1.64 g, 3.75 mmol) in anhydrous THF (3 mL) was added dropwise and the reaction 
was stirred for 2 hrs. The reaction was quenched with saturated ammonium chloride. 
Solvents were removed in vacuo and the resulting syrup was purified over silica (50 mL) 
eluting with 25% EtOAc in hexanes (150 mL), 50% EtOAc in hexanes (150 mL), and 
75% EtOAc in hexanes (150 mL) to yield the desired product (340 mg, 22%). 1H NMR 
(DMSO-d6): δ 7.36-7.32 (m, 6H), 7.26-7.23 (m, 2H), 4.02-3.99 (m, 4H), 3.12 (d, J = 
22.05 Hz, 2H), 2.82 (t, J = 7.05 Hz, 2H), 2.62 (t, J = 7.05 Hz, 2H), 1.20 (t, J = 7.00 Hz, 
6H). 13C NMR (DMSO-d6): δ 202.21, 139.56, 129.03, 128.68, 127.38, 62.17, 57.58, 
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 PPCS is the second enzyme in the CoA biosynthetic pathway and catalyzes the 
amide bond formation between PPA and L-cysteine, which is responsible for the 
installation of the biologically active thiol of phosphopantetheine.1, 2 PPCS is broadly 
classified into three types (Type I-III) based upon nucleotide triphosphate preference and 
whether it is expressed as fusion protein with PPCDC or as a monofunctional enzyme. 
Type I PPCSs are found in a majority of bacteria and archaea, utilize CTP for activation 
of PPA in the first half reaction, and are expressed as the C-terminal domain of a fusion 
protein with PPCDC. Type II PPCSs are found in eukaryotes, utilize both CTP and ATP, 
and expressed separately from PPCDC as a monofunctional enzyme. Type III PPCSs are 
found in certain bacteria, utilize CTP in the first half reaction of PPCS, and are expressed 
as a monofunctional enzyme.3 Based upon the difference in PPCS type, nucleotide 
triphosphate preference, sequence similarity between human and bacteria, and the fact 
that PPCS is essential for bacterial growth, PPCS was chosen for exploration as a 
potential novel antibacterial target. 
 Initially four intermediate mimics were designed based upon the activated 
cytidylate intermediate formed during bacterial PPCS catalysis (Figure 6.1). These 
 
Figure 6.1: Mechanism of intermediate mimic inhibition. 
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intermediate mimics were designed to take advantage the natural binding contacts of the 
activated intermediate and utilize the cytidine portion of the molecule as a selectivity 
handle for bacterial PPCS over human PPCS. The two phosphodiester mimics (8 and 10) 
and the two sulfamate mimics (17 and 19) were synthesized in twelve steps with an 
average yield of 18%. The intermediate mimics were evaluated as inhibitors against 
PPCS from E. coli, E. faecalis, S. pneumoniae, and human (Figure 6.2). Phosphodiester 
8 was the most potent inhibitor with IC50 values ranging from 10-68 nM and 100-1000 
fold selectivity for bacterial PPCS over human PPCS. The most potent compound was 
also shown to be a tight binding, slow onset inhibitor with respect to efPPCS with a Ki of 
24 nM. These molecules were the first selective inhibitors of bacterial PPCS and provide 
the foundation for further exploration of PPCS as antibacterial target. 
 
Figure 6.2: Selective inhibitors of PPCS. Standard error in parentheses 
 These first generation inhibitors were used as probes in a crystallographic study to 
establish the binding determinants of inhibitor potency. The structures of phosphodiester 
8, cyclic phosphodiester 10, and sulfamate 17 mimics bound to PPCS were solved to 2.37 
Å, 2.30 Å, and 2.11 Å, respectively. The structure of phosphodiester 8 bound to wild type 
E. coli PPCS domain was very similar to the intermediate bound PPCS mutant structure 
reported in literature. Sulfamate 17 binds to PPCS in the same manner as phosphodiester 
8 with the decrease in potency most likely due to the lack of Lys289 forming a contact 
with sulfamate 17. The structure of cyclic phosphodiester 10 bound PPCS varied greatly 
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from the other structures. In order for the cyclic phosphate moiety to bind in the terminal 
phosphate binding cradle, the gem dimethyl group must orient itself towards Asn353 and 
prevent the flexible binding clamp from closing on the inhibitor.  
 While there are many known mimics of pantothenate, there are few known 
mimics of PPA.6 The disulfide compound 24 was the first PPA mimic chemically 
synthesized and shown to be an inhibitor of PPCS. The reduced form of PPA mimic 24 
was shown to be competitive with respect to PPA and have a Ki of 12 µM. Although this 
molecule does not contain a moiety designed to give it selectivity for bacterial PPCS over 
human PPCS, this mimic proves that low micromolar inhibition is possible with a low 
molecular weight molecule and that the whole active site does not have to be occupied in 
order to inhibit PPCS catalysis.   
 Attempts to synthesize mechanistic traps designed to react with substrate cysteine 
in the second half reaction of PPCS were unsuccessful. A difluorophosphonate and a 
vinyl sulfone were designed to undergo nucleophilic attack of cysteine in the second half 
reaction. However, the difluorophosphonate moiety was not able to be installed into a 
panthenol or β-alanine portion of the intermediate mimic. The targeted vinyl sulfone 
compound synthesis seems more obtainable with a vinyl sulfone being installed into three 
different β-alanine/panthenol molecules. Although these vinyl sulfones were not 
successfully coupled to a cytidine moiety, they may prove useful as PanK inhibitors or 
PanK-activated inhibitors.  
 This study was significant because it produced the first selective inhibitors of 
PPCS and the first synthetic PPA mimic to inhibit PPCS. These inhibitors of PPCS 
provide a proof of concept that PPCS can be selectively inhibited at a low micromolar to 
low nanomolar potency, and up to 1000 fold selectivity for the bacterial PPCS over 
human PPCS. Going forward, the information gathered from the crystal structures of our 
various intermediate mimics bound to PPCS, coupled with the in vitro PPCS inhibition 
results, provide the foundation for the design of 2nd generation inhibitors with improved 
physiochemical properties to allow cellular entry.  It may be possible to modify several of 
these molecules by replacing the terminal phosphate moiety with a neutral isostere, such 
as a triazole, in order to improve their chances of cellular entry and allow for the first 
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